BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 2017;3:1335-42. [PMID: 28448665 DOI: 10.1001/jamaoncol.2017.0589] [Cited by in Crossref: 1510] [Cited by in F6Publishing: 1617] [Article Influence: 251.7] [Reference Citation Analysis]
Number Citing Articles
1 Matsuno K, Miyamoto H, Kitada H, Yoshimatsu S, Tamura F, Sakurai K, Fukubayashi K, Shono T, Setoyama H, Matsuyama T, Suko S, Narita R, Honda M, Tateyama M, Naoe H, Morinaga J, Tanaka Y, Gushima R. Comparison of endoscopic submucosal resection with ligation and endoscopic submucosal dissection for small rectal neuroendocrine tumors: A multicenter retrospective study. DEN Open 2023;3. [DOI: 10.1002/deo2.163] [Reference Citation Analysis]
2 Mo S, Zong L, Chen X, Ban X, Li M, Lu Z, Yu S, Chen J. Expression and Prognostic Value of B7 Family Immune Checkpoints in Pancreatic Neuroendocrine Tumors. Arch Pathol Lab Med 2023;147:193-201. [PMID: 35671167 DOI: 10.5858/arpa.2021-0377-OA] [Reference Citation Analysis]
3 Shah T, Manas DM, Ford SJ, Dasari BVM, Gibbs P, Venkataraman H, Moore J, Hughes S, Elshafie M, Karkhanis S, Smith S, Hoti E, O'Toole D, Caplin ME, Isaac J, Mazzafero V, Thorburn D. Where Are We Now with Liver Transplantation in Neuroendocrine Neoplasms? The Place of Liver Transplantation for Grades 1 and 2 Well-Differentiated Unresectable Liver Metastatic Neuroendocrine Tumours. Curr Oncol Rep 2023;25:135-44. [PMID: 36648705 DOI: 10.1007/s11912-022-01343-8] [Reference Citation Analysis]
4 Kjaer J, Norlén O, Hellman P, Stalberg P. Author´s Reply: Overall Survival in Patients with Stage IV Pan-NET Eligible for Liver Transplantation. World J Surg 2023. [PMID: 36705741 DOI: 10.1007/s00268-023-06916-7] [Reference Citation Analysis]
5 Liu M, Wei L, Liu W, Chen S, Guan M, Zhang Y, Guo Z, Liu R, Xie P. Trends in incidence and survival in patients with gastrointestinal neuroendocrine tumors: A SEER database analysis, 1977-2016. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1079575] [Reference Citation Analysis]
6 Batts TL, Sasaki E, Miller M, Sparago J, Bauer RW, Paulsen D, Boudreaux B, Liu CC, Byrum SD, Johnston AN. Neoplastic signatures: Comparative proteomics of canine hepatobiliary neuroendocrine tumors to normal niche tissue. PLoS One 2023;18:e0280928. [PMID: 36696389 DOI: 10.1371/journal.pone.0280928] [Reference Citation Analysis]
7 Ramesh A, Chatterjee A, Subramaniam RM. Neuroendocrine Neoplasms: Epidemiology, Diagnosis, and Management. PET Clin 2023:S1556-8598(22)00076-1. [PMID: 36707369 DOI: 10.1016/j.cpet.2022.10.002] [Reference Citation Analysis]
8 Khatri W, Spiro E, Henderson A, Rowe SP, Solnes LB. Gastro-Entero-Pancreatic Tumors: FDG Positron Emission Tomography/Computed Tomography. PET Clin 2023:S1556-8598(22)00094-3. [PMID: 36707371 DOI: 10.1016/j.cpet.2022.11.007] [Reference Citation Analysis]
9 Heaphy CM, Singhi AD. Reprint of: The Diagnostic and Prognostic Utility of Incorporating DAXX, ATRX, and Alternative Lengthening of Telomeres (ALT) to the Evaluation of Pancreatic Neuroendocrine Tumors (PanNETs). Hum Pathol 2023:S0046-8177(23)00015-1. [PMID: 36702689 DOI: 10.1016/j.humpath.2023.01.004] [Reference Citation Analysis]
10 Liverani C, Spadazzi C, Ibrahim T, Pieri F, Foca F, Calabrese C, De Vita A, Miserocchi G, Cocchi C, Vanni S, Ercolani G, Cavaliere D, Ranallo N, Chiadini E, Prisinzano G, Severi S, Sansovini M, Martinelli G, Bongiovanni A, Mercatali L. HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors. Front Endocrinol 2023;13. [DOI: 10.3389/fendo.2022.1045038] [Reference Citation Analysis]
11 Brighi N, Lamberti G, Andrini E, Mosconi C, Manuzzi L, Donati G, Lisotti A, Campana D. Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors. Current Oncology 2023;30:1381-1394. [DOI: 10.3390/curroncol30020106] [Reference Citation Analysis]
12 Wang Y, Wang F, Qin Y, Lou X, Ye Z, Zhang W, Gao H, Chen J, Xu X, Yu X, Ji S. Recent progress of experimental model in pancreatic neuroendocrine tumors: drawbacks and challenges. Endocrine 2023. [PMID: 36648608 DOI: 10.1007/s12020-023-03299-6] [Reference Citation Analysis]
13 Zappi A, Persano I, Galvani L, Parlagreco E, Andrini E, Campana D, Brizzi MP, Lamberti G, La Salvia A. Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review. J Clin Med 2023;12. [PMID: 36675645 DOI: 10.3390/jcm12020717] [Reference Citation Analysis]
14 Lugat A, Frampas É, Touchefeu Y, Mirallié É, Bras ML, Senellart H, Rauscher A, Fleury V, Campion L, Rohmer V, Couturier OF, Lebtahi R, Rouzet F, Ruszniewski P, Kraeber-Bodéré F, Bourgeois M, Ansquer C. Prospective Multicentric Assessment of (68)Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET. Cancers (Basel) 2023;15. [PMID: 36672462 DOI: 10.3390/cancers15020513] [Reference Citation Analysis]
15 Segura T, Medrano IH, Collazo S, Maté C, Sguera C, Del Rio-Bermudez C, Casero H, Salcedo I, García-García J, Alcahut-Rodríguez C, Taberna M; Savana Research Group. Symptoms timeline and outcomes in amyotrophic lateral sclerosis using artificial intelligence. Sci Rep 2023;13:702. [PMID: 36639403 DOI: 10.1038/s41598-023-27863-2] [Reference Citation Analysis]
16 Honan KA, Hassan S, Deswal A, Herrmann J, Song J, Monlezun D, Halperin D, Mahvash A, Dasari A, Koutroumpakis E, Akay M, Balanescu D, de Armas IS, Patel M, Nathan S, Kar B, Marmagkiolis K, Lopez-mattei J, Patel J, Gregoric I, Yao J, Iliescu CA. Bioprosthetic valve monitoring in patients with carcinoid heart disease. Front Cardiovasc Med 2023;9. [DOI: 10.3389/fcvm.2022.1072890] [Reference Citation Analysis]
17 Veerman CHAM, Siebinga H, de Vries-Huizing DMV, Tesselaar MET, Hendrikx JJMA, Stokkel MPM, Aalbersberg EA. The effect of long-acting somatostatin analogues on the uptake of [(177)Lu]Lu-HA-DOTATATE. Eur J Nucl Med Mol Imaging 2023. [PMID: 36598536 DOI: 10.1007/s00259-022-06094-z] [Reference Citation Analysis]
18 Rinke A, Denzer UW. Kolorektale NEN (ohne Fernmetastasen). Springer Reference Medizin 2023. [DOI: 10.1007/978-3-662-63317-5_48] [Reference Citation Analysis]
19 Hummelshøj NE, Gronbaek H, Bager P, Tabaksblat E, Dam G. Fatigue and quality of life in patients with neuroendocrine neoplasia. Scand J Gastroenterol 2023;58:45-53. [PMID: 35850607 DOI: 10.1080/00365521.2022.2100228] [Reference Citation Analysis]
20 Kjaer J, Smith S, Hellman P, Stålberg P, Crona J, Welin S, Norlén O. Overall Survival in Patients with Stage IV Pan-NET Eligible for Liver Transplantation. World J Surg 2023;47:340-7. [PMID: 36175647 DOI: 10.1007/s00268-022-06736-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
21 Minczeles NS, de Herder WW, Feelders RA, Verburg FA, Hofland J, Brabander T. Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in Neuroendocrine Tumor Patients. J Nucl Med 2023;64:40-6. [PMID: 35680417 DOI: 10.2967/jnumed.122.263856] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 Limbach KE, Wen W, Xing Q, Yan J, Yim JH. Baicalein activates 5' adenosine monophosphate-activated protein kinase, inhibits the mammalian target of rapamycin, and exhibits antiproliferative effects in pancreatic neuroendocrine tumors in vitro and in vivo. Surgery 2023;173:12-8. [PMID: 36207198 DOI: 10.1016/j.surg.2022.07.030] [Reference Citation Analysis]
23 Machado-Alba JE, Machado-Duque ME, Gaviria-Mendoza A, Arsof-Saab IN, Castellanos-Moreno CA, Botero L, Triana L. Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors. J Endocrinol Invest 2023;46:27-35. [PMID: 35913681 DOI: 10.1007/s40618-022-01875-7] [Reference Citation Analysis]
24 Ziogas IA, Tasoudis PT, Borbon LC, Sherman SK, Breheny PJ, Chandrasekharan C, Dillon JS, Bellizzi AM, Howe JR. Surgical Management of G3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Systematic Review and Meta-analysis. Ann Surg Oncol 2023;30:148-60. [PMID: 36227392 DOI: 10.1245/s10434-022-12643-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Marcal LP, Chuang HH, Tran Cao HS, Halperin DM. Pancreatic Neuroendocrine Tumors. Oncologic Imaging : a Multidisciplinary Approach 2023. [DOI: 10.1016/b978-0-323-69538-1.00014-8] [Reference Citation Analysis]
26 Kshattry S, White M, Tchack J, Laskin W, Kunz PL. A 46-Year-Old Woman With Chronic Dyspnea and Diarrhea. Chest 2023;163:e23-9. [PMID: 36628681 DOI: 10.1016/j.chest.2022.08.2214] [Reference Citation Analysis]
27 Keller HR, Senapathi SH, Morada A, Bertsch D, Cagir B. Survival in patients with neuroendocrine tumors of the colon, rectum and small intestine. Am J Surg 2023;225:58-65. [PMID: 36216612 DOI: 10.1016/j.amjsurg.2022.09.053] [Reference Citation Analysis]
28 Albers MB, Manoharan J, Bartsch DK. Hereditäre duodenopankreatische neuroendokrine Neoplasien. Springer Reference Medizin 2023. [DOI: 10.1007/978-3-662-63317-5_45] [Reference Citation Analysis]
29 Chen L, Jumai N, He Q, Liu M, Lin Y, Luo Y, Wang Y, Chen MH, Zeng Z, Zhang X, Zhang N. The role of quantitative tumor burden based on [(68) Ga]Ga-DOTA-NOC PET/CT in well-differentiated neuroendocrine tumors: beyond prognosis. Eur J Nucl Med Mol Imaging 2023;50:525-34. [PMID: 36181533 DOI: 10.1007/s00259-022-05971-x] [Reference Citation Analysis]
30 Paniccia A, Polanco PM, Boone BA, Wald AI, McGrath K, Brand RE, Khalid A, Kubiliun N, O'Broin-Lennon AM, Park WG, Klapman J, Tharian B, Inamdar S, Fasanella K, Nasr J, Chennat J, Das R, DeWitt J, Easler JJ, Bick B, Singh H, Fairley KJ, Sarkaria S, Sawas T, Skef W, Slivka A, Tavakkoli A, Thakkar S, Kim V, Vanderveldt HD, Richardson A, Wallace MB, Brahmbhatt B, Engels M, Gabbert C, Dugum M, El-Dika S, Bhat Y, Ramrakhiani S, Bakis G, Rolshud D, Millspaugh G, Tielleman T, Schmidt C, Mansour J, Marsh W, Ongchin M, Centeno B, Monaco SE, Ohori NP, Lajara S, Thompson ED, Hruban RH, Bell PD, Smith K, Permuth JB, Vandenbussche C, Ernst W, Grupillo M, Kaya C, Hogg M, He J, Wolfgang CL, Lee KK, Zeh H, Zureikat A, Nikiforova MN, Singhi AD. Prospective, Multi-Institutional, Real-Time Next-Generation Sequencing of Pancreatic Cyst Fluid Reveals Diverse Genomic Alterations That Improve the Clinical Management of Pancreatic Cysts. Gastroenterology 2023;164:117-133.e7. [PMID: 36209796 DOI: 10.1053/j.gastro.2022.09.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Russo A, Gangi A. The Evolving Landscape of Neuroendocrine Tumors. Surg Oncol Clin N Am 2023;32:185-98. [PMID: 36410917 DOI: 10.1016/j.soc.2022.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Xiao J, Yu H, Sui X, Liu G, Cao Y, Yanzhao Z, Zhang Y, Hu P, Cheng D, Shi H. A personal acquisition time regimen of (68)Ga-DOTATATE total-body PET/CT in patients with neuroendocrine tumor (NET): a feasibility study. Cancer Imaging 2022;22:78. [PMID: 36578034 DOI: 10.1186/s40644-022-00517-8] [Reference Citation Analysis]
33 Wang F, Wang J, Li Y, Wang X, Yu D, Zhang X. Correlation of four-phase CT findings of rectal neuroendocrine neoplasms with different World Health Organization grades. Abdom Radiol (NY) 2022. [PMID: 36576516 DOI: 10.1007/s00261-022-03771-3] [Reference Citation Analysis]
34 Ungefroren H, Konukiewitz B, Wellner UF, Schrader J, Keck T. The Use of PDX1 DNA Methylation to Distinguish Two Subtypes of Pancreatic Neuroendocrine Neoplasms with Different Prognoses. Cancers (Basel) 2022;15. [PMID: 36612156 DOI: 10.3390/cancers15010160] [Reference Citation Analysis]
35 Sharma R, Zafar H, Sherman SK, Niyazi F. Recurrent Gastrointestinal Pseudo-obstruction Because of Well-Differentiated Duodenal Neuroendocrine Tumor. ACG Case Rep J 2022;9:e00910. [PMID: 36600798 DOI: 10.14309/crj.0000000000000910] [Reference Citation Analysis]
36 Lim S, Chong L, Peeroo S, Onasanya O, He E, Banting S, Croagh D. Recurrence and outcomes of non-functional pancreatic neuroendocrine tumours post-resection: an Australian retrospective, multicentre cohort study. ANZ J Surg 2022. [PMID: 36562118 DOI: 10.1111/ans.18204] [Reference Citation Analysis]
37 Arrivi G, Verrico M, Roberto M, Barchiesi G, Faggiano A, Marchetti P, Mazzuca F, Tomao S. Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs): A Systematic Review and Pooled Analysis. Cancer Manag Res 2022;14:3507-23. [PMID: 36575665 DOI: 10.2147/CMAR.S372776] [Reference Citation Analysis]
38 Han L, Zhang Y, Zhang Q, Hu J, Li L, Shi X, Ding Z, Qian X. Clinicopathological features and survival outcomes of colorectal medullary carcinoma: a retrospective study based on the SEER database.. [DOI: 10.21203/rs.3.rs-2392043/v1] [Reference Citation Analysis]
39 Wang Z, Shi S, Ren H, Liu Q. Tumor Differentiation is the Dominant Prognostic Factor for Patients with Colorectal Neuroendocrine Neoplasms with Distant Metastasis. Int J Endocrinol 2022;2022:1720624. [PMID: 36578535 DOI: 10.1155/2022/1720624] [Reference Citation Analysis]
40 Loosen SH, Kostev K, Eschrich J, Krieg S, Krieg A, Luedde T, Jann H, Roderburg C. Clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy. Medicine (Baltimore) 2022;101:e32044. [PMID: 36550801 DOI: 10.1097/MD.0000000000032044] [Reference Citation Analysis]
41 Zhang Y, Zhang Y, Yang Y, Xu Z, Gao C, Liu M, Zhu W, Zhao H, Zhou H. Case report: Indocyanine green fluorescence-guided imaging in laparoscope, a more sensitive detection technique of lateral lymph nodes metastases from rectal neuroendocrine tumors. Front Oncol 2022;12:1101990. [PMID: 36591455 DOI: 10.3389/fonc.2022.1101990] [Reference Citation Analysis]
42 Liu X, Chen B, Chen J, Su Z, Sun S. The incidence, prevalence, and survival analysis of pancreatic neuroendocrine tumors in the United States. J Endocrinol Invest 2022. [DOI: 10.1007/s40618-022-01985-2] [Reference Citation Analysis]
43 Choi JH, Paik WH. Risk Stratification of Pancreatic Neuroendocrine Neoplasms Based on Clinical, Pathological, and Molecular Characteristics. J Clin Med 2022;11. [PMID: 36556070 DOI: 10.3390/jcm11247456] [Reference Citation Analysis]
44 Li Y, Cao Y, Wu X, Liu R, Wang K. HER-2-positive primary neuroendocrine neoplasms of the breast with signet ring feature: A case report and review of literature. Front Oncol 2022;12:1029007. [PMID: 36578949 DOI: 10.3389/fonc.2022.1029007] [Reference Citation Analysis]
45 April-monn SL, Detjen K, Kirchner P, Bräutigam K, Trippel MA, Marques IJ, Grob T, Statzer C, Maire RS, Kollàr A, Chouchane A, Kunze K, Horst D, Sadowski MC, Schrader J, Mercader N, Marinoni I, Wiedenmann B, Perren A. Patient-derived tumoroids of advanced high-grade neuroendocrine neoplasms mimic patient chemotherapy responses and guide the design of personalized combination therapies.. [DOI: 10.1101/2022.12.10.519855] [Reference Citation Analysis]
46 Greenberg J, Limberg J, Verma A, Kim D, Chen X, Lee YJ, Moore MD, Ullmann TM, Thiesmeyer JW, Loewenstein Z, Chen KJ, Egan CE, Stefanova D, Bareja R, Zarnegar R, Finnerty BM, Scognamiglio T, Du YN, Elemento O, Fahey TJ 3rd, Min IM. Metastatic pancreatic neuroendocrine tumors feature elevated T cell infiltration. JCI Insight 2022;7. [PMID: 36301668 DOI: 10.1172/jci.insight.160130] [Reference Citation Analysis]
47 Bongiovanni A, Nicolini S, Ibrahim T, Foca F, Sansovini M, Di Paolo A, Grassi I, Liverani C, Calabrese C, Ranallo N, Matteucci F, Paganelli G, Severi S. (177)Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical Trials. Cancers (Basel) 2022;14. [PMID: 36551507 DOI: 10.3390/cancers14246022] [Reference Citation Analysis]
48 Prieto TG, Baldavira CM, Machado-Rugolo J, Olivieri EHR, da Silva ECA, Ab' Saber AM, Takagaki TY, Capelozzi VL. Proposing Specific Neuronal Epithelial-to-Mesenchymal Transition Genes as an Ancillary Tool for Differential Diagnosis among Pulmonary Neuroendocrine Neoplasms. Genes (Basel) 2022;13. [PMID: 36553576 DOI: 10.3390/genes13122309] [Reference Citation Analysis]
49 Shi M, Jakobsson V, Greifenstein L, Khong PL, Chen X, Baum RP, Zhang J. Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists. Front Med (Lausanne) 2022;9:1034315. [PMID: 36569154 DOI: 10.3389/fmed.2022.1034315] [Reference Citation Analysis]
50 Ryan CE, Saif A, Rocha F, Philip P, Hernandez JM, Ahmad S, Soares H. Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors. Ann Surg Oncol 2022. [DOI: 10.1245/s10434-022-12906-1] [Reference Citation Analysis]
51 Wang M, Yin T, Huang P, Qin T, Chen D, Xu S, Gong J, Tian R, Guo X, Qin R. PIN1 As A Marker of Metastasis and Survival in Pancreatic Neuroendocrine Tumor Identified by Single-cell Sequencing and Proteomic Profiling.. [DOI: 10.21203/rs.3.rs-2325792/v1] [Reference Citation Analysis]
52 Roseland ME, Francis IR, Shampain KL, Stein EB, Wasnik AP, Millet JD. Gastric neuroendocrine neoplasms: a primer for radiologists. Abdom Radiol (NY) 2022;47:3993-4004. [PMID: 35411433 DOI: 10.1007/s00261-022-03509-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Concors SJ, Maxwell JE. Neuroendocrine hepatic metastatic disease: the surgeon's perspective. Abdom Radiol (NY) 2022;47:4073-80. [PMID: 35476146 DOI: 10.1007/s00261-022-03515-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Morishita S, Yoshida S, Kamatani Y, Suzuhigashi S, Kitou M, Nasu T. Primary grade 2 neuroendocrine tumor of the ileal mesentery: a case report. surg case rep 2022;8:146. [DOI: 10.1186/s40792-022-01482-x] [Reference Citation Analysis]
55 Ramesh S, Dolezal JM, Pearson AT. Applications of Deep Learning in Endocrine Neoplasms. Surgical Pathology Clinics 2022. [DOI: 10.1016/j.path.2022.09.014] [Reference Citation Analysis]
56 Ramirez RA, Cass AS, Das S, Low SW, Mehrad M, Rickman OB, Scherer PM, Thomas KE, Gillaspie EA. A multidisciplinary approach to the work up and management of pulmonary carcinoid tumors and DIPNECH: a narrative review. Transl Lung Cancer Res 2022;11:2567-87. [PMID: 36636417 DOI: 10.21037/tlcr-22-415] [Reference Citation Analysis]
57 Virarkar M, Gopireddy DR, Morani AC, Alkhasawneh A, Klimkowski SP, Kumar S, Lall C, Bhosale P. Rectal neuroendocrine neoplasms: what the radiologists should know. Abdom Radiol (NY) 2022;47:4016-31. [PMID: 35288791 DOI: 10.1007/s00261-022-03474-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Zellmer J, Yen HY, Kaiser L, Gildehaus FJ, Böning G, Steiger K, Hacker M, Bartenstein P, Todica A, Haug AR, Ilhan H. Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors. Biomedicines 2022;10. [PMID: 36551858 DOI: 10.3390/biomedicines10123102] [Reference Citation Analysis]
59 Gaspar TB, Lopes JM, Soares P, Vinagre J. An update on genetically engineered mouse models of pancreatic neuroendocrine neoplasms. Endocrine-Related Cancer 2022;29:R191-R208. [DOI: 10.1530/erc-22-0166] [Reference Citation Analysis]
60 Bloemen H, Kneepkens K, Deraedt K, Ivanova A, Sergeant G, Mebis J, Van der Speeten K. Evaluation of quality of clinical management of neuroendocrine tumors. Cancer Innovation 2022;1:305-315. [DOI: 10.1002/cai2.41] [Reference Citation Analysis]
61 Galgano SJ, Morani AC, Gopireddy DR, Sharbidre K, Bates DDB, Goenka AH, Arif-Tiwari H, Itani M, Iravani A, Javadi S, Faria S, Lall C, Bergsland E, Verma S, Francis IR, Halperin DM, Chatterjee D, Bhosale P, Yano M. Pancreatic neuroendocrine neoplasms: a 2022 update for radiologists. Abdom Radiol (NY) 2022;47:3962-70. [PMID: 35244755 DOI: 10.1007/s00261-022-03466-9] [Reference Citation Analysis]
62 Barrs C, Itani M, Zulfiqar M, Mhlanga J, Francis IR, Morani A, Bhosale P, Yano M, Iravani A. Gastroenteropancreatic neuroendocrine neoplasm imaging: standard reporting templates. Abdom Radiol (NY) 2022;47:3986-92. [PMID: 36201054 DOI: 10.1007/s00261-022-03677-0] [Reference Citation Analysis]
63 Schwarz JL, Williams JK, Keutgen XM, Liao C. Light It Up! The Use of DOTATATE in Diagnosis and Treatment of Neuroendocrine Neoplasms. Surgical Pathology Clinics 2022. [DOI: 10.1016/j.path.2022.09.013] [Reference Citation Analysis]
64 Klaiber U, Stättner S. Current standards in the surgical treatment of pancreatic and small intestinal neuroendocrine tumors. memo 2022;15:282-286. [DOI: 10.1007/s12254-022-00840-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Tacelli M, Bina N, Crinò SF, Facciorusso A, Celsa C, Vanni AS, Fantin A, Antonini F, Falconi M, Monica F, Capurso G, Arcidiacono PG, Barresi L; of the Italian Association of Hospital Gastroenterologists and Endoscopists. Reliability of grading preoperative pancreatic neuroendocrine tumors on EUS specimens: a systematic review with meta-analysis of aggregate and individual data. Gastrointest Endosc 2022;96:898-908.e23. [PMID: 35863518 DOI: 10.1016/j.gie.2022.07.014] [Reference Citation Analysis]
66 You T, Tang H, Xu X, Ying H, Sun Z, Cheng Y, Bai C. Patients with non-functional metastatic G2 pancreatic neuroendocrine tumor benefit from palliative surgery: A 20-year single-center retrospective analysis. J Neuroendocrinol 2022;34:e13211. [PMID: 36373196 DOI: 10.1111/jne.13211] [Reference Citation Analysis]
67 White BE, Rous B, Chandrakumaran K, Wong K, Bouvier C, Van Hemelrijck M, George G, Russell B, Srirajaskanthan R, Ramage JK. Incidence and survival of neuroendocrine neoplasia in England 1995–2018: A retrospective, population-based study. The Lancet Regional Health - Europe 2022;23:100510. [DOI: 10.1016/j.lanepe.2022.100510] [Reference Citation Analysis]
68 Huang XT, Xie JZ, Huang CS, Li JH, Chen W, Liang LJ, Yin XY. Development and validation of nomogram to predict lymph node metastasis preoperatively in patients with pancreatic neuroendocrine tumor. HPB (Oxford) 2022;24:2112-8. [PMID: 36127226 DOI: 10.1016/j.hpb.2022.08.015] [Reference Citation Analysis]
69 Chi Y, Song L, Liu W, Zhou Y, Miao Y, Fang W, Tan H, Shi S, Jiang H, Xu J, Jia R, Zheng B, Jiang L, Zhao J, Zhang R, Tan H, Wang Y, Chen Q, Yang M, Guo X, Tong Z, Qi Z, Zhao F, Yan X, Zhao H. S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): A randomised, open-label, multicentre phase 2 trial. eClinicalMedicine 2022;54:101667. [DOI: 10.1016/j.eclinm.2022.101667] [Reference Citation Analysis]
70 Jafari P, Husain AN, Setia N. All Together Now. Surgical Pathology Clinics 2022. [DOI: 10.1016/j.path.2022.09.012] [Reference Citation Analysis]
71 Yin GS, Phillips T. Rare Primary Neuroendocrine Tumor of the Submandibular Gland: a Literature Review and Case Report. SN Compr Clin Med 2022;4:153. [DOI: 10.1007/s42399-022-01226-w] [Reference Citation Analysis]
72 Ye Z, Chen H, Ji S, Hu Y, Lou X, Zhang W, Jing D, Fan G, Zhang Y, Chen X, Zhuo Q, Chen J, Xu X, Yu X, Xu J, Qin Y, Gao H. MEN1 promotes ferroptosis by inhibiting mTOR-SCD1 axis in pancreatic neuroendocrine tumors. Acta Biochim Biophys Sin (Shanghai) 2022;54:1599-609. [PMID: 36604142 DOI: 10.3724/abbs.2022162] [Reference Citation Analysis]
73 Chan DL, Hayes AR, Karfis I, Conner A, Furtado O’mahony L, Mileva M, Bernard E, Roach P, Marin G, Pavlakis N, Schembri G, Gnanasegaran G, Marin C, Vanderlinden B, Navalkissoor S, Caplin ME, Flamen P, Toumpanakis C, Bailey DL. Dual [68Ga]DOTATATE and [18F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score. Br J Cancer 2022. [DOI: 10.1038/s41416-022-02061-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Blázquez-encinas R, Moreno-montilla MT, García-vioque V, Gracia-navarro F, Alors-pérez E, Pedraza-arevalo S, Ibáñez-costa A, Castaño JP. The uprise of RNA biology in neuroendocrine neoplasms: altered splicing and RNA species unveil translational opportunities. Rev Endocr Metab Disord 2022. [DOI: 10.1007/s11154-022-09771-4] [Reference Citation Analysis]
75 Li Y, Fan Z, Zhang F, Yang J, Shi M, Liu S, Meng Y, Zhan H. Neoadjuvant therapy in pancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. Front Oncol 2022;12:981575. [PMID: 36505835 DOI: 10.3389/fonc.2022.981575] [Reference Citation Analysis]
76 Partelli S, Massironi S, Zerbi A, Niccoli P, Kwon W, Landoni L, Panzuto F, Tomazic A, Bongiovanni A, Kaltsas G, Sauvanet A, Bertani E, Mazzaferro V, Caplin M, Armstrong T, Weickert MO, Ramage J, Segelov E, Butturini G, Staettner S, Cives M, Frilling A, Moulton CA, He J, Boesch F, Selberheer A, Twito O, Castaldi A, De Angelis CG, Gaujoux S, Holzer K, Wilson CH, Almeamar H, Vigia E, Muffatti F, Lucà M, Lania A, Ewald J, Kim H, Salvia R, Rinzivillo M, Smid A, Gardini A, Tsoli M, Hentic O, Colombo S, Citterio D, Toumpanakis C, Ramsey E, Randeva HS, Srirajaskanthan R, Croagh D, Regi P, Gasteiger S, Invernizzi P, Ridolfi C, Giovannini M, Jang JY, Bassi C, Falconi M. Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial. Br J Surg 2022;109:1186-90. [PMID: 35986682 DOI: 10.1093/bjs/znac267] [Reference Citation Analysis]
77 Lan X, Fazio N, Abdel-rahman O. Exploring the Relationship between Obesity, Metabolic Syndrome and Neuroendocrine Neoplasms. Metabolites 2022;12:1150. [DOI: 10.3390/metabo12111150] [Reference Citation Analysis]
78 Mohamed A, Azmi AS, Asa SL, Tirumani SH, Mahipal A, Cjakrabarti S, Bajor D, Selfridge JE, Kaseb AO. Thymoquinone Plus Immunotherapy in Extra-Pulmonary Neuroendocrine Carcinoma: Case Series for a Novel Combination. Curr Oncol 2022;29:9018-30. [PMID: 36421360 DOI: 10.3390/curroncol29110707] [Reference Citation Analysis]
79 Abe K, Kitago M, Iwasaki E, Yagi H, Abe Y, Hasegawa Y, Hori S, Tanaka M, Nakano Y, Kitagawa Y. Reconsideration of operative indications in pancreatic neuroendocrine neoplasms. World J Surg Onc 2022;20:366. [DOI: 10.1186/s12957-022-02834-5] [Reference Citation Analysis]
80 Prosperi D, Gentiloni Silveri G, Panzuto F, Faggiano A, Russo VM, Caruso D, Polici M, Lauri C, Filice A, Laghi A, Signore A. Nuclear Medicine and Radiological Imaging of Pancreatic Neuroendocrine Neoplasms: A Multidisciplinary Update. J Clin Med 2022;11. [PMID: 36431313 DOI: 10.3390/jcm11226836] [Reference Citation Analysis]
81 Исянгулова АЗ, Гордиев МГ. Молекулярный профиль нейроэндокринных опухолей. Zlokač opuholi 2022;12:9-16. [DOI: 10.18027/2224-5057-2022-12-3s1-9-16] [Reference Citation Analysis]
82 Sedlack AJH, Saleh-Anaraki K, Kumar S, Ear PH, Lines KE, Roper N, Pacak K, Bergsland E, Quelle DE, Howe JR, Pommier Y, Del Rivero J. Preclinical Models of Neuroendocrine Neoplasia. Cancers (Basel) 2022;14. [PMID: 36428741 DOI: 10.3390/cancers14225646] [Reference Citation Analysis]
83 Zhang R, Guo Y, Wang Y, Hu L, Fang C, Yang Y, Yang X, Chen L, Chen J, Wang W, Sun X. Novel staging for gastric neuroendocrine neoplasms by incorporating the WHO grading into the TNM staging system. Cancer Medicine 2022. [DOI: 10.1002/cam4.5437] [Reference Citation Analysis]
84 Song L, Cao Y, Li J, Lu M, Tang L. Psychological distress and resilience in patients with gastroenteropancreatic neuroendocrine tumor. Front Endocrinol (Lausanne) 2022;13:947998. [PMID: 36465662 DOI: 10.3389/fendo.2022.947998] [Reference Citation Analysis]
85 Nakano S, Minaga K, Tani Y, Tonomura K, Hanawa Y, Morimura H, Terashita T, Matsumoto H, Iwagami H, Nakatani Y, Akamatsu T, Uenoyama Y, Maeda C, Ono K, Watanabe T, Yamashita Y. Primary Hepatic Neuroendocrine Carcinoma with Thrombocytopenia Due to Diffuse Bone Marrow and Splenic Infiltration: An Autopsy Case. Intern Med 2022;61:3361-8. [PMID: 35400708 DOI: 10.2169/internalmedicine.9465-22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Sun D, Ren Z, Xu E, Cai S, Qi Z, Chen Z, Liu J, Shi Q, Zhou P, Zhong Y. Long-term clinical outcomes of endoscopic submucosal dissection in rectal neuroendocrine tumors based on resection margin status: a real-world study. Surg Endosc 2022. [DOI: 10.1007/s00464-022-09710-z] [Reference Citation Analysis]
87 Tong H, Wang M, Liu J, Guo C, Wang Z, Wang J, Chen X. Bone Loss in Patients with Pancreatic Neuroendocrine Tumors. J Clin Med 2022;11. [PMID: 36431178 DOI: 10.3390/jcm11226701] [Reference Citation Analysis]
88 Lysanyuk MV, Romashchenko PN, Maistrenko NA. Modern opportunities and problematic aspects of diagnostics and treatment of patients with neuroendocrine tumors. Perm Medical Journal 2022;39:58-68. [DOI: 10.17816/pmj39558-68] [Reference Citation Analysis]
89 Liang W, Xu X, Liu Y, Cui J, Gao Y, Wang C, Zhuang Z, Zhang K, Xi H, Cai A, Wei B, Chen L. Defining the impact of platelet-to-lymphocyte ratio on patient survival with gastric neuroendocrine neoplasm: a retrospective cohort analysis. World J Surg Onc 2022;20:356. [DOI: 10.1186/s12957-022-02822-9] [Reference Citation Analysis]
90 Gulde S, Foscarini A, April-Monn SL, Genio E, Marangelo A, Satam S, Helbling D, Falconi M, Toledo RA, Schrader J, Perren A, Marinoni I, Pellegata NS. Combined Targeting of Pathogenetic Mechanisms in Pancreatic Neuroendocrine Tumors Elicits Synergistic Antitumor Effects. Cancers (Basel) 2022;14. [PMID: 36428573 DOI: 10.3390/cancers14225481] [Reference Citation Analysis]
91 Gebauer N, Ziehm M, Gebauer J, Riecke A, Meyhöfer S, Kulemann B, von Bubnoff N, Steinestel K, Bauer A, Witte HM. The Glasgow Prognostic Score Predicts Survival Outcomes in Neuroendocrine Neoplasms of the Gastro–Entero–Pancreatic (GEP-NEN) System. Cancers 2022;14:5465. [DOI: 10.3390/cancers14215465] [Reference Citation Analysis]
92 Chang T, Chu P, Lin H, Huang K, Hung W, Shan Y, Chen L, Tsai H. PTEN regulates invasiveness in pancreatic neuroendocrine tumors through DUSP19-mediated VEGFR3 dephosphorylation. J Biomed Sci 2022;29:92. [DOI: 10.1186/s12929-022-00875-2] [Reference Citation Analysis]
93 Jacenik D, Lebish EJ, Beswick EJ. MK2 Promotes the Development and Progression of Pancreatic Neuroendocrine Tumors Mediated by Macrophages and Metabolomic Factors. IJMS 2022;23:13561. [DOI: 10.3390/ijms232113561] [Reference Citation Analysis]
94 Modica R, La Salvia A, Liccardi A, Cannavale G, Minotta R, Benevento E, Faggiano A, Colao A. Lipid Metabolism and Homeostasis in Patients with Neuroendocrine Neoplasms: From Risk Factor to Potential Therapeutic Target. Metabolites 2022;12:1057. [DOI: 10.3390/metabo12111057] [Reference Citation Analysis]
95 Rösner E, Kaemmerer D, Sänger J, Lupp A. Evaluation of PD-L1 expression in a large set of gastroenteropancreatic neuroendocrine tumours and correlation with clinicopathological data. Transl Oncol 2022;25:101526. [PMID: 36067541 DOI: 10.1016/j.tranon.2022.101526] [Reference Citation Analysis]
96 Greenberg JA, Ivanov NA, Egan CE, Lee YJ, Zarnegar R, Fahey TJ 3rd, Finnerty BM, Min IM. Sex-Based Clinicopathologic and Survival Differences Among Patients with Pancreatic Neuroendocrine Tumors. J Gastrointest Surg 2022;26:2321-9. [PMID: 35915373 DOI: 10.1007/s11605-022-05345-6] [Reference Citation Analysis]
97 Maruska B, Razzak AN, Zepeda JL, Novotny J, Jha P. Presentation of Lung Carcinoid Tumor as Post-obstructive Pneumonia. Cureus 2022;14:e31859. [PMID: 36579277 DOI: 10.7759/cureus.31859] [Reference Citation Analysis]
98 Thompson O, Hall L, Roberts K, Bradley E, Powell-Brett S, Pande R, Shah T. Survival benefit of pancreatic enzyme replacement therapy in patients undergoing treatment of pancreatic neuroendocrine tumours. HPB (Oxford) 2022;24:1921-9. [PMID: 35811220 DOI: 10.1016/j.hpb.2022.06.001] [Reference Citation Analysis]
99 Nibhondhratana P, Watcharadetwittaya S, Sa-ngiamwibool P. CD44v6 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms: Clinicopathological Correlation and Prognosis. Pathology - Research and Practice 2022. [DOI: 10.1016/j.prp.2022.154213] [Reference Citation Analysis]
100 Heaphy CM, Singhi AD. The diagnostic and prognostic utility of incorporating DAXX, ATRX, and alternative lengthening of telomeres to the evaluation of pancreatic neuroendocrine tumors. Hum Pathol 2022;129:11-20. [PMID: 35872157 DOI: 10.1016/j.humpath.2022.07.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
101 Harris PE, Zhernosekov K. The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next? Front Endocrinol 2022;13. [DOI: 10.3389/fendo.2022.941832] [Reference Citation Analysis]
102 Kawasaki K, Rekhtman N, Quintanal-villalonga Á, Rudin CM. Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies. Nat Rev Clin Oncol 2022. [DOI: 10.1038/s41571-022-00696-0] [Reference Citation Analysis]
103 Chauhan A, Del Rivero J, Ramirez RA, Soares HP, Li D. Treatment Sequencing Strategies in Advanced Neuroendocrine Tumors: A Review. Cancers 2022;14:5248. [DOI: 10.3390/cancers14215248] [Reference Citation Analysis]
104 Raderer M, Kiesewetter B. The NET G3 enigma: dealing with a “new” entity. memo 2022. [DOI: 10.1007/s12254-022-00848-z] [Reference Citation Analysis]
105 Sebastian-valles F, Sánchez de la Blanca Carrero N, Rodríguez-laval V, Martinez-hernández R, Serrano-somavilla A, Knott-torcal C, Muñoz de Nova JL, Martín-pérez E, Marazuela M, Sampedro-nuñez MA. Impact of Change in Body Composition during Follow-Up on the Survival of GEP-NET. Cancers 2022;14:5189. [DOI: 10.3390/cancers14215189] [Reference Citation Analysis]
106 Vosburgh E. Tumors of the Diffuse Neuroendocrine and Gastroenteropancreatic System. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm083.pub2] [Reference Citation Analysis]
107 Budek M, Nuszkiewicz J, Piórkowska A, Czuczejko J, Szewczyk-Golec K. Inflammation Related to Obesity in the Etiopathogenesis of Gastroenteropancreatic Neuroendocrine Neoplasms. Biomedicines 2022;10:2660. [PMID: 36289922 DOI: 10.3390/biomedicines10102660] [Reference Citation Analysis]
108 Wang Y, Cai H, Zhang Y, Zhuang J, Liu X, Guan G. A modified mTNM staging system based on lymph node ratio for colon neuroendocrine tumors: A recursive partitioning analysis. Front Surg 2022;9:961982. [PMID: 36338645 DOI: 10.3389/fsurg.2022.961982] [Reference Citation Analysis]
109 Yamamoto S, Sakakibara N, Hirano H, Morizane C, Honma Y, Hijioka S, Okusaka T, Higashi T, Kawai A. The real-world selection of first-line systemic therapy regimen for metastatic gastroenteropancreatic neuroendocrine neoplasm in Japan. Sci Rep 2022;12:17601. [PMID: 36266484 DOI: 10.1038/s41598-022-22718-8] [Reference Citation Analysis]
110 Shotwell MK, Alyami BA, Sankaramangalam K, Alharbi A, Patel B. Cardiac Metastasis of Neuroendocrine Tumor Without Cardiovascular Symptoms. JACC Case Rep 2022;4:1357-9. [PMID: 36299651 DOI: 10.1016/j.jaccas.2022.08.039] [Reference Citation Analysis]
111 Ngongoni R, Visser B. Surgery, Liver Directed Therapy and Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumor Liver Metastases. Cancers 2022;14:5103. [DOI: 10.3390/cancers14205103] [Reference Citation Analysis]
112 Ingenerf M, Kiesl S, Winkelmann M, Auernhammer CJ, Rübenthaler J, Grawe F, Fabritius MP, Ricke J, Schmid-tannwald C. Treatment Assessment of pNET and NELM after Everolimus by Quantitative MRI Parameters. Biomedicines 2022;10:2618. [DOI: 10.3390/biomedicines10102618] [Reference Citation Analysis]
113 Yagi K, Ono H, Kudo A, Kinowaki Y, Asano D, Watanabe S, Ishikawa Y, Ueda H, Akahoshi K, Tanaka S, Tanabe M. Inactivation of MGMT is Associated With the Efficacy of Streptozocin and High-grade Pancreatic Neuroendocrine Neoplasms.. [DOI: 10.21203/rs.3.rs-2161835/v1] [Reference Citation Analysis]
114 Li D, Darden C, Osman N, Sayeed S, Jackson L, Garbinsky D, Chauhan A. Real-World Clinical and Patient-Reported Outcomes from the Longitudinal Telotristat Ethyl Treatment Registry of Patients with Neuroendocrine Tumors. Cancer Manag Res 2022;14:3009-20. [PMID: 36262750 DOI: 10.2147/CMAR.S386419] [Reference Citation Analysis]
115 Yahyazadeh H, Beheshti M, Tahbaz SV. Gastrointestinal Neuroendocrine Tumours: A Single-Centre Experience. Forum of Clinical Oncology 2022;0. [DOI: 10.2478/fco-2022-0004] [Reference Citation Analysis]
116 Castle JT, Levy BE, Chauhan A. Pediatric Neuroendocrine Neoplasms: Rare Malignancies with Incredible Variability. Cancers (Basel) 2022;14:5049. [PMID: 36291833 DOI: 10.3390/cancers14205049] [Reference Citation Analysis]
117 Guo N, Liang Z, Xiong LJ. Clinicopathological characteristics, survival outcomes and prognostic factors in the cT1N0M0 pancreatic neuroendocrine tumors: A SEER-based study. Medicine 2022;101:e31019. [DOI: 10.1097/md.0000000000031019] [Reference Citation Analysis]
118 Huang XT, Xie JZ, Cai JP, Fang P, Huang CS, Chen W, Liang LJ, Yin XY. Values of spleen-preserving distal pancreatectomy in well-differentiated non-functioning pancreatic neuroendocrine tumors: a comparative study. Gastroenterol Rep (Oxf) 2022;10:goac056. [PMID: 36263393 DOI: 10.1093/gastro/goac056] [Reference Citation Analysis]
119 Mahmoudi L, Fallah R, Roshanaei G, Asghari-Jafarabadi M. A bayesian approach to model the underlying predictors of early recurrence and postoperative death in patients with colorectal Cancer. BMC Med Res Methodol 2022;22:269. [PMID: 36224555 DOI: 10.1186/s12874-022-01746-y] [Reference Citation Analysis]
120 Saoudi González N, Castet F, Élez E, Macarulla T, Tabernero J. Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers. Front Oncol 2022;12:1021772. [DOI: 10.3389/fonc.2022.1021772] [Reference Citation Analysis]
121 La Salvia A, Carletti R, Verrico M, Feola T, Puliani G, Bassi M, Sesti F, Pernazza A, Mazzilli R, Lamberti G, Siciliani A, Mancini M, Manai C, Venuta F, Ibrahim M, Tomao S, D'Amati G, Di Gioia C, Giannetta E, Cappuzzo F, Faggiano A. Angioside: The role of Angiogenesis and Hypoxia in Lung Neuroendocrine Tumours According to Primary Tumour Location in Left or Right Parenchyma. J Clin Med 2022;11:5958. [PMID: 36233825 DOI: 10.3390/jcm11195958] [Reference Citation Analysis]
122 Lelièvre M, Triumbari EKA, Brixi H, Perrier M, Cadiot G, Deguelte S, Morland D. Bone metastases in midgut neuroendocrine tumors: imaging characteristics, distribution, and risk factors. Endocrine 2022. [PMID: 36203032 DOI: 10.1007/s12020-022-03160-2] [Reference Citation Analysis]
123 Hu HF, Li Z, Chen K, Liu MQ, Ye Z, Chen XM, Zhang Y, Yu XJ, Xu XW, Ji SR. Multimodality imaging differentiation of pancreatic neuroendocrine tumors and solid pseudopapillary tumors with a nomogram model: A large single-center study. Front Surg 2022;9:970178. [PMID: 36277293 DOI: 10.3389/fsurg.2022.970178] [Reference Citation Analysis]
124 Menon N, Mandelkern M. Utility of PET Scans in the Diagnosis and Management of Gastrointestinal Tumors. Dig Dis Sci 2022;67:4633-53. [PMID: 35908126 DOI: 10.1007/s10620-022-07616-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
125 Saied AA, Shroyer MN, Taylor JM, Midkiff CC. Functional Insulinomas in a Rhesus Macaque (Macaca mulatta). Journal of Comparative Pathology 2022;198:1-5. [DOI: 10.1016/j.jcpa.2022.07.003] [Reference Citation Analysis]
126 Scheufele F, Friess H. Diagnostik und Therapie neuroendokriner Tumoren des Pankreas. Gastro-News 2022;9:34-39. [DOI: 10.1007/s15036-022-3115-9] [Reference Citation Analysis]
127 El Bakouri A, El wassi A, Eddaoudi Y, Bouali M, El Hattabi K, Bensardi F, Fadil A. Fortuitous discovery of an early neuroendocrine tumor during appendicular peritonitis. Annals of Medicine and Surgery 2022;82:104735. [DOI: 10.1016/j.amsu.2022.104735] [Reference Citation Analysis]
128 Hubbard JA, Wolfe RC. Management of Carcinoid Syndrome and Carcinoid Crisis in the Perioperative Environment. Journal of PeriAnesthesia Nursing 2022. [DOI: 10.1016/j.jopan.2022.08.016] [Reference Citation Analysis]
129 Deniz GI, Akyel R, Akgun E, Taskın OC, Kapran Y. Neuroendocrine Tumor of Tailgut Cyst with Unexpected Metastases. Nucl Med Mol Imaging. [DOI: 10.1007/s13139-022-00775-1] [Reference Citation Analysis]
130 Mitra S, Sekar A, Khosla D, Gupta V, Vaiphei K. Immunohistochemistry based molecular subtyping of pancreatic neuroendocrine tumor correlates with clinicopathological outcome: A single institute retrospective study.. [DOI: 10.21203/rs.3.rs-2088495/v1] [Reference Citation Analysis]
131 Chen J, Liu Y, Xu K, Ren F, Li B, Sun H. Establishment and validation of a clinicopathological prognosis model of gastroenteropancreatic neuroendocrine carcinomas. Front Oncol 2022;12:999012. [DOI: 10.3389/fonc.2022.999012] [Reference Citation Analysis]
132 Wang S, Wei J, Guo Y, Xu Q, Lv X, Yu Y, Liu M. Construction and validation of nomograms based on the log odds of positive lymph nodes to predict the prognosis of lung neuroendocrine tumors. Front Immunol 2022;13:987881. [DOI: 10.3389/fimmu.2022.987881] [Reference Citation Analysis]
133 Mohindroo C, McAllister F, De Jesus-Acosta A. Genetics of Pancreatic Neuroendocrine Tumors. Hematol Oncol Clin North Am 2022:S0889-8588(22)00073-9. [PMID: 36154786 DOI: 10.1016/j.hoc.2022.07.005] [Reference Citation Analysis]
134 Paulson S, Ray D, Aranha S, Scales A, Wang Y, Liu E. Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology Setting: A Prospective, Observational Study. Oncol Ther 2022. [PMID: 36136274 DOI: 10.1007/s40487-022-00208-1] [Reference Citation Analysis]
135 Komarnicki P, Musiałkiewicz J, Stańska A, Maciejewski A, Gut P, Mastorakos G, Ruchała M. Circulating Neuroendocrine Tumor Biomarkers: Past, Present and Future. JCM 2022;11:5542. [DOI: 10.3390/jcm11195542] [Reference Citation Analysis]
136 Pozas J, Alonso-Gordoa T, Román MS, Santoni M, Thirlwell C, Grande E, Molina-Cerrillo J. Novel therapeutic approaches in GEP-NETs based on genetic and epigenetic alterations. Biochim Biophys Acta Rev Cancer 2022;1877:188804. [PMID: 36152904 DOI: 10.1016/j.bbcan.2022.188804] [Reference Citation Analysis]
137 Kurzyńska A, Pach D, Skalniak AE, Stefańska A, Opalińska M, Przybylik-mazurek E, Hubalewska-dydejczyk A. Prevalence of Selected Single-Nucleotide Variants in Patients with Neuroendocrine Tumors—Potential Clinical Relevance. JCM 2022;11:5536. [DOI: 10.3390/jcm11195536] [Reference Citation Analysis]
138 Nosov NA, Popov SA, Rozengauz EV, Stanzhevskii AA, Mus VF, Maystrenko DN. <sup>68</sup>Ga-DOTATATE PET/CT Capabilities in Diagnosing of Neuroendocrine Tumors Recurrence. jour 2022;5:18-28. [DOI: 10.37174/2587-7593-2022-5-3-18-28] [Reference Citation Analysis]
139 Mandair D, Kamieniarz L, Pizanias M, Weickert MO, Narayan A, O'Mahony LF, Caplin M, Ramage J, Prachalias A, Srirajaskanthan R, Toumpanakis C. Diagnostic features and management options for duodenal neuroendocrine neoplasms: a retrospective, multi-centre study. Sci Rep 2022;12:15762. [PMID: 36130981 DOI: 10.1038/s41598-022-19738-9] [Reference Citation Analysis]
140 Gonzáles-Yovera JG, Roseboom PJ, Concepción-Zavaleta M, Gutiérrez-Córdova I, Plasencia-Dueñas E, Quispe-Flores M, Ramos-Yataco A, Alcalde-Loyola C, Massucco-Revoredo F, Paz-Ibarra J, Concepción-Urteaga L. Diagnosis and management of small bowel neuroendocrine tumors: A state-of-the-art. World J Methodol 2022; 12(5): 381-391 [DOI: 10.5662/wjm.v12.i5.381] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Li X, Ma Q, Chang C, Li H, Cao D. First-line treatment of camrelizumab combined with chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma: Study protocol for a prospective, multicenter, phase II study. Front Oncol 2022;12:958905. [DOI: 10.3389/fonc.2022.958905] [Reference Citation Analysis]
142 Romero Serrano SA, Baez Ariza EA, Pardo Gonzalez SY, Martínez Martínez S. Presentación polipoide de un tumor neuroendocrino: reporte de caso y revisión de la literatura. Rev colomb Gastroenterol 2022;37:325-329. [DOI: 10.22516/25007440.813] [Reference Citation Analysis]
143 Iabichino G, Di Leo M, Arena M, Rubis Passoni GG, Morandi E, Turpini F, Viaggi P, Luigiano C, De Luca L. Diagnosis, treatment, and current concepts in the endoscopic management of gastroenteropancreatic neuroendocrine neoplasms. World J Gastroenterol 2022; 28(34): 4943-4958 [DOI: 10.3748/wjg.v28.i34.4943] [Reference Citation Analysis]
144 Ciobanu OA, Martin SC, Herlea V, Fica S. Insights into Epigenetic Changes Related to Genetic Variants and Cells-of-Origin of Pancreatic Neuroendocrine Tumors: An Algorithm for Practical Workup. Cancers 2022;14:4444. [DOI: 10.3390/cancers14184444] [Reference Citation Analysis]
145 Muscogiuri G, Barrea L, Cantone MC, Guarnotta V, Mazzilli R, Verde L, Vetrani C, Colao A, Faggiano A; NIKE. Neuroendocrine Tumors: A Comprehensive Review on Nutritional Approaches. Cancers (Basel) 2022;14:4402. [PMID: 36139562 DOI: 10.3390/cancers14184402] [Reference Citation Analysis]
146 Fu M, Yu L, Yang L, Chen Y, Chen X, Hu Q, Sun H. Predictive value of the preoperative prognostic nutritional index for postoperative progression in patients with pancreatic neuroendocrine neoplasms. Front Nutr 2022;9. [DOI: 10.3389/fnut.2022.945833] [Reference Citation Analysis]
147 Rosery V, Mika S, Schmid KW, Reis H, Stuschke M, Treckmann J, Markus P, Schumacher B, Albers D, Mende B, Lahner H, Wiesweg M, Schuler M, Siveke JT, Kasper S. Identification of a new prognostic score for patients with high-grade metastatic GEP-NEN treated with palliative chemotherapy. J Cancer Res Clin Oncol 2022. [PMID: 36071236 DOI: 10.1007/s00432-022-04314-5] [Reference Citation Analysis]
148 Lepage C, Phelip JM, Lievre A, Le-Malicot K, Dahan L, Tougeron D, Toumpanakis C, Di-Fiore F, Lombard-Bohas C, Borbath I, Coriat R, Lecomte T, Guimbaud R, Petorin C, Legoux JL, Michel P, Scoazec JY, Smith D, Walter T. Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study. Eur J Cancer 2022;175:31-40. [PMID: 36087395 DOI: 10.1016/j.ejca.2022.07.033] [Reference Citation Analysis]
149 Pritchard DM. New Mouse Model Suggests That Some Neuroendocrine Tumors May Originate From Neural Crest-Derived Cells. Cell Mol Gastroenterol Hepatol 2022;14:1170-1. [PMID: 36084750 DOI: 10.1016/j.jcmgh.2022.08.005] [Reference Citation Analysis]
150 Sandra I, Cazacu IM, Croitoru VM, Mihaila M, Herlea V, Diculescu MM, Dima SO, Croitoru AE. Circulating Angiogenic Markers in Gastroenteropancreatic Neuroendocrine Neoplasms: A Systematic Review. CIMB 2022;44:4001-4014. [DOI: 10.3390/cimb44090274] [Reference Citation Analysis]
151 Xu M, Yan J, Hu B, Wu C, Gu H, Qi Z, Chen T, Yang W, Zheng Y, Dong H, Sheng W, Long J. Evolutionary Trajectories of Primary and Metastatic Pancreatic Neuroendocrine Tumors Based on Genomic Variations. Genes (Basel) 2022;13:1588. [PMID: 36140756 DOI: 10.3390/genes13091588] [Reference Citation Analysis]
152 Evans LM, Geenen KR, O'Shea A, Hedgire SS, Ferrone CR, Thiele EA. Tuberous sclerosis complex-associated nonfunctional pancreatic neuroendocrine tumors: Management and surgical outcomes. Am J Med Genet A 2022;188:2666-71. [PMID: 35612824 DOI: 10.1002/ajmg.a.62850] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
153 Saleh M, Bhosale PR, Yano M, Itani M, Elsayes AK, Halperin D, Bergsland EK, Morani AC. New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms. Abdom Radiol (NY) 2022;47:3078-100. [PMID: 33095312 DOI: 10.1007/s00261-020-02833-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
154 Xu R, Jiao D, Long Q, Li X, Shan K, Kong X, Ou H, Ding D, Tang Q. Highly bright aggregation-induced emission nanodots for precise photoacoustic/NIR-II fluorescence imaging-guided resection of neuroendocrine neoplasms and sentinel lymph nodes. Biomaterials 2022. [DOI: 10.1016/j.biomaterials.2022.121780] [Reference Citation Analysis]
155 Szidonya L, Park EA, Kwak JJ, Mallak N. Molecular and Anatomic Imaging of Neuroendocrine Tumors. Surgical Oncology Clinics of North America 2022. [DOI: 10.1016/j.soc.2022.06.009] [Reference Citation Analysis]
156 Hemminki K, Försti A, Hemminki O, Liska V, Hemminki A. Long-term survival trends for primary liver and pancreatic cancers in the Nordic countries. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100602] [Reference Citation Analysis]
157 Chang D, González APG, Migaly J. Management of neuroendocrine tumors of the rectum. Seminars in Colon and Rectal Surgery 2022;33:100901. [DOI: 10.1016/j.scrs.2022.100901] [Reference Citation Analysis]
158 Raj N, Cruz E, O'shaughnessy S, Calderon C, Chou JF, Capanu M, Heffernan O, Demore A, Punn S, Le T, Hauser H, Saltz L, Reidy-lagunes D. A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors. JCO Oncology Practice 2022;18:e1533-e1541. [DOI: 10.1200/op.22.00055] [Reference Citation Analysis]
159 Weniger M, Werner J. Seltene chirurgische Tumoren im biliopankreatoduodenalen Bereich. Onkologie up2date 2022;04:237-253. [DOI: 10.1055/a-1841-4757] [Reference Citation Analysis]
160 Ehms B, Kaemmerer D, Sänger J, Schulz S, Lupp A. Reassessment of somatostatin receptor SST4 expression in bronchopulmonary and gastroenteropancreatic neuroendocrine neoplasms using the novel rabbit monoclonal anti-human SST4 antibody 7H49L61. Sci Rep 2022;12:14722. [PMID: 36042228 DOI: 10.1038/s41598-022-19014-w] [Reference Citation Analysis]
161 Corbett V, Hallenbeck P, Rychahou P, Chauhan A. Evolving role of seneca valley virus and its biomarker TEM8/ANTXR1 in cancer therapeutics. Front Mol Biosci 2022;9:930207. [DOI: 10.3389/fmolb.2022.930207] [Reference Citation Analysis]
162 Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, Hann CL, Ibrahim T, Byers LA, Sasano H, Umejiego J, Pavel M. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. Oncologist 2022;27:940-51. [PMID: 35983951 DOI: 10.1093/oncolo/oyac161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
163 Fanciulli G, Modica R, La Salvia A, Campolo F, Florio T, Mikovic N, Plebani A, Di Vito V, Colao A, Faggiano A. Immunotherapy of Neuroendocrine Neoplasms: Any Role for the Chimeric Antigen Receptor T Cells? Cancers 2022;14:3991. [DOI: 10.3390/cancers14163991] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
164 Escobar KM, Vicente-villardon JL, Villacís Gonzalez RE, Castillo Cordova PH, Sánchez Rodríguez JM, De la Cruz-velez M, Siteneski A. Neuroendocrine Tumors: An Analysis of Prevalence, Incidence, and Survival in a Hospital-Based Study in Ecuador. Healthcare 2022;10:1569. [DOI: 10.3390/healthcare10081569] [Reference Citation Analysis]
165 Lauricella E, Mandriani B, Cavallo F, Pezzicoli G, Chaoul N, Porta C, Cives M. Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications. Front Oncol 2022;12:957068. [DOI: 10.3389/fonc.2022.957068] [Reference Citation Analysis]
166 Zhang W, Gao H, Liu W, Qin Y, Ye Z, Lou X, Wang F, Zhang Y, Chen X, Chen J, Yu X, Zhuo Q, Xu X, Ji S. A real-life treatment cohort of pancreatic neuroendocrine tumors: High-grade increase in metastases confers poor survival. Front Endocrinol 2022;13:941210. [DOI: 10.3389/fendo.2022.941210] [Reference Citation Analysis]
167 Agarwal P, Mohamed A. Systemic Therapy of Advanced Well-differentiated Small Bowel Neuroendocrine Tumors Progressive on Somatostatin Analogues. Curr Treat Options Oncol 2022. [PMID: 35939200 DOI: 10.1007/s11864-022-00998-6] [Reference Citation Analysis]
168 Fu M, Yu L, Yang L, Chen Y, Chen X, Hu Q, Sun H. Gender differences in pancreatic neuroendocrine neoplasms: A retrospective study based on the population of Hubei Province, China. Front Endocrinol 2022;13:885895. [DOI: 10.3389/fendo.2022.885895] [Reference Citation Analysis]
169 Jia J, Zeng X, Li C, Yang L, Huang Y, Tong X, Jiang Q, Zhang P, Tao K. A Combination of Preoperative Computed Tomography-Defined Sarcopenia and Systemic Inflammation on Survival in Patients with Poorly Differentiated Neuroendocrine Neoplasms Following Radical Resection. Nutr Cancer 2023;75:186-96. [PMID: 35920394 DOI: 10.1080/01635581.2022.2102660] [Reference Citation Analysis]
170 Chiti G, Grazzini G, Flammia F, Matteuzzi B, Tortoli P, Bettarini S, Pasqualini E, Granata V, Busoni S, Messserini L, Pradella S, Massi D, Miele V. Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a radiomic model to predict tumor grade. Radiol med 2022;127:928-938. [DOI: 10.1007/s11547-022-01529-x] [Reference Citation Analysis]
171 Lewandowski RJ, Toskich BB, Brown DB, El-Haddad G, Padia SA. Role of Radioembolization in Metastatic Neuroendocrine Tumors. Cardiovasc Intervent Radiol 2022. [PMID: 35918431 DOI: 10.1007/s00270-022-03206-y] [Reference Citation Analysis]
172 de Jorge Huerta L, Solares Fernández I, Sánchez-Moreno B, Males Maldonado D, de Ibarrola Andrés C, Díaz-Simón R. Sporadic, non-functional, gastrin-producing duodenal neuroendocrine tumors: A retrospective study of an infrequent disease. J Dig Dis 2022;23:455-61. [PMID: 36168962 DOI: 10.1111/1751-2980.13129] [Reference Citation Analysis]
173 Wheless M, Das S. Systemic Therapy for Pancreatic Neuroendocrine Tumors. Clinical Colorectal Cancer 2022. [DOI: 10.1016/j.clcc.2022.08.003] [Reference Citation Analysis]
174 Ramim JE, Matheos de Lima BA, Bulzico DA, Pujatti PB, Bergmann A. Prospective Cohort Real-World Study on Neuroendocrine Tumor Patient's Quality of Life During Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE. Pancreas 2022;51:784-9. [PMID: 36395404 DOI: 10.1097/MPA.0000000000002101] [Reference Citation Analysis]
175 Zheng J, Pulvirenti A, Javed AA, Michelakos T, Paniccia A, Lee KK, Ferrone CR, Wei AC, He J, Zureikat AH; additional members of the Pancreatic Neuroendocrine Disease Alliance (PANDA). Minimally Invasive vs Open Pancreatectomy for Pancreatic Neuroendocrine Tumors: Multi-Institutional 10-Year Experience of 1,023 Patients. J Am Coll Surg 2022;235:315-30. [PMID: 35839409 DOI: 10.1097/XCS.0000000000000257] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
176 Guo Y, Zhang L, Zhang N, Chen L, Luo Q, Liu M, Yang D, Chen J. Bcl-2 and Noxa are potential prognostic indicators for patients with gastroenteropancreatic neuroendocrine neoplasms. Endocrine 2022. [PMID: 35895181 DOI: 10.1007/s12020-022-03114-8] [Reference Citation Analysis]
177 Tan Q, Wang X, Li Y, Liu Y, Liu X, Ke N. Prognostic Factors of Small Non-Functional Pancreatic Neuroendocrine Tumors and the Risk of Lymph Node Metastasis: A Population-Level Study. Front Endocrinol (Lausanne) 2022;13:907415. [PMID: 35873006 DOI: 10.3389/fendo.2022.907415] [Reference Citation Analysis]
178 Lamberti G, La Salvia A. Neuroendocrine Tumors: Challenges and Future Perspectives. JCM 2022;11:4351. [DOI: 10.3390/jcm11154351] [Reference Citation Analysis]
179 Osama MA, Mathayoth M, Agarwal S, Chatterjee P. Cystic Pancreatic Neuroendocrine Tumor: A Diagnostic Dilemma. J Lab Physicians. [DOI: 10.1055/s-0042-1750079] [Reference Citation Analysis]
180 Karlafti E, Charalampidou M, Fotiadou G, Abba Deka I, Raptou G, Kyriakidis F, Panidis S, Ioannidis A, Protopapas AA, Netta S, Paramythiotis D. Ampullary Large-Cell Neuroendocrine Carcinoma, a Diagnostic Challenge of a Rare Aggressive Neoplasm: A Case Report and Literature Review. Diagnostics 2022;12:1797. [DOI: 10.3390/diagnostics12081797] [Reference Citation Analysis]
181 Bartsch DK, Windel S, Kanngießer V, Jesinghaus M, Holzer K, Rinke A, Maurer E. Vessel-Sparing Lymphadenectomy Should Be Performed in Small Intestine Neuroendocrine Neoplasms. Cancers (Basel) 2022;14:3610. [PMID: 35892869 DOI: 10.3390/cancers14153610] [Reference Citation Analysis]
182 Pedraza-Arevalo S, Alors-Pérez E, Blázquez-Encinas R, Herrera-Martínez AD, Jiménez-Vacas JM, Fuentes-Fayos AC, Reyes Ó, Ventura S, Sánchez-Sánchez R, Ortega-Salas R, Serrano-Blanch R, Gálvez-Moreno MA, Gahete MD, Ibáñez-Costa A, Luque RM, Castaño JP. Spliceosomic dysregulation unveils NOVA1 as a candidate actionable therapeutic target in pancreatic neuroendocrine tumors. Transl Res 2022:S1931-5244(22)00170-0. [PMID: 35882361 DOI: 10.1016/j.trsl.2022.07.005] [Reference Citation Analysis]
183 Modica R, Scandurra C, Maldonato NM, Dolce P, Dipietrangelo GG, Centello R, Di Vito V, Giannetta E, Isidori AM, Lenzi A, Faggiano A, Colao A. Health-related quality of life in patients with neuroendocrine neoplasms: a two-wave longitudinal study. J Endocrinol Invest 2022. [PMID: 35867331 DOI: 10.1007/s40618-022-01872-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
184 Bancheno WM, Adidam SR, Melaku MA. Metastatic rectal neuroendocrine carcinoma presenting with treatment-refractory immune thrombocytopenia: A case report and literature review. Medicine (Baltimore) 2022;101:e29616. [PMID: 35866784 DOI: 10.1097/MD.0000000000029616] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
185 Cai Y, Liu Z, Jiang L, Ma D, Zhou Z, Ju H, Zhu Y. Patterns of Lymph Node Metastasis and Optimal Surgical Strategy in Small (≤20 mm) Gastroenteropancreatic Neuroendocrine Tumors. Front Endocrinol 2022;13:871830. [DOI: 10.3389/fendo.2022.871830] [Reference Citation Analysis]
186 Sharma R, Slater S, Evans J, Martinez M, Ward C, Izadi H, Wernig F, Thomas R. ArTisaN trial protocol: a single Centre, open-label, phase II trial of the safety and efficacy of TheraSphere selective internal radiation therapy (SIRT) in the treatment of inoperable metastatic (liver) neuroendocrine neoplasia (NENs). BMC Cancer 2022;22:800. [PMID: 35858849 DOI: 10.1186/s12885-022-09859-9] [Reference Citation Analysis]
187 Cuny T, van Koetsveld PM, Mondielli G, Dogan F, de Herder WW, Barlier A, Hofland LJ. Reciprocal Interactions between Fibroblast and Pancreatic Neuroendocrine Tumor Cells: Putative Impact of the Tumor Microenvironment. Cancers 2022;14:3481. [DOI: 10.3390/cancers14143481] [Reference Citation Analysis]
188 Wang Y, Huang B, Fu Q, Wang J, Ye M, Hu M, Qu K, Liu K, Hu X, Wei S, Sun K, Xiao W, Zhang B, Li H, Li J, Zhang Q, Liang T. Comprehensive Clinical Analysis of Gallbladder Neuroendocrine Neoplasms: A Large-Volume Multicenter Study During One Decade. Ann Surg Oncol 2022. [PMID: 35849293 DOI: 10.1245/s10434-022-12107-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
189 Levy S, Arthur JD, Banks M, Kok NFM, Fenwick SW, Diaz-Nieto R, van Leerdam ME, Cuthbertson DJ, Valk GD, Kuhlmann KFD, Tesselaar MET. Primary Tumor Resection is Associated with Improved Disease-Specific Mortality in Patients with Stage IV Small Intestinal Neuroendocrine Tumors (NETs): A Comparison of Upfront Surgical Resection Versus a Watch and Wait Strategy in Two Specialist NET Centers. Ann Surg Oncol 2022. [PMID: 35842528 DOI: 10.1245/s10434-022-12030-0] [Reference Citation Analysis]
190 Ren SJ, Wang X, Ke NW, Tan QQ, Yang F, Yao WQ, Tan CL, Liu XB. Clinicopathological features and long-term prognosis of purely cystic pancreatic neuroendocrine tumors: A single center experience. Asian J Surg 2022:S1015-9584(22)00975-7. [PMID: 35850904 DOI: 10.1016/j.asjsur.2022.07.029] [Reference Citation Analysis]
191 Rossi RE, Elvevi A, Gallo C, Palermo A, Invernizzi P, Massironi S. Endoscopic techniques for diagnosis and treatment of gastro-entero-pancreatic neuroendocrine neoplasms: Where we are. World J Gastroenterol 2022; 28(26): 3258-3273 [DOI: 10.3748/wjg.v28.i26.3258] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
192 Modica R, Liccardi A, Minotta R, Cannavale G, Benevento E, Colao A. Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives. Expert Rev Endocrinol Metab 2022;:1-15. [PMID: 35822906 DOI: 10.1080/17446651.2022.2099840] [Reference Citation Analysis]
193 Duan S, Sawyer TW, Sontz RA, Wieland BA, Diaz AF, Merchant JL. GFAP-directed Inactivation of Men1 Exploits Glial Cell Plasticity in Favor of Neuroendocrine Reprogramming. Cell Mol Gastroenterol Hepatol 2022;14:1025-51. [PMID: 35835391 DOI: 10.1016/j.jcmgh.2022.06.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
194 Li Z, Ren H, Zhao L, Zhang X, Wang T, Sun C, Niu P, Wang W, Fei H, Guo C, Chen Y, Zhao D. Better Prognosis of Gastric Neuroendocrine Carcinoma Than Gastric Adenocarcinoma among Whites in the United States: A Propensity Score Matching Analysis Based on SEER. Current Oncology 2022;29:4879-4892. [DOI: 10.3390/curroncol29070387] [Reference Citation Analysis]
195 Longo-Muñoz F, Castellano D, Alexandre J, Chawla SP, Fernández C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Moreno V, Sanz-García E, Awada A, Santaballa A, Subbiah V. Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study. Eur J Cancer 2022;172:340-8. [PMID: 35830841 DOI: 10.1016/j.ejca.2022.06.024] [Reference Citation Analysis]
196 Ye J, Wu H, Li J, Liu C. Impact of Surgery on Non-Functional Pancreatic Neuroendocrine Tumors ≤2 cm: Analyses With Propensity Score–Based Inverse Probability of Treatment Weighting. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.890564] [Reference Citation Analysis]
197 Borbon LC, Tran CG, Sherman SK, Ear PH, Chandrasekharan C, Bellizzi AM, Dillon JS, O'Dorisio TM, Howe JR. Is There a Role for Surgical Resection of Grade 3 Neuroendocrine Neoplasms? Ann Surg Oncol 2022. [PMID: 35802214 DOI: 10.1245/s10434-022-12100-3] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
198 Zamponi V, La Salvia A, Tarsitano MG, Mikovic N, Rinzivillo M, Panzuto F, Giannetta E, Faggiano A, Mazzilli R. Effect of Neuroendocrine Neoplasm Treatment on Human Reproductive Health and Sexual Function. J Clin Med 2022;11:3983. [PMID: 35887747 DOI: 10.3390/jcm11143983] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
199 Hasegawa S, Kobayashi N, Wild D, Kaul F, Okubo N, Suzuki A, Kurita Y, Takano S, Nakajima A, Ichikawa Y. Factors Contributing to Tumor Shrinkage after Peptide Receptor Radionuclide Therapy in Patients with Unresectable Neuroendocrine Tumors. Cancers 2022;14:3317. [DOI: 10.3390/cancers14143317] [Reference Citation Analysis]
200 Melone V, Salvati A, Palumbo D, Giurato G, Nassa G, Rizzo F, Palo L, Giordano A, Incoronato M, Vitale M, Mian C, Di Biase I, Cristiano S, Narciso V, Cantile M, Di Mauro A, Tatangelo F, Tafuto S, Modica R, Pivonello C, Salvatore M, Colao A, Weisz A, Tarallo R. Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omics analysis. J Transl Med 2022;20. [DOI: 10.1186/s12967-022-03511-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
201 Poleé IN, Hermans BCM, van der Zwan JM, Bouwense SAW, Dercksen MW, Eskens FALM, Havekes B, Hofland J, Kerkhofs TMA, Klümpen HJ, Latten-Jansen LM, Speel EM, Verburg FA, Walenkamp AME, Geurts SME, de Vos-Geelen J. Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study. Eur J Cancer 2022;172:252-63. [PMID: 35803176 DOI: 10.1016/j.ejca.2022.06.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
202 Martinez EO, Jorns JM, Kong AL, Kijak J, Lee WY, Huang CC, Cortina CS. Primary Breast Neuroendocrine Tumors: An Analysis of the National Cancer Database. Ann Surg Oncol 2022. [PMID: 35789311 DOI: 10.1245/s10434-022-12123-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
203 Léost F, Delpon G, Garcion E, Gestin J, Hatt M, Potiron V, Rbah-vidal L, Supiot S. « Adaptation of the tumour and its ecosystem to radiotherapies: Mechanisms, imaging and therapeutic approaches » XIVe édition du workshop organisé par le réseau « Vectorisation, Imagerie, Radiothérapies » du Cancéropôle Grand-Ouest, 22–25 septembre 2021, Le Bono, France. Bulletin du Cancer 2022. [DOI: 10.1016/j.bulcan.2022.06.005] [Reference Citation Analysis]
204 Nadalin S, Peters M, Königsrainer A. Lebermetastasen neuroendokriner Tumoren. Chirurgie 2022;93:659-666. [DOI: 10.1007/s00104-022-01656-1] [Reference Citation Analysis]
205 Molasy B, Zemła P, Mrowiec S, Grudzińska E, Kuśnierz K. Evaluation of Risk Factors for Distant and Lymph Node Metastasis of Pancreatic Neuroendocrine Tumors. TCRM 2022;Volume 18:745-52. [DOI: 10.2147/tcrm.s361332] [Reference Citation Analysis]
206 Esposito G, Cazzato M, Rinzivillo M, Pilozzi E, Lahner E, Annibale B, Panzuto F. Management of type-I gastric neuroendocrine neoplasms: A 10-years prospective single centre study. Dig Liver Dis 2022;54:890-5. [PMID: 34903498 DOI: 10.1016/j.dld.2021.11.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
207 van Beek DJ, Takkenkamp TJ, Wong-Lun-Hing EM, de Kleine RHJ, Walenkamp AME, Klaase JM, Nijkamp MW, Valk GD, Molenaar IQ, Hagendoorn J, van Santvoort HC, Borel Rinkes IHM, Hoogwater FJH, Vriens MR. Risk factors for complications after surgery for pancreatic neuroendocrine tumors. Surgery 2022;172:127-36. [PMID: 35341591 DOI: 10.1016/j.surg.2022.02.007] [Reference Citation Analysis]
208 Wang M, Cheng S, Zhu L, Xu T, Zhang J, Zhang Y, Ping J, Wang R. Metastasis Prevalence and Survival of Patients with T1-2 Gastric Neuroendocrine Tumor Treated with Endoscopic Therapy and Surgery. Dig Dis Sci 2022;67:3228-38. [PMID: 34272627 DOI: 10.1007/s10620-021-07143-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
209 Yang Z, Liang J, Leng K, Shi G. Survival Benefit of Surgical Resection for Pancreatic Neuroendocrine Tumors With Oligometastatic Liver Metastasis: A Retrospective and Propensity Score-Matching Analysis. Front Oncol 2022;12:903560. [DOI: 10.3389/fonc.2022.903560] [Reference Citation Analysis]
210 Ranallo N, Iamurri AP, Foca F, Liverani C, De Vita A, Mercatali L, Calabrese C, Spadazzi C, Fabbri C, Cavaliere D, Galassi R, Severi S, Sansovini M, Tartaglia A, Pieri F, Crudi L, Bianchini D, Barone D, Martinelli G, Frassineti GL, Ibrahim T, Calabrò L, Berardi R, Bongiovanni A. Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis. Cancers 2022;14:3231. [DOI: 10.3390/cancers14133231] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
211 Rossi RE, Massironi S. The Increasing Incidence of Neuroendocrine Neoplasms Worldwide: Current Knowledge and Open Issues. JCM 2022;11:3794. [DOI: 10.3390/jcm11133794] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
212 Mcguinness MJ, Woodhouse B, Harmston C, Parker K, Kramer N, Findlay M, Print C, Merrie A, Lawrence B. Survival of patients with small bowel neuroendocrine neoplasms in Auckland, Aotearoa New Zealand. ANZ Journal of Surgery. [DOI: 10.1111/ans.17851] [Reference Citation Analysis]
213 Stang A, Wellmann I, Holleczek B, Fell B, Terner S, Lutz MP, Kajüter H. Incidence and relative survival of pancreatic adenocarcinoma and pancreatic neuroendocrine neoplasms in Germany, 2009-2018. An in-depth analysis of two population-based cancer registries. Cancer Epidemiol 2022;79:102204. [PMID: 35777306 DOI: 10.1016/j.canep.2022.102204] [Reference Citation Analysis]
214 Krogh S, Grønbæk H, Knudsen AR, Kissmeyer-nielsen P, Hummelshøj NE, Dam G. Predicting Progression, Recurrence, and Survival in Pancreatic Neuroendocrine Tumors: A Single Center Analysis of 174 Patients. Front Endocrinol 2022;13:925632. [DOI: 10.3389/fendo.2022.925632] [Reference Citation Analysis]
215 Hollebecque A, Salvagni S, Plummer R, Niccoli P, Capdevila J, Curigliano G, Moreno V, de Braud F, de Villambrosia SG, Martin-Romano P, Baudin E, Arias M, de Alvaro J, Parra-Palau JL, Sánchez-Pérez T, Aronchik I, Filvaroff EH, Lamba M, Nikolova Z, de Bono JS. Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies. Cancer 2022. [PMID: 35737639 DOI: 10.1002/cncr.34366] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
216 Zandee WT, Merola E, Poczkaj K, de Mestier L, Klümpen HJ, Geboes K, de Herder WW, Munir A. Evaluation of multidisciplinary team decisions in neuroendocrine neoplasms: Impact of expert centres. Eur J Cancer Care (Engl) 2022;:e13639. [PMID: 35735226 DOI: 10.1111/ecc.13639] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
217 Xu Y, Yan L, Chen T, Hu P, Bai J, Ye T, Long Q, Tang Q. Prognosis of patients with poorly differentiated gastric neuroendocrine neoplasms: a multi-center study in China. Future Oncol 2022. [PMID: 35730464 DOI: 10.2217/fon-2022-0140] [Reference Citation Analysis]
218 Platoff RM, Lou J, Bush K, Zhu C, Spitz E, Gaughan JP, Atabek U, Spitz F, Hong YK. Gastric Neuroendocrine Tumor Treatment and Survival Outcome Depends on Facility Type. Am Surg 2022;:31348221109460. [PMID: 35722860 DOI: 10.1177/00031348221109460] [Reference Citation Analysis]
219 Gopan A, Sen Sarma M, Har B, Singh RK, Agrawal V, Yachha SK. An unusual cause of obstructive jaundice in childhood: Intra-choledochal malignant neuroendocrine tumour. J Paediatr Child Health 2022. [PMID: 35716114 DOI: 10.1111/jpc.16060] [Reference Citation Analysis]
220 Xu A, Suz P, Reljic T, Are AC, Kumar A, Powers B, Strosberg J, Denbo JW, Fleming JB, Anaya DA. Perioperative Carcinoid Crisis: A Systematic Review and Meta-Analysis. Cancers (Basel) 2022;14:2966. [PMID: 35740631 DOI: 10.3390/cancers14122966] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
221 Ban X, Mo S, Lu Z, Jia C, Shao H, Chang X, Mao X, Zhang Y, Pang J, Zhang Y, Yu S, Chen J. Expression and methylation status of MMR and MGMT in well-differentiated pancreatic neuroendocrine tumors and potential clinical applications. Endocrine 2022. [PMID: 35708896 DOI: 10.1007/s12020-022-03102-y] [Reference Citation Analysis]
222 Refardt J, Hofland J, Wild D, Christ E. Molecular Imaging of Neuroendocrine Neoplasms. J Clin Endocrinol Metab 2022;107:e2662-70. [PMID: 35380158 DOI: 10.1210/clinem/dgac207] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
223 Staal FC, Taghavi M, Hong EK, Tissier R, van Treijen M, Heeres BC, van der Zee D, Tesselaar ME, Beets-Tan RG, Maas M. CT-based radiomics to distinguish progressive from stable neuroendocrine liver metastases treated with somatostatin analogues: an explorative study. Acta Radiol 2022;:2841851221106598. [PMID: 35702011 DOI: 10.1177/02841851221106598] [Reference Citation Analysis]
224 Xu S, Ye C, Chen R, Li Q, Ruan J. The Landscape and Clinical Application of the Tumor Microenvironment in Gastroenteropancreatic Neuroendocrine Neoplasms. Cancers (Basel) 2022;14:2911. [PMID: 35740577 DOI: 10.3390/cancers14122911] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
225 Bremer SCB, Bittner G, Elakad O, Dinter H, Gaedcke J, König AO, Amanzada A, Ellenrieder V, Freiherr von Hammerstein-Equord A, Ströbel P, Bohnenberger H. Enhancer of Zeste Homolog 2 (EZH2) Is a Marker of High-Grade Neuroendocrine Neoplasia in Gastroenteropancreatic and Pulmonary Tract and Predicts Poor Prognosis. Cancers (Basel) 2022;14:2828. [PMID: 35740494 DOI: 10.3390/cancers14122828] [Reference Citation Analysis]
226 Fine GC, Covington MF, Koppula BR, Salem AE, Wiggins RH, Hoffman JM, Morton KA. PET-CT in Clinical Adult Oncology-VI. Primary Cutaneous Cancer, Sarcomas and Neuroendocrine Tumors. Cancers (Basel) 2022;14:2835. [PMID: 35740501 DOI: 10.3390/cancers14122835] [Reference Citation Analysis]
227 Crabtree JS. Epigenetic Regulation in Gastroenteropancreatic Neuroendocrine Tumors. Front Oncol 2022;12:901435. [DOI: 10.3389/fonc.2022.901435] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
228 Abdel-Rahman O, Ghosh S. A Real-World Study of the Incidence and Outcomes of Early-Onset Well-differentiated Neuroendocrine Neoplasms. Am J Clin Oncol 2022. [PMID: 35696696 DOI: 10.1097/COC.0000000000000925] [Reference Citation Analysis]
229 Li ZF, Lu HZ, Chen YT, Bai XF, Wang TB, Fei H, Zhao DB. Mixed large and small cell neuroendocrine carcinoma of the stomach: A case report and review of literature. World J Clin Cases 2022; 10(16): 5502-5509 [DOI: 10.12998/wjcc.v10.i16.5502] [Reference Citation Analysis]
230 Czernin J, Calais J. How Many Theranostics Centers Will We Need in the United States? J Nucl Med 2022;63:805-6. [PMID: 35649664 DOI: 10.2967/jnumed.122.264144] [Reference Citation Analysis]
231 Choi SI. Diagnosis and Treatment of Gastric Neuroendocrine Tumors. JDCR 2022;10:1-8. [DOI: 10.52927/jdcr.2022.10.1.1] [Reference Citation Analysis]
232 Sirtl S, Mahajan UM, Auernhammer CJ, Dziadkiewicz P, Hohmann E, Wójcik M, Kos-Kudła B, Hartleb M, Knösel T, Schirra J, Mayerle J, Schulz C, Żorniak M. Impact of tumor size and location on endoscopic ultrasound-guided sampling of pancreatic neuroendocrine tumors: A recursive partitioning analysis. Pancreatology 2022;22:644-50. [PMID: 35589512 DOI: 10.1016/j.pan.2022.04.014] [Reference Citation Analysis]
233 Bösch F, Ghadimi M, Angele MK. Personalisierte Resektionsverfahren bei neuroendokrinen Neoplasien des Pankreas. Zentralbl Chir 2022;147:264-269. [DOI: 10.1055/a-1823-1275] [Reference Citation Analysis]
234 Wong W, Perez Holguin RA, Olecki EJ, Stahl KA, Dixon M, Peng J, Dasari A, Shen C. Predictors and Outcomes of Minimally Invasive Surgery for Small Bowel Neuroendocrine Tumors : Minimally Invasive Surgery for SBNETs. J Gastrointest Surg 2022;26:1252-65. [PMID: 35132564 DOI: 10.1007/s11605-022-05264-6] [Reference Citation Analysis]
235 Ehlken H, Younis F, Wolter S, Schrader J. Spannungsfeld endoskopische Resektionsverfahren bei GEP-NET // Endoscopic resection for GEP-NET. Zentralbl Chir 2022;147:256-263. [DOI: 10.1055/a-1829-7370] [Reference Citation Analysis]
236 Mogl MT, Öllinger R, Jann H, Gebauer B, Fehrenbach U, Amthauer H, Wetz C, Schmelzle M, Raschzok N, Krenzien F, Goretzki PE, Pratschke J, Schoening W. Differenzierte Therapiestrategie bei Lebermetastasen gastro-entero-pankreatischer Neuroendokriner Neoplasien. Zentralbl Chir 2022;147:270-280. [DOI: 10.1055/a-1830-8442] [Reference Citation Analysis]
237 Ilhan H, Schnitzer ML, Rübenthaler J. Neuroendokrine Tumoren – von der morphologischen zur funktionellen Bildgebung. Radiopraxis 2022;15:E35-E47. [DOI: 10.1055/a-1714-2040] [Reference Citation Analysis]
238 Borbath I, Garcia-carbonero R, Bikmukhametov D, Jimenez-fonseca P, Castaño A, Barkmanova J, Sedlackova E, Kollár A, Christ E, Kaltsas G, Kos-kudla B, Maasberg S, Verslype C, Pape U. The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms. European Journal of Cancer 2022;168:80-90. [DOI: 10.1016/j.ejca.2022.03.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
239 Li MX, Lopez-Aguiar AG, Poultsides G, Rocha F, Weber S, Fields R, Idrees K, Cho C, Maithel SK, Zhang XF, Pawlik TM. Surgical Treatment of Neuroendocrine Tumors of the Terminal Ileum or Cecum: Ileocecectomy Versus Right Hemicolectomy. J Gastrointest Surg 2022;26:1266-74. [PMID: 35149952 DOI: 10.1007/s11605-022-05269-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
240 Hartrampf P, Werner R, Buck A. Theranostics bei gut bis mäßig differenzierten GEP-NEN. Zentralbl Chir 2022;147:249-255. [DOI: 10.1055/a-1826-3423] [Reference Citation Analysis]
241 Mandriani B, Pellè E, Mannavola F, Palazzo A, Marsano RM, Ingravallo G, Cazzato G, Ramello MC, Porta C, Strosberg J, Abate-Daga D, Cives M. Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors. J Immunother Cancer 2022;10:e004854. [PMID: 35764366 DOI: 10.1136/jitc-2022-004854] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
242 Weng Y, Ran J, Peng Y, Xiang Y, Xu L. Comparison of characteristics between true rectal neuroendocrine tumors and rectal hyperplastic polyps among patients with endoscope-diagnosed rectal neuroendocrine tumors. J Gastrointest Oncol 2022;13:1121-31. [PMID: 35837162 DOI: 10.21037/jgo-22-369] [Reference Citation Analysis]
243 Christ E, Wild D, Refardt J. Molecular Imaging in neuroendocrine neoplasias. Presse Med 2022;51:104115. [PMID: 35131317 DOI: 10.1016/j.lpm.2022.104115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
244 Luecke S, Fottner C, Lahner H, Jann H, Zolnowski D, Quietzsch D, Grabowski P, Cremer B, Maasberg S, Pape UF, Mueller HH, Gress TM, Rinke A, The Members Of The German Net Registry. Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice. Cancers (Basel) 2022;14:2718. [PMID: 35681701 DOI: 10.3390/cancers14112718] [Reference Citation Analysis]
245 Mohamed A, Vijayvergia N, Kurian M, Liu L, Fu P, Das S. Exploring Real World Outcomes with Nivolumab Plus Ipilimumab in Patients with Metastatic Extra-Pulmonary Neuroendocrine Carcinoma (EP-NEC). Cancers (Basel) 2022;14:2695. [PMID: 35681675 DOI: 10.3390/cancers14112695] [Reference Citation Analysis]
246 Xu Y, Xiong Q, Yang Y, Weng N, Li J, Liu J, Yang X, Zeng Z, Zhang Z, Zhu Q. Serum Nardilysin as a Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma. JCM 2022;11:3101. [DOI: 10.3390/jcm11113101] [Reference Citation Analysis]
247 Buchholz M, Strotmann J, Majchrzak-stiller B, Hahn S, Peters I, Horn J, Müller T, ö-Umlaut P, Uhl W, Braumann C. New Therapy Options for Neuroendocrine Carcinoma of the Pancreas—The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo. Cancers 2022;14:2685. [DOI: 10.3390/cancers14112685] [Reference Citation Analysis]
248 Li YL, Cheng ZX, Yu FH, Tian C, Tan HY. Advances in medical treatment for pancreatic neuroendocrine neoplasms. World J Gastroenterol 2022; 28(20): 2163-2175 [DOI: 10.3748/wjg.v28.i20.2163] [Reference Citation Analysis]
249 Zhang X, Lu L, Liu J, Liu W, Li L, Wei Y, Fan J, Ma L, Gong P. A Nomogram to Accurately Identify Pancreatic Neuroendocrine Tumors Metastasizing to Distant Organs: A Study Based on Two National Population-Based Cohorts From the United States and China. Clin Med Insights Oncol 2022;16:11795549221099853. [PMID: 35620244 DOI: 10.1177/11795549221099853] [Reference Citation Analysis]
250 Dai M, Mullins CS, Lu L, Alsfasser G, Linnebacher M. Recent advances in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. World J Gastrointest Surg 2022; 14(5): 383-396 [DOI: 10.4240/wjgs.v14.i5.383] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
251 Que QY, Zhang LC, Bao JQ, Ling SB, Xu X. Role of surgical treatments in high-grade or advanced gastroenteropancreatic neuroendocrine neoplasms. World J Gastrointest Surg 2022; 14(5): 397-408 [DOI: 10.4240/wjgs.v14.i5.397] [Reference Citation Analysis]
252 Li MX, Lopez-Aguiar AG, Poultsides G, Rocha F, Weber S, Fields R, Idrees K, Cho C, Maithel SK, Zhang XF, Pawlik TM. Surgical outcomes of gastro-entero-pancreatic neuroendocrine tumors G3 versus neuroendocrine carcinoma. J Surg Oncol 2022. [PMID: 35616186 DOI: 10.1002/jso.26928] [Reference Citation Analysis]
253 Lin ZQ, Li X, Yang Y, Wang Y, Zhang XY, Zhang XX, Guo J. Nonfunctional pancreatic neuroendocrine tumours misdiagnosed as autoimmune pancreatitis: A case report and review of literature. World J Clin Cases 2022; 10(15): 4886-4894 [DOI: 10.12998/wjcc.v10.i15.4886] [Reference Citation Analysis]
254 Krug S, Schrader J, Rinke A. Updates on Diagnostic and Therapeutic Management of Gastrointestinal and Pancreatic NET. Cancers (Basel) 2022;14:2628. [PMID: 35681608 DOI: 10.3390/cancers14112628] [Reference Citation Analysis]
255 Hiltunen N, Rintala J, Väyrynen JP, Böhm J, Karttunen TJ, Huhta H, Helminen O. Monocarboxylate Transporters 1 and 4 and Prognosis in Small Bowel Neuroendocrine Tumors. Cancers 2022;14:2552. [DOI: 10.3390/cancers14102552] [Reference Citation Analysis]
256 Prinzi N, Corti F, Torchio M, Niger M, Antista M, Pagani F, Beninato T, Pulice I, Rossi RE, Coppa J, Cascella T, Giacomelli L, Di Bartolomeo M, Milione M, de Braud F, Pusceddu S. Metastatic pheochromocytomas and paragangliomas: where are we? Tumori 2022;:3008916221078621. [PMID: 35593402 DOI: 10.1177/03008916221078621] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
257 Bartolomei M, Berruti A, Falconi M, Fazio N, Ferone D, Lastoria S, Pappagallo G, Seregni E, Versari A. Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise. Cancers (Basel) 2022;14:2501. [PMID: 35626105 DOI: 10.3390/cancers14102501] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
258 Canakis A, Lee LS. Current updates and future directions in diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms. World J Gastrointest Endosc 2022; 14(5): 267-290 [DOI: 10.4253/wjge.v14.i5.267] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
259 Sekiguchi M, Hotta K, Takeuchi Y, Tanaka S, Yamamoto H, Shinmura K, Harada K, Uraoka T, Hisabe T, Sano Y, Kondo H, Horimatsu T, Kikuchi H, Kawamura T, Nagata S, Yamamoto K, Tajika M, Tsuji S, Kusaka T, Okuyama Y, Yoshida N, Moriyama T, Hasebe A, So S, Kobara H, Kashida H, Miyanaga R, Kato S, Hayashi Y, Sada M, Fukuzawa M, Kato H, Takayama T, Konishi J, Matsushita HO, Narasaka T, Ohata K, Togashi K, Nakamura H, Moriichi K, Oda Y, Kanda N, Kuwai T, Terai S, Sanomura M, Kitamura S, Miyamoto H, Kiriyama S, Mizuno C, Saito Y, Sekine S, Ito S, Nakahira H, Oka S, Hayashi Y, Yoshimura K, Ishikawa H, Matsuda T; C-NET STUDY Group. Characteristics of colorectal neuroendocrine tumors in patients prospectively enrolled in a Japanese multicenter study: a first report from the C-NET STUDY. J Gastroenterol 2022. [PMID: 35554678 DOI: 10.1007/s00535-022-01877-5] [Reference Citation Analysis]
260 Zhang Z, Wang F, Li Z, Ye Z, Zhuo Q, Xu W, Liu W, Liu M, Fan G, Qin Y, Zhang Y, Chen X, Yu X, Xu X, Ji S. Value of lymphadenectomy in patients with surgically resected pancreatic neuroendocrine tumors. BMC Surg 2022;22:160. [PMID: 35538535 DOI: 10.1186/s12893-022-01595-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
261 Levy S, Kilgallen AB, Korse CM, Oerlemans MIFJ, Sluijter JPG, van Laake LW, Valk GD, Tesselaar MET. Elevated Serotonin and NT-proBNP Levels Predict and Detect Carcinoid Heart Disease in a Large Validation Study. Cancers (Basel) 2022;14:2361. [PMID: 35625964 DOI: 10.3390/cancers14102361] [Reference Citation Analysis]
262 El Ghannudi S, Ouvrard E, Mikail N, Leroy Freschini B, Schindler TH, Imperiale A. Cutting-Edge Imaging of Cardiac Metastases from Neuroendocrine Tumors: Lesson from a Case Series. Diagnostics 2022;12:1182. [DOI: 10.3390/diagnostics12051182] [Reference Citation Analysis]
263 Kulke MH, Ou FS, Niedzwiecki D, Huebner L, Kunz P, Kennecke HF, Wolin EM, Chan JA, O'Reilly EM, Meyerhardt JA, Venook A. Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance). Endocr Relat Cancer 2022;29:335-44. [PMID: 35324465 DOI: 10.1530/ERC-21-0239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
264 Yin F, Wu ZH, Lai JP. New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. World J Gastroenterol 2022; 28(17): 1751-1767 [DOI: 10.3748/wjg.v28.i17.1751] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
265 Papaefthymiou A, Laskaratos FM, Koffas A, Manolakis A, Gkolfakis P, Coda S, Sodergren M, Suzuki N, Toumpanakis C. State of the Art in Endoscopic Therapy for the Management of Gastroenteropancreatic Neuroendocrine Tumors. Curr Treat Options Oncol 2022. [PMID: 35511346 DOI: 10.1007/s11864-022-00986-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
266 Kiesewetter B, Mazal P, Kretschmer-Chott E, Mayerhoefer ME, Raderer M. Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice. ESMO Open 2022;7:100478. [PMID: 35525183 DOI: 10.1016/j.esmoop.2022.100478] [Reference Citation Analysis]
267 Syguła A, Ledwon A, Hasse-Lazar K, Jurecka-Lubieniecka B, Michalik B, Paliczka-Cieślik E, Zeman M, Chmielik E, Sczasny J, Jarzab B, Handkiewicz-Junak D. In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2022. [PMID: 35503379 DOI: 10.1007/s00259-022-05792-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
268 Coelho S, Costa C, Santos AP, Souteiro P, Oliveira J, Oliveira J, Azevedo I, Torres I, Bento MJ. Pancreatic neuroendocrine neoplasms: survival trend analysis of a comprehensive center. Endocrine Oncology 2022;2:32-41. [DOI: 10.1530/eo-22-0043] [Reference Citation Analysis]
269 Naveed Ahmad JA, Schroeder BB, Ruhoy SM, Kennecke HF, Lin BS. Severe Thrombocytopenia in Patients With Advanced Neuroendocrine Tumor Treated With Peptide Receptor Radioligand Therapy. Clin Nucl Med 2022;47:409-13. [PMID: 35307721 DOI: 10.1097/RLU.0000000000004130] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
270 van der Velden D, Staal F, Aalbersberg E, Castagnoli F, Wilthagen E, Beets-tan R. Prognostic value of CT characteristics in GEP-NET: a systematic review. Critical Reviews in Oncology/Hematology 2022. [DOI: 10.1016/j.critrevonc.2022.103713] [Reference Citation Analysis]
271 Hackeng WM, Brosens LAA, Kim JY, O'Sullivan R, Sung YN, Liu TC, Cao D, Heayn M, Brosnan-Cashman J, An S, Morsink FHM, Heidsma CM, Valk GD, Vriens MR, Nieveen van Dijkum E, Offerhaus GJA, Dreijerink KMA, Zeh H, Zureikat AH, Hogg M, Lee K, Geller D, Marsh JW, Paniccia A, Ongchin M, Pingpank JF, Bahary N, Aijazi M, Brand R, Chennat J, Das R, Fasanella KE, Khalid A, McGrath K, Sarkaria S, Singh H, Slivka A, Nalesnik M, Han X, Nikiforova MN, Lawlor RT, Mafficini A, Rusev B, Corbo V, Luchini C, Bersani S, Pea A, Cingarlini S, Landoni L, Salvia R, Milione M, Milella M, Scarpa A, Hong SM, Heaphy CM, Singhi AD. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. Gut 2022;71:961-73. [PMID: 33849943 DOI: 10.1136/gutjnl-2020-322595] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 27.0] [Reference Citation Analysis]
272 Yang Z, Shi G. Comparative outcomes of pancreatic neuroendocrine neoplasms: A population-based analysis of the SEER database. European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.05.016] [Reference Citation Analysis]
273 Alonso-Gordoa T, Manneh R, Grande E, Molina-Cerrillo J. High-Dose Somatostatin Analogs for the Treatment of Neuroendocrine Neoplasms: where are we Now? Curr Treat Options Oncol 2022. [PMID: 35501552 DOI: 10.1007/s11864-022-00983-z] [Reference Citation Analysis]
274 Tan Q, Wang X, Chen C, Liu X, Chen Y, Tan C. Prognostic value of preoperative diabetes mellitus in patients with non-functional pancreatic neuroendocrine neoplasms. The American Journal of Surgery 2022. [DOI: 10.1016/j.amjsurg.2022.05.026] [Reference Citation Analysis]
275 Feng LH, Su T, Lu Y, Ren S, Huang L, Qin X, Liao T. A model for predicting the overall survival of gastroenteropancreatic neuroendocrine neoplasms after surgery. Scand J Gastroenterol 2022;57:581-8. [PMID: 35001789 DOI: 10.1080/00365521.2021.2024247] [Reference Citation Analysis]
276 Feng Z, He X, Zhang X, Wu Y, Xing B, Knowles A, Shan Q, Miller S, Hojnacki T, Ma J, Katona BW, Gade TPF, Schrader J, Metz DC, June CH, Hua X. Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues. Nat Cancer 2022;3:581-94. [PMID: 35314826 DOI: 10.1038/s43018-022-00344-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
277 Lee ONY, Tan KV, Tripathi V, Yuan H, Chan WW, Chiu KWH. The Role of 68Ga-DOTA-SSA PET/CT in the Management and Prediction of Peptide Receptor Radionuclide Therapy Response for Patients With Neuroendocrine Tumors: A Systematic Review and Meta-analysis. Clin Nucl Med 2022. [PMID: 35485851 DOI: 10.1097/RLU.0000000000004235] [Reference Citation Analysis]
278 Ranallo N, Bocchini M, Menis J, Pilotto S, Severi S, Liverani C, Bongiovanni A. Delta-like ligand 3 (DLL3): an attractive actionable target in tumors with neuroendocrine origin. Expert Rev Anticancer Ther 2022. [PMID: 35477310 DOI: 10.1080/14737140.2022.2071703] [Reference Citation Analysis]
279 Juhlin CC, Zedenius J, Höög A. Metastatic Neuroendocrine Neoplasms of Unknown Primary: Clues from Pathology Workup. Cancers (Basel) 2022;14:2210. [PMID: 35565339 DOI: 10.3390/cancers14092210] [Reference Citation Analysis]
280 Stankiewicz R, Grąt M. Current status of surgical management of patients with gastroenteropancreatic neuroendocrine neoplasms. World J Gastrointest Surg 2022; 14(4): 276-285 [DOI: 10.4240/wjgs.v14.i4.276] [Reference Citation Analysis]
281 Li J, Cheng Y, Bai C, Xu J, Shen L, Li J, Zhou Z, Li Z, Chi Y, Yu X, Li E, Xu N, Liu T, Lou W, Bai Y, Yuan X, Wang X, Yuan Y, Chen J, Guan S, Fan S, Su W. Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep). Eur J Cancer 2022;169:1-9. [PMID: 35489301 DOI: 10.1016/j.ejca.2022.03.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
282 Sharma R, Earla B, Baidoo K, Zeiger MA, Madigan JP, Escorcia FE, Sadowski SM. Upregulation of Somatostatin Receptor Type 2 in a Receptor-Deficient In Vivo Pancreatic Neuroendocrine Tumor Model Improves Tumor Response to Targeted 177Lu-DOTATATE.. [DOI: 10.1101/2022.04.25.489401] [Reference Citation Analysis]
283 Tsunokake J, Fujishima F, Watanabe H, Sato I, Miura K, Sakamoto K, Suzuki H, Sawai T, Itakura Y, Hoshi T, Kunimitsu A, Yamauchi T, Akaishi R, Ozawa Y, Fukutomi T, Okamoto H, Sato C, Taniyama Y, Kamei T, Sasano H. Tumor Microenvironment in Mixed Neuroendocrine Non-Neuroendocrine Neoplasms: Interaction between Tumors and Immune Cells, and Potential Effects of Neuroendocrine Differentiation on the Tumor Microenvironment. Cancers (Basel) 2022;14:2152. [PMID: 35565281 DOI: 10.3390/cancers14092152] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
284 Wang Z, Zhang T, Wu W, Wu L, Li J, Huang B, Liang Y, Li Y, Li P, Li K, Wang W, Guo R, Wang Q. Detection and Localization of Solid Tumors Utilizing the Cancer-Type-Specific Mutational Signatures. Front Bioeng Biotechnol 2022;10:883791. [DOI: 10.3389/fbioe.2022.883791] [Reference Citation Analysis]
285 Sperling F, Misiak D, Hüttelmaier S, Michl P, Griesmann H. IGF2BP1 Promotes Proliferation of Neuroendocrine Neoplasms by Post-Transcriptional Enhancement of EZH2. Cancers 2022;14:2121. [DOI: 10.3390/cancers14092121] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
286 Koizumi T, Otsuki K, Tanaka Y, Kanda S. Epidemiology of neuroendocrine neoplasmas in Japan: based on analysis of hospital-based cancer registry data, 2009 - 2015. BMC Endocr Disord 2022;22:105. [PMID: 35443668 DOI: 10.1186/s12902-022-01016-4] [Reference Citation Analysis]
287 Wang X, Qiu JJ, Tan CL, Chen YH, Tan QQ, Ren SJ, Yang F, Yao WQ, Cao D, Ke NW, Liu XB. Development and Validation of a Novel Radiomics-Based Nomogram With Machine Learning to Preoperatively Predict Histologic Grade in Pancreatic Neuroendocrine Tumors. Front Oncol 2022;12:843376. [PMID: 35433485 DOI: 10.3389/fonc.2022.843376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
288 Kaliszewski K, Ludwig M, Greniuk M, Mikuła A, Zagórski K, Rudnicki J. Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Cancers (Basel) 2022;14:2028. [PMID: 35454934 DOI: 10.3390/cancers14082028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
289 Krieg S, Roderburg C, Fung S, Luedde T, Knoefel WT, Krieg A. Nuclear survivin is a prognosticator in gastroenteropancreatic neuroendocrine neoplasms: a meta-analysis. J Cancer Res Clin Oncol. [DOI: 10.1007/s00432-022-04013-1] [Reference Citation Analysis]
290 Cox T, O'Connell M, Leeuwenkamp O, Palimaka S, Reed N. Real-world comparison of healthcare resource utilization and costs of [177Lu]Lu-DOTA-TATE in patients with progressive neuroendocrine tumors in England: a matched cohort analysis using data from the Hospital Episode Statistics dataset. Curr Med Res Opin 2022;:1-33. [PMID: 35418254 DOI: 10.1080/03007995.2022.2065146] [Reference Citation Analysis]
291 Muñoz de Nova JL, Hernando J, Sampedro Núñez M, Vázquez Benítez GT, Triviño Ibáñez EM, del Olmo García MI, Barriuso J, Capdevila J, Martín-Pérez E. Management of incidentally discovered appendiceal neuroendocrine tumors after an appendicectomy. World J Gastroenterol 2022; 28(13): 1304-1314 [DOI: 10.3748/wjg.v28.i13.1304] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
292 Halperin DM, Liu S, Dasari A, Fogelman D, Bhosale P, Mahvash A, Estrella JS, Rubin L, Morani AC, Knafl M, Overeem TA, Fu SC, Solis LM, Parra Cuentas E, Verma A, Chen HL, Gite S, Subashchandrabose P, Dervin S, Schulze K, Darbonne WC, Yun C, Wistuba II, Futreal PA, Woodman SE, Yao JC. Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial. JAMA Oncol 2022. [PMID: 35389428 DOI: 10.1001/jamaoncol.2022.0212] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
293 Abdel-Rahman O, Pham TM, Pokhrel A, Ruether D, Sawyer MB. Changes in Survival Outcomes of Patients With Neuroendocrine Neoplasms Over the Past 15 Years: A Real-World Study. Am J Clin Oncol 2022. [PMID: 35383575 DOI: 10.1097/COC.0000000000000906] [Reference Citation Analysis]
294 Virarkar M, Vulasala SS, Morani AC, Waters R, Gopireddy DR, Kumar S, Bhosale P, Lall C. Neuroendocrine Neoplasms of the Gynecologic Tract. Cancers (Basel) 2022;14:1835. [PMID: 35406607 DOI: 10.3390/cancers14071835] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
295 Zheng-Pywell R, Lopez-Aguiar A, Fields RC, Vickers S, Yates C, Dudeja V, Chen H, Reddy S, Maithel SK, Rose JB. Are We Undertreating Black Patients with Nonfunctional Pancreatic Neuroendocrine Tumors? Critical Analysis of Current Surveillance Guidelines by Race. J Am Coll Surg 2022;234:599-606. [PMID: 35380181 DOI: 10.1097/XCS.0000000000000105] [Reference Citation Analysis]
296 Li D, Imbesi GJ, Yen L, Kim H, Sun CL, Crook CJ, Ballena R, Zhang YH, Allen R, Sedrak M, Singh G. Feasibility and Satisfaction of Using NET VITALS Self-assessment Tool Among Patients With Neuroendocrine Tumors. Pancreas 2022;51:319-24. [PMID: 35775639 DOI: 10.1097/MPA.0000000000002034] [Reference Citation Analysis]
297 Ginghina O, Hudita A, Zamfir M, Spanu A, Mardare M, Bondoc I, Buburuzan L, Georgescu SE, Costache M, Negrei C, Nitipir C, Galateanu B. Liquid Biopsy and Artificial Intelligence as Tools to Detect Signatures of Colorectal Malignancies: A Modern Approach in Patient's Stratification. Front Oncol 2022;12:856575. [PMID: 35356214 DOI: 10.3389/fonc.2022.856575] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
298 Crook C, Zhang YH, Li D. Pharmacotherapeutic Management of Well-Differentiated Neuroendocrine Tumors in Older Patients: Current Status and Potential Therapies. Drugs Aging 2022;39:257-69. [PMID: 35332446 DOI: 10.1007/s40266-022-00934-1] [Reference Citation Analysis]
299 Kamigaichi Y, Yamashita K, Oka S, Tamari H, Shimohara Y, Nishimura T, Inagaki K, Okamoto Y, Tanaka H, Yuge R, Urabe Y, Arihiro K, Tanaka S. Clinical outcomes of endoscopic resection for rectal neuroendocrine tumors: Advantages of endoscopic submucosal resection with a ligation device compared to conventional EMR and ESD. DEN Open 2022;2. [DOI: 10.1002/deo2.35] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
300 Mansfield BA, Halfdanarson TR, Hallemeier CL. Dramatic Response of a Pancreas Neuroendocrine Tumor Liver Metastasis to High-Dose Focal External Beam Radiotherapy: A Case Report. Pancreas 2022;51:e72-3. [PMID: 35775645 DOI: 10.1097/MPA.0000000000002039] [Reference Citation Analysis]
301 Deprez PH, Moons LMG, OʼToole D, Gincul R, Seicean A, Pimentel-Nunes P, Fernández-Esparrach G, Polkowski M, Vieth M, Borbath I, Moreels TG, Nieveen van Dijkum E, Blay JY, van Hooft JE. Endoscopic management of subepithelial lesions including neuroendocrine neoplasms: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2022;54:412-29. [PMID: 35180797 DOI: 10.1055/a-1751-5742] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
302 Gan Y, Su S, Fang C, Li C, Wen TF. Poorly Differentiated and Undifferentiated Pancreatic Neuroendocrine Carcinoma Management and Outcomes: A Surveillance, Epidemiology, and End Results Assessment. Pancreas 2022;51:e64-5. [PMID: 35687071 DOI: 10.1097/MPA.0000000000002022] [Reference Citation Analysis]
303 Hue JJ, Sugumar K, Mohamed A, Selfridge JE, Bajor D, Hardacre JM, Ammori JB, Rothermel LD, Winter JM, Ocuin LM. Assessing the Role of Operative Intervention in Elderly Patients With Nonfunctional Pancreatic Neuroendocrine Neoplasms. Pancreas 2022;51:380-7. [PMID: 35695765 DOI: 10.1097/MPA.0000000000002023] [Reference Citation Analysis]
304 Healey AJ. Cystic neoplasms of the pancreas. Surgery (Oxford) 2022;40:249-257. [DOI: 10.1016/j.mpsur.2022.01.005] [Reference Citation Analysis]
305 Harrow B, Fagnani F, Nevoret C, Truong-Thanh XM, de Zélicourt M, de Mestier L. Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting. Adv Ther 2022;39:1754-71. [PMID: 35190997 DOI: 10.1007/s12325-022-02060-1] [Reference Citation Analysis]
306 Helderman NC, Elsayed FA, van Wezel T, Terlouw D, Langers AM, van Egmond D, Kilinç G, Hristova ( H, Sarasqueta AF, Morreau H, Nielsen M, Suerink M. Mismatch Repair Deficiency and MUTYH Variants in Small Intestine-Neuroendocrine Tumors. Human Pathology 2022. [DOI: 10.1016/j.humpath.2022.04.003] [Reference Citation Analysis]
307 Gomollón F, Gisbert JP, Guerra I, Plaza R, Pajares Villarroya R, Moreno Almazán L, López Martín MC, Domínguez Antonaya M, Vera Mendoza MI, Aparicio J, Martínez V, Tagarro I, Fernández-Nistal A, Lumbreras S, Maté C, Montoto C; Premonition-CD Study Group. Clinical characteristics and prognostic factors for Crohn's disease relapses using natural language processing and machine learning: a pilot study. Eur J Gastroenterol Hepatol 2022;34:389-97. [PMID: 34882644 DOI: 10.1097/MEG.0000000000002317] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
308 Ehrlichman PD, Vijayvergia N. Unlocking the Code to Management of Neuroendocrine Neoplasms: A Clinician's Perspective. JCO Oncol Pract 2022;18:267-9. [PMID: 34731030 DOI: 10.1200/OP.21.00628] [Reference Citation Analysis]
309 Vayzband V, Doukas S, Esparragoza P. Esophageal Neuroendocrine Carcinoma: Case Report and Literature Review. Cureus 2022. [DOI: 10.7759/cureus.23607] [Reference Citation Analysis]
310 Del Calvo H, Nguyen DT, Chan EY, Chihara R, Graviss EA, Kim MP. Anatomic Pulmonary Resection is Associated With Improved Survival in Typical Carcinoid Lung Tumor Patients. J Surg Res 2022;275:352-60. [PMID: 35339287 DOI: 10.1016/j.jss.2022.02.048] [Reference Citation Analysis]
311 Yan L, Xu Y, Pan J, Bai J, Long Q, He N, Hu P, Liu M, Ji H, Li X, Tang Q, Wang J. Prognostic Evaluation of Patients with Rectal Neuroendocrine Neoplasms and Hepatic Metastases: A SEER Database Analysis. Journal of Oncology 2022;2022:1-9. [DOI: 10.1155/2022/2451282] [Reference Citation Analysis]
312 Li J, Cheng Y, Bai C, Xu J, Shen L, Li J, Zhou Z, Li Z, Chi Y, Yu X, Li E, Xu N, Liu T, Lou W, Bai Y, Yuan X, Wang X, Yuan Y, Chen J, Guan S, Fan S, Su W. Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies. ESMO Open 2022;7:100453. [PMID: 35344750 DOI: 10.1016/j.esmoop.2022.100453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
313 Montes Escobar K, Vicente Villardón JL, Alarcón Cano DF, Siteneski A. Clinical related factors to neuroendocrine tumors in Ecuadorian patients: a logistic biplot approach. Investigación Clínica 2022;63:19-31. [DOI: 10.54817/ic.v63n1a02] [Reference Citation Analysis]
314 Gallo C, Rossi RE, Cavalcoli F, Barbaro F, Boškoski I, Invernizzi P, Massironi S. Rectal neuroendocrine tumors: Current advances in management, treatment, and surveillance. World J Gastroenterol 2022; 28(11): 1123-1138 [DOI: 10.3748/wjg.v28.i11.1123] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
315 Sun TY, Hendifar A, Padda SK. Lung Neuroendocrine Tumors: How Does Molecular Profiling Help? Curr Oncol Rep 2022. [PMID: 35305210 DOI: 10.1007/s11912-022-01253-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
316 La Salvia A, Persano I, Siciliani A, Verrico M, Bassi M, Modica R, Audisio A, Zanata I, Trabalza Marinucci B, Trevisi E, Puliani G, Rinzivillo M, Parlagreco E, Baldelli R, Feola T, Sesti F, Razzore P, Mazzilli R, Mancini M, Panzuto F, Volante M, Giannetta E, Romero C, Appetecchia M, Isidori A, Venuta F, Ambrosio MR, Zatelli MC, Ibrahim M, Colao A, Brizzi MP, García-Carbonero R, Faggiano A. Prognostic significance of laterality in lung neuroendocrine tumors. Endocrine 2022. [PMID: 35301675 DOI: 10.1007/s12020-022-03015-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
317 Hou J, Long T, Yang Y, Chen D, Hu S, Azhdarinia A. The Potential Prognostic Value of Dual-Imaging PET Parameters Based on 18F-FDG and 18F-OC for Neuroendocrine Neoplasms. Molecular Imaging 2022;2022:1-9. [DOI: 10.1155/2022/6511179] [Reference Citation Analysis]
318 Fang JM, Li J, Shi J. An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. World J Gastroenterol 2022; 28(10): 1009-1023 [DOI: 10.3748/wjg.v28.i10.1009] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
319 Liu Y, Liu H, Chen W, Yu H, Yao W, Fan W, Li J, Chen M, Chen J, Wang Y. Prolonged progression-free survival achieved by octreotide LAR plus transarterial embolization in low-to-intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden. Cancer Med 2022. [PMID: 35289113 DOI: 10.1002/cam4.4628] [Reference Citation Analysis]
320 Siebenhüner AR, Langheinrich M, Friemel J, Schäfer N, Eshmuminov D, Lehmann K. Orchestrating Treatment Modalities in Metastatic Pancreatic Neuroendocrine Tumors-Need for a Conductor. Cancers (Basel) 2022;14:1478. [PMID: 35326628 DOI: 10.3390/cancers14061478] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
321 Magi L, Rinzivillo M, Panzuto F. What Gastroenterologists Should Know about Carcinoid Syndrome. Gastroenterology Insights 2022;13:127-38. [DOI: 10.3390/gastroent13010014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
322 Zhou J, Zhao R, Pan Y, Ju H, Huang X, Jiang Y, Jin J, Zhang Y. The Diagnostic and Grading Accuracy of 68Ga-DOTATATE and 18F-FDG PET/MR for Pancreatic Neuroendocrine Neoplasms. Front Oncol 2022;12:796391. [PMID: 35273910 DOI: 10.3389/fonc.2022.796391] [Reference Citation Analysis]
323 Strzelczyk J, Wójcik-giertuga M, Cuber P, Biernacki K, Kos-kudła B, Strzelczyk JK, Gagat M. Assessment of the Concentration of Endogenous Factors Regulating Angiogenesis, VASH-1 and VEGF-A, in the Blood Serum of Patients with Neuroendocrine Neoplasms. BioMed Research International 2022;2022:1-8. [DOI: 10.1155/2022/9084393] [Reference Citation Analysis]
324 Gosain R, Gupta M, Roy AM, Strosberg J, Glaser KM, Iyer R. Health-Related Quality of Life (HRQoL) in Neuroendocrine Tumors: A Systematic Review. Cancers 2022;14:1428. [DOI: 10.3390/cancers14061428] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
325 Sasaki N, Shinji S, Shichi Y, Ishiwata T, Arai T, Yamada T, Takahashi G, Ohta R, Sonoda H, Matsuda A, Iwai T, Takeda K, Yonaga K, Ueda K, Kuriyama S, Miyasaka T, Yoshida H. TGF-β1 increases cellular invasion of colorectal neuroendocrine carcinoma cell line through partial epithelial-mesenchymal transition. Biochem Biophys Rep 2022;30:101239. [PMID: 35252596 DOI: 10.1016/j.bbrep.2022.101239] [Reference Citation Analysis]
326 Rizen EN, Phan AT. Neuroendocrine Tumors: a Relevant Clinical Update. Curr Oncol Rep 2022. [PMID: 35254612 DOI: 10.1007/s11912-022-01217-z] [Reference Citation Analysis]
327 Zhang S, Chen J, Zhang R, Xu L, Wang Y, Yuan Z, Hou X, Feng J. Pulmonary neuroendocrine tumors: study of 266 cases focusing on clinicopathological characteristics, immunophenotype, and prognosis. J Cancer Res Clin Oncol. [DOI: 10.1007/s00432-022-03970-x] [Reference Citation Analysis]
328 Kaslow SR, Vitiello GA, Prendergast K, Hani L, Cohen SM, Wolfgang C, Berman RS, Lee AY, Correa-Gallego C. Surgical Treatment of Patients with Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: An NCDB Analysis. Ann Surg Oncol 2022. [PMID: 35246811 DOI: 10.1245/s10434-022-11477-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
329 Mejia A, Vivian E, Nwogu C, Shah J, Longoria R, Vo A, Shahin I, Verma J, Bageac A. Peptide receptor radionuclide therapy implementation and results in a predominantly gastrointestinal neuroendocrine tumor population: A two-year experience in a nonuniversity setting. Medicine (Baltimore) 2022;101:e28970. [PMID: 35244064 DOI: 10.1097/MD.0000000000028970] [Reference Citation Analysis]
330 Wong TY, Zhang KS, Gandhi RT, Collins ZS, O'Hara R, Wang EA, Vaheesan K, Matsuoka L, Sze DY, Kennedy AS, Brown DB. Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry. BMC Cancer 2022;22:224. [PMID: 35232410 DOI: 10.1186/s12885-022-09302-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
331 Hendifar AE, Mehr SH, McHaffie DR. Best Practices for the Coordinated Care of Patients With Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy. Pancreas 2022;51:213-8. [PMID: 35584377 DOI: 10.1097/MPA.0000000000002002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
332 Ilhan H, Schnitzer M, Rübenthaler J. Neuroendokrine Tumoren – von der morphologischen zur funktionellen Bildgebung. Onkologie up2date 2022;04:93-106. [DOI: 10.1055/a-1712-0674] [Reference Citation Analysis]
333 van Treijen MJC, Schoevers JMH, Heeres BC, van der Zee D, Maas M, Valk GD, Tesselaar MET. Defining disease status in gastroenteropancreatic neuroendocrine tumors: Choi-criteria or RECIST? Abdom Radiol (NY) 2022;47:1071-81. [PMID: 34989825 DOI: 10.1007/s00261-021-03393-1] [Reference Citation Analysis]
334 Wang W, Yang CX, Yu XZ, Zhang SL, Wang J, Wang J. Clinicopathological characteristics and prognostic factors of patients with primary gallbladder neuroendocrine carcinomas. J Dig Dis 2022;23:166-73. [PMID: 35187836 DOI: 10.1111/1751-2980.13088] [Reference Citation Analysis]
335 Lee L, Ramos-Alvarez I, Jensen RT. Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies. Cancers (Basel) 2022;14:1250. [PMID: 35267558 DOI: 10.3390/cancers14051250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
336 Bertani E, Zugni F, Radice D, Spada F, Bonomo G, Fumagalli Romario U, Fazio N, Funicelli L. Predicting resectability of primary tumor and mesenteric lymph-node masses in patients with small-intestine neuroendocrine tumors. Updates Surg. [DOI: 10.1007/s13304-022-01251-3] [Reference Citation Analysis]
337 Merola E, Michielan A, Rozzanigo U, Erini M, Sferrazza S, Marcucci S, Sartori C, Trentin C, de Pretis G, Chierichetti F. Therapeutic strategies for gastroenteropancreatic neuroendocrine neoplasms: State-of-the-art and future perspectives. World J Gastrointest Surg 2022; 14(2): 78-106 [DOI: 10.4240/wjgs.v14.i2.78] [Reference Citation Analysis]
338 van Leeuwaarde RS, González-Clavijo AM, Pracht M, Emelianova G, Cheung WY, Thirlwell C, Öberg K, Spada F. A Multinational Pilot Study on Patients' Perceptions of Advanced Neuroendocrine Neoplasms on the EORTC QLQ-C30 and EORTC QLQ-GINET21 Questionnaires. J Clin Med 2022;11:1271. [PMID: 35268362 DOI: 10.3390/jcm11051271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
339 Takayanagi D, Cho H, Machida E, Kawamura A, Takashima A, Wada S, Tsunoda T, Kohno T, Shiraishi K. Update on Epidemiology, Diagnosis, and Biomarkers in Gastroenteropancreatic Neuroendocrine Neoplasms. Cancers (Basel) 2022;14:1119. [PMID: 35267427 DOI: 10.3390/cancers14051119] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
340 Borbath I, Pape UF, Deprez PH, Bartsch DK, Caplin M, Falconi M, Garcia-Carbonero R, Grozinsky-Glasberg S, Jensen RT, Arnold R, Ruszniewski P, Toumpanakis C, Valle JW, O Toole D; Members of the Advisory Board of the European Neuroendocrine Tumor Society (ENETS). ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors. J Neuroendocrinol 2022;:e13105. [PMID: 35233848 DOI: 10.1111/jne.13105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
341 Maxwell JE, Naraev B, Halperin DM, Choti MA, Halfdanarson TR. Shifting Paradigms in the Pathophysiology and Treatment of Carcinoid Crisis. Ann Surg Oncol 2022. [PMID: 35165817 DOI: 10.1245/s10434-022-11371-0] [Reference Citation Analysis]
342 Cheng J, Patel G, Dawood A, Aqeel A. Gastric and Duodenal Neuroendocrine Tumor Incidentally Found on Endoscopy During the Evaluation of Iron-Deficiency Anemia. Cureus. [DOI: 10.7759/cureus.22208] [Reference Citation Analysis]
343 Hashimoto S, Nakaoka K, Tanaka H, Kuzuya T, Kawabe N, Nagasaka M, Nakagawa Y, Miyahara R, Shibata T, Hirooka Y. Transabdominal ultrasonographic diagnosis of relatively rare pancreatic neoplasms. J Med Ultrason (2001) 2022. [PMID: 35149959 DOI: 10.1007/s10396-022-01192-9] [Reference Citation Analysis]
344 Magi L, Prosperi D, Lamberti G, Marasco M, Ambrosini V, Rinzivillo M, Campana D, Gentiloni G, Annibale B, Signore A, Panzuto F. Role of [18F]FDG PET/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors. Endocrine 2022. [PMID: 35149933 DOI: 10.1007/s12020-022-03000-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
345 Kartal İ. Childhood neuroendocrine tumors of the digestive system: A single center experience. Medicine (Baltimore) 2022;101:e28795. [PMID: 35147110 DOI: 10.1097/MD.0000000000028795] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
346 Pedraza-arevalo S, Alors-pérez E, Blázquez-encinas R, Herrera-martínez AD, Jiménez-vacas JM, Fuentes-fayos AC, Reyes Ó, Ventura S, Sánchez-sánchez R, Ortega-salas R, Serrano-blanch R, Gálvez-moreno MA, Gahete MD, Ibáñez-costa A, Luque RM, Castaño JP. Spliceosomic dysregulation unveils NOVA1 as an actionable therapeutic target in pancreatic neuroendocrine tumors.. [DOI: 10.1101/2022.02.09.479525] [Reference Citation Analysis]
347 Duan S, Sawyer TW, Sontz RA, Wieland BA, Diaz AF, Merchant JL. GFAP-directed Inactivation of Men1 Exploits Glial Cell Plasticity in Favor of Neuroendocrine Reprogramming.. [DOI: 10.1101/2022.02.10.479845] [Reference Citation Analysis]
348 Shah HA, Faulkes R, Coldham C, Shetty S, Shah T. Effects of transplantation-related immunosuppression on co-existent neuroendocrine tumours. QJM 2022;115:661-4. [PMID: 35143660 DOI: 10.1093/qjmed/hcac036] [Reference Citation Analysis]
349 Bober B, Saracyn M, Zaręba K, Lubas A, Mazurkiewicz P, Wilińska E, Kamiński G. Early Complications of Radioisotope Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms-A Preliminary Study. J Clin Med 2022;11:919. [PMID: 35207193 DOI: 10.3390/jcm11040919] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
350 Chauhan A, Prieur A, Kolesar J, Arnold S, Payen L, Mahi Y, Vire B, Sands M, Evers BM, Joubert D, Anthony L. hPG80 (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors. Cancers (Basel) 2022;14:863. [PMID: 35205614 DOI: 10.3390/cancers14040863] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
351 Matsuoka S, Koizumi T, Otsuki K, Tanaka Y, Kanda S, Ide S, Mishima S, Takeda T, Miura K, Eguchi T, Hamanaka K, Shimizu K. Epidemiological analysis of lung and mediastinal neuroendocrine neoplasms in Japan based on the national database. Cancer Epidemiol 2022;77:102116. [PMID: 35144127 DOI: 10.1016/j.canep.2022.102116] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
352 Shi WK, Hou R, Li YH, Qiu XY, Liu YX, Wu B, Xiao Y, Zhou JL, Lin GL. Long-term outcomes of transanal endoscopic microsurgery for the treatment of rectal neuroendocrine tumors. BMC Surg 2022;22:43. [PMID: 35120483 DOI: 10.1186/s12893-022-01494-2] [Reference Citation Analysis]
353 Prisciandaro M, Antista M, Raimondi A, Corti F, Morano F, Centonze G, Sabella G, Mangogna A, Randon G, Pagani F, Prinzi N, Niger M, Corallo S, Castiglioni di Caronno E, Massafra M, Bartolomeo MD, Braud FD, Milione M, Pusceddu S. Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective. Front Oncol 2022;12:780716. [DOI: 10.3389/fonc.2022.780716] [Reference Citation Analysis]
354 Weniger M, Werner J. Seltene chirurgische Tumoren im biliopankreatoduodenalen Bereich. Allgemein- und Viszeralchirurgie up2date 2022;16:53-69. [DOI: 10.1055/a-1324-8816] [Reference Citation Analysis]
355 Şentürk M, Acar B, Yildirim MA, Çakir M, Küçükkartallar T, Vatansev C. Clinicopathological Characteristics of Gastroenteropancreatic Neuroendocrine Tumors: 10 Years of Experience From a Single Center. Pancreas 2022;51:159-63. [PMID: 35404891 DOI: 10.1097/MPA.0000000000001981] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
356 Bangla VG, Wolin EM, Kim MK, Divino CM. Resection Prolongs Overall Survival for Nonmetastatic Midgut Small Bowel Neuroendocrine Tumors: A National Cancer Data Base Study. Pancreas 2022;51:171-6. [PMID: 35404893 DOI: 10.1097/MPA.0000000000001982] [Reference Citation Analysis]
357 Pusceddu S, Prinzi N, Tafuto S, Ibrahim T, Filice A, Brizzi MP, Panzuto F, Baldari S, Grana CM, Campana D, Davì MV, Giuffrida D, Zatelli MC, Partelli S, Razzore P, Marconcini R, Massironi S, Gelsomino F, Faggiano A, Giannetta E, Bajetta E, Grimaldi F, Cives M, Cirillo F, Perfetti V, Corti F, Ricci C, Giacomelli L, Porcu L, Di Maio M, Seregni E, Maccauro M, Lastoria S, Bongiovanni A, Versari A, Persano I, Rinzivillo M, Pignata SA, Rocca PA, Lamberti G, Cingarlini S, Puliafito I, Ambrosio MR, Zanata I, Bracigliano A, Severi S, Spada F, Andreasi V, Modica R, Scalorbi F, Milione M, Sabella G, Coppa J, Casadei R, Di Bartolomeo M, Falconi M, de Braud F. Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors. JAMA Netw Open 2022;5:e220290. [PMID: 35201309 DOI: 10.1001/jamanetworkopen.2022.0290] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
358 Chen G, Xu Q, Qian S, Wang Z, Wang S. Survival Analysis in Gastrointestinal Neuroendocrine Carcinoma With Bone Metastasis at Diagnosis. Front Surg 2022;9:820725. [DOI: 10.3389/fsurg.2022.820725] [Reference Citation Analysis]
359 Inaba Y, Hijioka S, Iwama I, Asai T, Miyamura H, Chatani S, Hasegawa T, Murata S, Kato M, Sato Y, Yamaura H, Onaya H, Shimizu J, Hara K. Clinical usefulness of Somatostatin Receptor Scintigraphy in the Diagnosis of Neuroendocrine Neoplasms. Asia Ocean J Nucl Med Biol. 2022;10:1-13. [PMID: 35083344 DOI: 10.22038/aojnmb.2021.56254.1390] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
360 Ricci AD, Pusceddu S, Panzuto F, Gelsomino F, Massironi S, De Angelis CG, Modica R, Ricco G, Torchio M, Rinzivillo M, Prinzi N, Rizzi F, Lamberti G, Campana D. Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study. J Clin Med 2022;11:713. [PMID: 35160165 DOI: 10.3390/jcm11030713] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
361 Puliani G, Sesti F, Anastasi E, Verrico M, Tarsitano MG, Feola T, Campolo F, Di Gioia CRT, Venneri MA, Angeloni A, Appetecchia M, Lenzi A, Isidori AM, Faggiano A, Giannetta E; Nettare Unit. Angiogenic factors as prognostic markers in neuroendocrine neoplasms. Endocrine 2022. [PMID: 35088292 DOI: 10.1007/s12020-021-02942-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
362 Badawy M, Johnson G, Jain M, Kendi AT, Johnson DR, Porter A, Yang M, Sonbol MB. Intracranial neuroendocrine tumour simulating meningioma for several years: an overview of diagnosis and treatment. BJR|case reports. [DOI: 10.1259/bjrcr.20210222] [Reference Citation Analysis]
363 Cope J, Srirajaskanthan R. Rectal Neuroendocrine Neoplasms: Why Is There a Global Variation? Curr Oncol Rep 2022. [PMID: 35084662 DOI: 10.1007/s11912-021-01172-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
364 Al-toubah T, Morse B, Strosberg J. Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors. Current Oncology 2022;29:510-5. [DOI: 10.3390/curroncol29020046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
365 Krug S, Khosravian M, Weissbach J, George K, Damm M, Garbe J, Walldorf J, Reuken PA, Amin T, Siebenhüner A, Rosendahl J, Gress TM, Michl P, Schrader J, Rinke A. The Patient's Point of View: COVID-19 and Neuroendocrine Tumor Disease. Cancers (Basel) 2022;14:613. [PMID: 35158882 DOI: 10.3390/cancers14030613] [Reference Citation Analysis]
366 Fermi F, Andreasi V, Muffatti F, Crippa S, Tamburrino D, Partelli S, Falconi M. How to Select Patients Affected by Neuroendocrine Neoplasms for Surgery. Curr Oncol Rep. [DOI: 10.1007/s11912-022-01200-8] [Reference Citation Analysis]
367 Durmo R, Filice A, Fioroni F, Cervati V, Finocchiaro D, Coruzzi C, Besutti G, Fanello S, Frasoldati A, Versari A. Predictive and Prognostic Role of Pre-Therapy and Interim 68Ga-DOTATOC PET/CT Parameters in Metastatic Advanced Neuroendocrine Tumor Patients Treated with PRRT. Cancers (Basel) 2022;14:592. [PMID: 35158862 DOI: 10.3390/cancers14030592] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
368 Del Olmo-García MI, Prado-Wohlwend S, Bello P, Segura A, Merino-Torres JF. Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions. Cancers (Basel) 2022;14:584. [PMID: 35158852 DOI: 10.3390/cancers14030584] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
369 Sabat C, Palmieri LJ, Brezault C, Ginestet C, Assaf A, Coriat R. Re: "Does surgery provide a survival advantage in nondisseminated poorly differentiated gastroenteropancreatic neuroendocrine neoplasms". Surgery 2022:S0039-6060(21)00872-2. [PMID: 35086731 DOI: 10.1016/j.surg.2021.08.050] [Reference Citation Analysis]
370 Kaewput C, Vinjamuri S. Role of Combined 68Ga DOTA-Peptides and 18F FDG PET/CT in the Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasms. Diagnostics 2022;12:280. [DOI: 10.3390/diagnostics12020280] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
371 Exarchou K, Stephens NA, Moore AR, Howes NR, Pritchard DM. New Developments in Gastric Neuroendocrine Neoplasms. Curr Oncol Rep. [DOI: 10.1007/s11912-021-01175-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
372 Havasi A, Sur D, Cainap SS, Lungulescu CV, Gavrilas LI, Cainap C, Vlad C, Balacescu O. Current and New Challenges in the Management of Pancreatic Neuroendocrine Tumors: The Role of miRNA-Based Approaches as New Reliable Biomarkers. Int J Mol Sci 2022;23:1109. [PMID: 35163032 DOI: 10.3390/ijms23031109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
373 Alexandraki KI, Zatelli MC, Grossman AB. "The past is a different country, they do things differently there": using the SEER data-base to assess prognosis in neuroendocrine tumours. Endocrine 2022. [PMID: 35037238 DOI: 10.1007/s12020-021-02959-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
374 Marchese U, Gaillard M, Pellat A, Tzedakis S, Abou Ali E, Dohan A, Barat M, Soyer P, Fuks D, Coriat R. Multimodal Management of Grade 1 and 2 Pancreatic Neuroendocrine Tumors. Cancers (Basel) 2022;14:433. [PMID: 35053593 DOI: 10.3390/cancers14020433] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
375 Herring B, Jang S, Whitt J, Goliwas K, Aburjania Z, Dudeja V, Ren B, Berry J, Bibb J, Frost A, Chen H, Rose JB, Jaskula-Sztul R. Ex Vivo Modeling of Human Neuroendocrine Tumors in Tissue Surrogates. Front Endocrinol (Lausanne) 2021;12:710009. [PMID: 35002949 DOI: 10.3389/fendo.2021.710009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
376 Yan H, Yin L, Han H, Jin Y, Liu Z. Relationship between Primary Tumor Resection for Metastatic Small Intestine Neuroendocrine Tumors and Survival: A Propensity Score-Matched Analysis. J Invest Surg 2022;:1-9. [PMID: 34991432 DOI: 10.1080/08941939.2021.2024306] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
377 Felux K, Mccarty B, Turner D, Gray T, Patel V. Poorly Differentiated Large Cell Neuroendocrine Carcinoma of the Colon: A Case Report. Cureus 2022. [DOI: 10.7759/cureus.20949] [Reference Citation Analysis]
378 Duan H, Iagaru A, Aparici CM. Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging. Nanotheranostics 2022;6:103-17. [PMID: 34976584 DOI: 10.7150/ntno.64141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
379 Wang J, Liu J, He C, Sun T, Yan Y, Che G, Li X, Sun H, Ma H. Trends in Incidence and Survival of Patients with Pancreatic Neuroendocrine Neoplasm, 1987-2016. J Oncol 2021;2021:4302675. [PMID: 34976056 DOI: 10.1155/2021/4302675] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
380 Bodei L, Jayaprakasam VS, Kidd M, Gilardi L, Volterrani D, Paganelli G, Grana CM, Modlin IM. Diagnostic Applications of Nuclear Medicine: Neuroendocrine Tumors. Nuclear Oncology 2022. [DOI: 10.1007/978-3-031-05494-5_18] [Reference Citation Analysis]
381 Osama M, Rao S, Bhardwaj P, Mediratta G, Bhalla S, Badwal S. Neuroendocrine carcinoma of ovary: Hitherto rare entity in primary ovarian tumors. Indian J Pathol Microbiol 2022;0:0. [DOI: 10.4103/ijpm.ijpm_954_21] [Reference Citation Analysis]
382 Nagel I, Herrmann K, Lahner H, Rischpler C, Weber F. Combined medical therapy, nuclear medicine therapy and other therapies in metastatic neuroendocrine tumor. Nuclear Medicine and Molecular Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00156-3] [Reference Citation Analysis]
383 Prado-wohlwend S, Bernal-vergara J, Utrera-costero A, Cañón-sánchez J, Agudelo-cifuentes M, Bello-arques P. Terapia con péptidos radiomarcados con [177Lu]Lu-DOTA-TATE. Revista Española de Medicina Nuclear e Imagen Molecular 2022;41:55-65. [DOI: 10.1016/j.remn.2021.11.001] [Reference Citation Analysis]
384 Liao T, Su T, Huang L, Li B, Feng LH. Development and validation of a novel nomogram for predicting survival rate in pancreatic neuroendocrine neoplasms. Scand J Gastroenterol 2022;57:85-90. [PMID: 34592854 DOI: 10.1080/00365521.2021.1984571] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
385 徐 新. Clinical Pathology, Diagnosis and Treatment of Gastric Neuroendocrine Neoplasms. ACM 2022;12:4192-4200. [DOI: 10.12677/acm.2022.125608] [Reference Citation Analysis]
386 Streit L, Moog S, Hugel S, Rame M, Tanguy E, Andry V, Schmid HA, Brunaud L, Bihain F, Nominé-Criqui C, Goumon Y, Lacomme S, Lomazzi S, Vix M, Mutter D, Vitale N, Ory S, Gasman S. Somatostatin analogue pasireotide (SOM230) inhibits catecholamine secretion in human pheochromocytoma cells. Cancer Lett 2022;524:232-44. [PMID: 34637845 DOI: 10.1016/j.canlet.2021.10.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
387 Kasai Y, Masui T, Takaori K, Yoshino K, Nakakura EK. Pancreatic Resection for Neuroendocrine Neoplasms of the Pancreas. The IASGO Textbook of Multi-Disciplinary Management of Hepato-Pancreato-Biliary Diseases 2022. [DOI: 10.1007/978-981-19-0063-1_52] [Reference Citation Analysis]
388 Lima Cavalcanti ID. Chemotherapeutic Protocols for the Treatment of Gastrointestinal Tract Cancer. Chemotherapy Protocols and Infusion Sequence 2022. [DOI: 10.1007/978-3-031-10839-6_5] [Reference Citation Analysis]
389 Bartsch D, Wiese D. Neuroendokrine Neoplasien. Allgemein- und Viszeralchirurgie II 2022. [DOI: 10.1016/b978-3-437-24812-2.00004-4] [Reference Citation Analysis]
390 Katiyar V, Das S, University of Louisville, Department of Medicine, Division of Medical Oncology and Hematology, Louisville, KY, USA, Vanderbilt University Medical Center, Department of Medicine, Division of Medical Oncology, Nashville, TN, USA. Advances in Targeted Therapy for Patients with Neuroendocrine Tumours. Oncology & Haematology 2022;18:66. [DOI: 10.17925/ohr.2022.18.1.66] [Reference Citation Analysis]
391 Signore A, Prosperi D, Gentiloni G, Di Girolamo M, Lauri C, Filice A, Panzuto F. Therapy of NET with radiolabeled SST analogs. Nuclear Medicine and Molecular Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00155-1] [Reference Citation Analysis]
392 Kone LB, Javadi C, Keilson JM, Maithel SK, Poultsides G, Maker AV. The Role of Surgery in Managing Primary and Metastatic Hepatopancreaticobiliary Cancers. Cancer Metastasis Through the Lymphovascular System 2022. [DOI: 10.1007/978-3-030-93084-4_40] [Reference Citation Analysis]
393 La Rosa S. Gastric Neuroendocrine Neoplasm. Endocrine Pathology 2022. [DOI: 10.1007/978-3-030-62345-6_5187] [Reference Citation Analysis]
394 Patel RR, De B, Verma V. Pulmonary Carcinoid. Medical Radiology 2022. [DOI: 10.1007/174_2022_347] [Reference Citation Analysis]
395 O’brien SR, Pryma DA. Neuroendocrine Tumors: Therapy with 131I-MIBG. Nuclear Oncology 2022. [DOI: 10.1007/978-3-319-26067-9_93-1] [Reference Citation Analysis]
396 De Robertis R, D’onofrio M, Tinazzi Martini P, Gobbo S, Mastrosimini MG, Stefanizzi L, Beleù A, Geraci L, Scarpa A, Capelli P. Neuroendocrine Neoplasms. Imaging and Pathology of Pancreatic Neoplasms 2022. [DOI: 10.1007/978-3-031-09831-4_3] [Reference Citation Analysis]
397 Duchateau NM, Canovai E, Vianna RM, Vanuytsel T, Verslype C, Mazariegos GV, Monbaliu D, Pirenne J, Ceulemans LJ. Combined liver-intestinal and multivisceral transplantation for neuroendocrine tumors extending beyond the liver: A systematic literature review. Transplantation Reviews 2022. [DOI: 10.1016/j.trre.2022.100678] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
398 Uccella S. Neuroendocrine Tumor (NET). Encyclopedia of Pathology 2022. [DOI: 10.1007/978-3-319-28845-1_5314-1] [Reference Citation Analysis]
399 Hayes AR, Furtado O'Mahony L, Quigley AM, Gnanasegaran G, Caplin ME, Navalkissoor S, Toumpanakis C. The Combined Interpretation of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Classification System With Prognostic Impact. Clin Nucl Med 2022;47:26-35. [PMID: 34874347 DOI: 10.1097/RLU.0000000000003937] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
400 Kasai Y, Masui T, Nakakura EK, Nakano K, Sato A, Uchida Y, Yogo A, Nagai K, Anazawa T, Hope TA, Kim GE, Whitman J, Le BK, Takaori K, Bergsland EK, Hatano E, Uemoto S. Preoperative risk stratification of lymph node metastasis for non-functional pancreatic neuroendocrine neoplasm: An international dual-institutional study. Pancreatology 2022;22:123-9. [PMID: 34736838 DOI: 10.1016/j.pan.2021.10.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
401 Bodei L, Jayaprakasam VS, Kidd M, Gilardi L, Volterrani D, Paganelli G, Grana CM, Modlin IM. Diagnostic Applications of Nuclear Medicine: Neuroendocrine Tumors. Nuclear Oncology 2022. [DOI: 10.1007/978-3-319-26067-9_18-2] [Reference Citation Analysis]
402 Rindi G, Inzani F. Appendiceal Neuroendocrine Neoplasms. Endocrine Pathology 2022. [DOI: 10.1007/978-3-030-62345-6_5262] [Reference Citation Analysis]
403 Rosiek V, Wójcik-giertuga M, Kos-kudła B. Serum tumor markers for detection of bone metastases in patients with lung neuroendocrine neoplasms”. Cancer Treatment and Research Communications 2022;31:100533. [DOI: 10.1016/j.ctarc.2022.100533] [Reference Citation Analysis]
404 O’brien SR, Pryma DA. Neuroendocrine Tumors: Therapy with 131I-MIBG. Nuclear Oncology 2022. [DOI: 10.1007/978-3-031-05494-5_93] [Reference Citation Analysis]
405 Fanti S, Ambrosini V. PET Imaging in Neuro-Endocrine Neoplasms (NEN). Nuclear Medicine and Molecular Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00034-x] [Reference Citation Analysis]
406 Uccella S. Neuroendocrine Tumor (NET). Endocrine Pathology 2022. [DOI: 10.1007/978-3-030-62345-6_5314] [Reference Citation Analysis]
407 Lugat A, Gaschet J, Chérel M, Allard M, Guérard F, Kraeber-bodéré F, Ansquer C. Alpha-particle Therapy of Endocrine Tumors: Current State and Future Directions. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_34] [Reference Citation Analysis]
408 German J, Burke LMB, Rowell JV. Clinical, Laboratory, and Radiological Diagnosis of Pancreatic Islet Cell Tumors. Diagnosis and Management of Endocrine Disorders in Interventional Radiology 2022. [DOI: 10.1007/978-3-030-87189-5_5] [Reference Citation Analysis]
409 Majumder S, Halfdanarson TR, Berger CK, Foote PH, Cao X, Mcglinch MC, Gysbers BJ, de La Fuente J, Robran MJ, Doering KA, Burger KN, Bamlet WE, Oberg AL, Mahoney DW, Graham RP, Taylor WR, Petersen GM, Kisiel JB. Discovery and Validation of Methylated DNA Markers From Pancreatic Neuroendocrine Tumors. Gastro Hep Advances 2022;1:409-416. [DOI: 10.1016/j.gastha.2022.01.006] [Reference Citation Analysis]
410 Kearney J, Johnson J, Kim HJ. Surgical Treatment of Pancreatic Islet Cell Tumors. Diagnosis and Management of Endocrine Disorders in Interventional Radiology 2022. [DOI: 10.1007/978-3-030-87189-5_15] [Reference Citation Analysis]
411 Albers MB, Manoharan J, Bartsch DK. Hereditäre duodenopankreatische neuroendokrine Neoplasien. Springer Reference Medizin 2022. [DOI: 10.1007/978-3-662-61724-3_45-1] [Reference Citation Analysis]
412 Ikeda K, Miyake H, Nagai H, Yoshioka Y, Yuasa N, Fujino M. A Case of Cecal MiNEN (Mixed Adenocarcinoma-neuroendocrine Carcinoma). Nihon Rinsho Geka Gakkai Zasshi (J Jpn Surg Assoc) 2022;83:351-357. [DOI: 10.3919/jjsa.83.351] [Reference Citation Analysis]
413 Wonn SM, Pommier RF. Carcinoid Syndrome and Carcinoid Crisis. Endocrine Emergencies 2022. [DOI: 10.1016/b978-0-323-76097-3.00017-x] [Reference Citation Analysis]
414 Majala S, Vesterinen T, Seppänen H, Mustonen H, Sundström J, Schalin-Jäntti C, Gullichsen R, Schildt J, Kemppainen J, Arola J, Kauhanen S. Correlation of Somatostatin Receptor 1-5 Expression, [68Ga]Ga-DOTANOC, [18F]F-FDG PET/CT and Clinical Outcome in a Prospective Cohort of Pancreatic Neuroendocrine Neoplasms. Cancers (Basel) 2021;14:162. [PMID: 35008325 DOI: 10.3390/cancers14010162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
415 Al-Toubah T, Halfdanarson T, Gile J, Morse B, Sommerer K, Strosberg J. Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms. ESMO Open 2021;7:100364. [PMID: 34973511 DOI: 10.1016/j.esmoop.2021.100364] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
416 Spada F, Campana D, Lamberti G, Laudicella R, Dellamano R, Dellamano L, Leeuwenkamp O, Baldari S. [177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective. Eur J Nucl Med Mol Imaging 2021. [PMID: 34950969 DOI: 10.1007/s00259-021-05656-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
417 Yu Q, Li Z, Han X. Giant mediastinal neuroendocrine tumor successfully resected after transarterial chemoembolization of drug-eluting embolic microspheres: A case report. Medicine (Baltimore) 2021;100:e28247. [PMID: 34941097 DOI: 10.1097/MD.0000000000028247] [Reference Citation Analysis]
418 Kraft A, Croitoru A, Moldovan C, Lupescu I, Tomescu D, Purnichescu-Purtan R, Herlea V, Popescu I, Botea F. Is Long-Term Survival in Metastases from Neuroendocrine Neoplasms Improved by Liver Resection? Medicina (Kaunas) 2021;58:22. [PMID: 35056330 DOI: 10.3390/medicina58010022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
419 Kohno S, Ikegami M, Ikegami T, Aoki H, Ogawa M, Yano F, Eto K. Risk Factors Associated with the Development of Metastases in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Retrospective Analysis. JCM 2021;11:60. [DOI: 10.3390/jcm11010060] [Reference Citation Analysis]
420 Korol P, Ivakh M. Modern hybrid imaging of neuroendocrine tumors (clinical lecture). УРОЖ 2021;29:108-118. [DOI: 10.46879/ukroj.4.2021.108-118] [Reference Citation Analysis]
421 Van Den Heede K, Chidambaram S, Van Slycke S, Brusselaers N, Warfvinge CF, Ohlsson H, Nordenström E, Almquist M. Effect of primary tumour resection without curative intent in patients with metastatic neuroendocrine tumours of the small intestine and right colon: meta-analysis. British Journal of Surgery 2021. [DOI: 10.1093/bjs/znab413] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
422 Natalicchio A, Faggiano A, Zatelli MC, Argentiero A, D'Oronzo S, Marrano N, Beretta GD, Acquati S, Adinolfi V, Di Bartolo P, Danesi R, Ferrari P, Gori S, Morviducci L, Russo A, Tuveri E, Montagnani M, Gallo M, Silvestris N, Giorgino F. Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. Crit Rev Oncol Hematol 2021;:103572. [PMID: 34954047 DOI: 10.1016/j.critrevonc.2021.103572] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
423 Xu JX, Wu DH, Ying LW, Hu HG. Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification. World J Gastroenterol 2021; 27(47): 8123-8137 [DOI: 10.3748/wjg.v27.i47.8123] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
424 Opalińska M, Sowa-Staszczak A, Olearska H, Ulatowska-Bialas M, Gilis-Januszewska A, Hubalewska-Dydejczyk A. Clinical Approach to Neuroendocrine Neoplasm Associated With Ovarian Teratoma. Front Endocrinol (Lausanne) 2021;12:770266. [PMID: 34917031 DOI: 10.3389/fendo.2021.770266] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
425 Li S, Niu M, Deng W, Li N, Wei C, Zhang C, Luo S. Efficacy of Chemotherapy versus Transcatheter Arterial Chemoembolization in Patients with Advanced Primary Hepatic Neuroendocrine Carcinoma and an Analysis of the Prognostic Factors: A Retrospective Study. Cancer Manag Res 2021;13:9085-93. [PMID: 34916851 DOI: 10.2147/CMAR.S343572] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
426 Chen X, Lee SK, Song M, Zhang T, Han MS, Chen YT, Chen Z, Ma X, Tung CH, Du YN. RHAMMB-mediated bifunctional nanotherapy targeting Bcl-xL and mitochondria for pancreatic neuroendocrine tumor treatment. Mol Ther Oncolytics 2021;23:277-87. [PMID: 34761107 DOI: 10.1016/j.omto.2021.10.002] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
427 Caplin ME. Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients? EJC Suppl 2021;16:1-4. [PMID: 34912477 DOI: 10.1016/j.ejcsup.2021.06.001] [Reference Citation Analysis]
428 Knigin A, Avniel-Polak S, Leibowitz G, Oleinikov K, Gross DJ, Grozinsky-Glasberg S. The Autophagy Inhibitor Chloroquine, Alone or in Combination with mTOR Inhibitors, Displays Anti-Tumor Effects in In Vitro and In Vivo Lung Carcinoid Models. Cancers (Basel) 2021;13:6327. [PMID: 34944946 DOI: 10.3390/cancers13246327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
429 Theiler D, Cattaneo M, Dierickx LO, Igaz P, Grozinsky-Glasberg S, Bournaud C, O'Dorisio T, O'Dorisio MS, Wild D, Christ E, Nicolas GP. Safety and Efficacy of Peptide-Receptor Radionuclide Therapy in Elderly Neuroendocrine Tumor Patients. Cancers (Basel) 2021;13:6290. [PMID: 34944910 DOI: 10.3390/cancers13246290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
430 Prado-Wohlwend S, Bernal-Vergara JC, Utrera-Costero A, Cañón-Sánchez JR, Agudelo-Cifuentes M, Bello-Arques P; Endocrinology Working Group of the SEMNIM. Peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2021:S2253-8089(21)00164-6. [PMID: 34920969 DOI: 10.1016/j.remnie.2021.11.001] [Reference Citation Analysis]
431 Hou J, Yang Y, Chen N, Chen D, Hu S. Prognostic Value of Volume-Based Parameters Measured by SSTR PET/CT in Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2021;8:771912. [PMID: 34901087 DOI: 10.3389/fmed.2021.771912] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
432 Kennedy J, Chicheportiche A, Keidar Z. Quantitative SPECT/CT for dosimetry of peptide receptor radionuclide therapy. Semin Nucl Med 2021:S0001-2998(21)00091-X. [PMID: 34911637 DOI: 10.1053/j.semnuclmed.2021.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
433 Mathew A, Führer D, Lahner H. Sunitinib-Induced Hypothyroidism and Survival in Pancreatic Neuroendocrine Tumors. Horm Metab Res 2021;53:794-800. [PMID: 34891209 DOI: 10.1055/a-1658-3077] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
434 Halperin R, Ahron-Hananel G, Badarna M, Greidinger D, Uri I, Percik R, Tirosh A. Plasma Hemoglobin and Red Blood Cell Mass Levels as Dynamic Prognostic Markers for Progression and Survival in Pancreatic Neuroendocrine Tumors. Horm Metab Res 2021;53:810-7. [PMID: 34891211 DOI: 10.1055/a-1672-4653] [Reference Citation Analysis]
435 Maurer E, Heinzel-Gutenbrunner M, Rinke A, Rütz J, Holzer K, Figiel J, Luster M, Bartsch DK. Relevant prognostic factors in patients with stage IV small intestine neuroendocrine neoplasms. J Neuroendocrinol 2021;:e13076. [PMID: 34964186 DOI: 10.1111/jne.13076] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
436 Tsai HJ, Hsiao CF, Chang JS, Chen LT, Chao YJ, Yen CJ, Shan YS. The Prognostic and Predictive Role of Chromogranin A in Gastroenteropancreatic Neuroendocrine Tumors - A Single-Center Experience. Front Oncol 2021;11:741096. [PMID: 34868938 DOI: 10.3389/fonc.2021.741096] [Reference Citation Analysis]
437 Singhal S, Patel G, Singh RB, Potdar R. Grade 3 Neuroendocrine Tumor (G3NET): An Unusual Tumor With A Histochemical Surprise. Cureus 2021;13:e19103. [PMID: 34868755 DOI: 10.7759/cureus.19103] [Reference Citation Analysis]
438 Schüttler D, Mourouzis K, Auernhammer CJ, Rizas KD. Development of severe intrapulmonary shunting in a patient with carcinoid heart disease after closure of a persistent foramen ovale: a case report. European Heart Journal - Case Reports 2021;5. [DOI: 10.1093/ehjcr/ytab494] [Reference Citation Analysis]
439 Carter AM, Kumar N, Herring B, Tan C, Guenter R, Telange R, Howse W, Viol F, McCaw TR, Bickerton HH, Gupta P, Gillardon F, Woltering EA, Dhall D, Totenhagen J, Banerjee RR, Kurian EM, Reddy S, Chen H, Schrader J, Bart Rose J, Mukhtar MS, Bibb JA. Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors. Oncogenesis 2021;10:83. [PMID: 34862365 DOI: 10.1038/s41389-021-00372-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
440 Patil MS, Nezami N, Bercu ZL, Martin LG, Dariushnia SR, Xing M, Newsome J, Kokabi N. Selective Intra-Arterial Calcium Stimulation Venous Sampling Test for Preoperative Localization of Occult Neuroendocrine Tumors: Recall for an Old Technique. Digestive Disease Interventions 2021;05:287-293. [DOI: 10.1055/s-0041-1723804] [Reference Citation Analysis]
441 Brosch-lenz J, Gosewisch A. Bild-basierte Patienten-individuelle Dosimetrie bei internen Radionuklidtherapien von neuroendokrinen Tumoren. Der Nuklearmediziner 2021;44:355-368. [DOI: 10.1055/a-1556-8361] [Reference Citation Analysis]
442 Del Olmo-Garcia MI, Prado-Wohlwend S, Andres A, Soriano JM, Bello P, Merino-Torres JF. Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms. Biomedicines 2021;9:1810. [PMID: 34944626 DOI: 10.3390/biomedicines9121810] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
443 Marini I, Sansovini M, Bongiovanni A, Nicolini S, Grassi I, Ranallo N, Monti M, DI Iorio V, Germanò L, Caroli P, Sarnelli A, Paganelli G, Severi S. Theragnostic in neuroendocrine tumors. Q J Nucl Med Mol Imaging 2021;65:342-52. [PMID: 34881852 DOI: 10.23736/S1824-4785.21.03426-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
444 Ilhan H, Schnitzer ML, Rübenthaler J. Neuroendokrine Tumoren – von der morphologischen zur funktionellen Bildgebung. Der Nuklearmediziner 2021;44:313-325. [DOI: 10.1055/a-1652-4899] [Reference Citation Analysis]
445 O'Neill S, Haji A, Ryan S, Clement D, Sarras K, Hayee B, Mulholland N, Ramage JK, Srirajaskanthan R. Nodal metastases in small rectal neuroendocrine tumours. Colorectal Dis 2021;23:3173-9. [PMID: 34731512 DOI: 10.1111/codi.15978] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
446 de Ponthaud C, Menegaux F, Gaujoux S. Updated Principles of Surgical Management of Pancreatic Neuroendocrine Tumours (pNETs): What Every Surgeon Needs to Know. Cancers (Basel) 2021;13:5969. [PMID: 34885079 DOI: 10.3390/cancers13235969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
447 Frey S, Mirallié E, Le Bras M, Regenet N. What Are the Place and Modalities of Surgical Management for Pancreatic Neuroendocrine Neoplasms? A Narrative Review. Cancers (Basel) 2021;13:5954. [PMID: 34885063 DOI: 10.3390/cancers13235954] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
448 Duan S, Rico K, Merchant JL. Gastrin: From Physiology to Gastrointestinal Malignancies. Function (Oxf) 2022;3:zqab062. [PMID: 35330921 DOI: 10.1093/function/zqab062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
449 Walter MA, Nesti C, Spanjol M, Kollár A, Bütikofer L, Gloy VL, Dumont RA, Seiler CA, Christ ER, Radojewski P, Briel M, Kaderli RM. Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis. Cochrane Database Syst Rev 2021;11:CD013700. [PMID: 34822169 DOI: 10.1002/14651858.CD013700.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
450 Michael M, Thursfield V, Te Marvelde L, Kong G, Hicks RJ. Incidence, prevalence, and survival trends for neuroendocrine neoplasms in Victoria, Australia, from 1982 to 2019: Based on site, grade, and region. Asia Pac J Clin Oncol 2021. [PMID: 34821050 DOI: 10.1111/ajco.13671] [Reference Citation Analysis]
451 Kasprzak A. Somatostatin and Its Receptor System in Colorectal Cancer. Biomedicines 2021;9:1743. [PMID: 34829972 DOI: 10.3390/biomedicines9111743] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
452 Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol 2021;22:1752-63. [PMID: 34793718 DOI: 10.1016/S1470-2045(21)00572-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 17.5] [Reference Citation Analysis]
453 Erstad DJ, Dasari A, Taggart MW, Kaur H, Konishi T, Bednarski BK, Chang GJ. Prognosis for Poorly Differentiated, High-Grade Rectal Neuroendocrine Carcinomas. Ann Surg Oncol 2021. [PMID: 34787737 DOI: 10.1245/s10434-021-11016-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
454 Andreasi V, Ricci C, Partelli S, Guarneri G, Ingaldi C, Muffatti F, Crippa S, Casadei R, Falconi M. Predictors of disease recurrence after curative surgery for nonfunctioning pancreatic neuroendocrine neoplasms (NF-PanNENs): a systematic review and meta-analysis. J Endocrinol Invest 2021. [PMID: 34773595 DOI: 10.1007/s40618-021-01705-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
455 Tawfik B, Ray D, Moynihan M, Princic N. Costs of treatment change following first-line somatostatin analog monotherapy among patients with neuroendocrine tumors. J Med Econ 2021;24:1337-45. [PMID: 34763589 DOI: 10.1080/13696998.2021.2005374] [Reference Citation Analysis]
456 Vivanet G, Gervaso L, Laffi A, Rubino M, Spada F, Fazio N. Ten years-experience of sunitinib in the treatment of advanced pan-NETs: an update on safety profile. Expert Opin Drug Saf 2021;:1-8. [PMID: 34724869 DOI: 10.1080/14740338.2022.2000964] [Reference Citation Analysis]
457 Yu WM, Li R, Sun BL, Du JK, Tuo HF. Primary hepatic neuroendocrine tumour with multiple liver metastases: A case report with literature review. Int J Surg Case Rep 2021;89:106590. [PMID: 34784532 DOI: 10.1016/j.ijscr.2021.106590] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
458 Hu T, Wang W, He C. Second Primary Malignancies in Patients with Pancreatic Neuroendocrine Neoplasms: A Population-Based Study on Occurrence, Risk Factors, and Prognosis. J Oncol 2021;2021:1565089. [PMID: 34754307 DOI: 10.1155/2021/1565089] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
459 Rico K, Duan S, Pandey RL, Chen Y, Chakrabarti JT, Starr J, Zavros Y, Else T, Katona BW, Metz DC, Merchant JL. Genome analysis identifies differences in the transcriptional targets of duodenal versus pancreatic neuroendocrine tumours. BMJ Open Gastroenterol 2021;8:e000765. [PMID: 34750164 DOI: 10.1136/bmjgast-2021-000765] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
460 Thomasian NM, Kamel IR, Bai HX. Machine intelligence in non-invasive endocrine cancer diagnostics. Nat Rev Endocrinol 2021. [PMID: 34754064 DOI: 10.1038/s41574-021-00543-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
461 Anoshkin K, Vasilyev I, Karandasheva K, Shugay M, Kudryavtseva V, Egorov A, Gurevich L, Mironova A, Serikov A, Kutsev S, Strelnikov V. New Regions With Molecular Alterations in a Rare Case of Insulinomatosis: Case Report With Literature Review. Front Endocrinol (Lausanne) 2021;12:760154. [PMID: 34737724 DOI: 10.3389/fendo.2021.760154] [Reference Citation Analysis]
462 Vesterinen T, Säilä J, Blom S, Pennanen M, Leijon H, Arola J. Automated assessment of Ki-67 proliferation index in neuroendocrine tumors by deep learning. APMIS 2021. [PMID: 34741788 DOI: 10.1111/apm.13190] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
463 Li Q, Chen Q, Chen J, Wang Z, Wang P, Zhao H, Zhao J. Prognostic nomogram for predicting long-term survival in bronchopulmonary carcinoid tumor patients receiving resection. Ann Transl Med 2021;9:1402. [PMID: 34733954 DOI: 10.21037/atm-21-1929] [Reference Citation Analysis]
464 Elias E, Ardalan A, Lindberg M, Reinsbach SE, Muth A, Nilsson O, Arvidsson Y, Larsson E. Independent somatic evolution underlies clustered neuroendocrine tumors in the human small intestine. Nat Commun 2021;12:6367. [PMID: 34737276 DOI: 10.1038/s41467-021-26581-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
465 Refardt J, Hofland J, Wild D, Christ E. New Directions in Imaging Neuroendocrine Neoplasms. Curr Oncol Rep 2021;23:143. [PMID: 34735669 DOI: 10.1007/s11912-021-01139-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
466 Stensbøl AB, Krogh J, Holmager P, Klose M, Oturai P, Kjaer A, Hansen CP, Federspiel B, Langer SW, Knigge U, Andreassen M. Incidence, Clinical Presentation and Trends in Indication for Diagnostic Work-Up of Small Intestinal and Pancreatic Neuroendocrine Tumors. Diagnostics (Basel) 2021;11:2030. [PMID: 34829377 DOI: 10.3390/diagnostics11112030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
467 Lysanyuk MV, Romashchenko PN, Maistrenko NA. Current aspects of diagnosis and treatment of patients with neuroendocrine tumors. Bulletin of the Russian Military Medical Academy 2021;23:83-92. [DOI: 10.17816/brmma72345] [Reference Citation Analysis]
468 Chen Q, Chen J, Huang Z, Zhao H, Cai J. Comparable survival benefit of local excision versus radical resection for 10- to 20-mm rectal neuroendocrine tumors. Eur J Surg Oncol 2021:S0748-7983(21)00779-4. [PMID: 34753616 DOI: 10.1016/j.ejso.2021.10.029] [Reference Citation Analysis]
469 Shaib WL, Zakka K, Penley M, Jiang R, Akce M, Wu C, Maithel SK, Sarmiento JM, Kooby D, Behera M, Alese OB, El-Rayes BF. Role of Resection of the Primary in Metastatic Well-Differentiated Neuroendocrine Tumors. Pancreas 2021;50:1382-91. [PMID: 35041337 DOI: 10.1097/MPA.0000000000001936] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
470 Ricci C, Mosconi C, Ingaldi C, Vara G, Verna M, Pettinari I, Alberici L, Campana D, Ambrosini V, Minni F, Golfieri R, Casadei R. The 3-Dimensional-Computed Tomography Texture Is Useful to Predict Pancreatic Neuroendocrine Tumor Grading. Pancreas 2021;50:1392-9. [PMID: 35041338 DOI: 10.1097/MPA.0000000000001927] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
471 Bateni SB, Coburn NG, Law CHL, Singh S, Myrehaug S, Assal A, Hallet J. Incidence and Predictors of Second Primary Cancers in Patients With Neuroendocrine Tumors. JAMA Oncol 2021;7:1718-20. [PMID: 34591069 DOI: 10.1001/jamaoncol.2021.4531] [Reference Citation Analysis]
472 Pasquer A, Walter T, Milot L, Hervieu V, Poncet G. Principles of Surgical Management of Small Intestinal NET. Cancers (Basel) 2021;13:5473. [PMID: 34771639 DOI: 10.3390/cancers13215473] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
473 Kuai L, Zhang Y, Luo Y, Li W, Li XD, Zhang HP, Liu TY, Yin SY, Li B. Prognostic Nomogram for Liver Metastatic Colon Cancer Based on Histological Type, Tumor Differentiation, and Tumor Deposit: A TRIPOD Compliant Large-Scale Survival Study. Front Oncol 2021;11:604882. [PMID: 34712601 DOI: 10.3389/fonc.2021.604882] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
474 Mileva M, Wimana Z, Flamen P, Karfis I. Everolimus-induced somatostatin receptor overexpression in a rectal neuroendocrine tumor patient may promote somatostatin receptor-guided radionuclide therapy (peptide receptor radiotherapy) as an additional treatment option. World J Nucl Med 2021;20:316-8. [PMID: 34703403 DOI: 10.4103/wjnm.WJNM_120_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
475 Randhawa S, Trikalinos N, Patterson GA. Neuroendocrine Tumors of the Lung. Thorac Surg Clin 2021;31:469-76. [PMID: 34696859 DOI: 10.1016/j.thorsurg.2021.05.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
476 Egal ESA, Jacenik D, Soares HP, Beswick EJ. Translational challenges in pancreatic neuroendocrine tumor immunotherapy. Biochim Biophys Acta Rev Cancer 2021;1876:188640. [PMID: 34695532 DOI: 10.1016/j.bbcan.2021.188640] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
477 Touloupas C, Faron M, Hadoux J, Deschamps F, Roux C, Ronot M, Yevich S, Joskin J, Gelli M, Barbé R, Lamartina L, Tissot H, Scoazec JY, Malka D, Ducreux M, Baudin E, de Baère T, Tselikas L. Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience. Cancers (Basel) 2021;13:5366. [PMID: 34771531 DOI: 10.3390/cancers13215366] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
478 Matrood S, Apostolidis L, Schrader J, Krug S, Lahner H, Ramaswamy A, Librizzi D, Kender Z, Kröcher A, Kreutzfeldt S, Gress TM, Rinke A. Multicenter Analysis of Presacral Neuroendocrine Neoplasms-Clinicopathological Characterization and Treatment Outcomes of a Rare Disease. Front Endocrinol (Lausanne) 2021;12:709256. [PMID: 34690926 DOI: 10.3389/fendo.2021.709256] [Reference Citation Analysis]
479 Shi M, Fan Z, Xu J, Yang J, Li Y, Gao C, Su P, Wang X, Zhan H. Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs. Biochim Biophys Acta Rev Cancer 2021;1876:188637. [PMID: 34678439 DOI: 10.1016/j.bbcan.2021.188637] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
480 Tacelli M, Petrone MC, Capurso G, Muffatti F, Andreasi V, Partelli S, Doglioni C, Falconi M, Arcidiacono PG. Diagnostic accuracy of EUS-FNA in the evaluation of pancreatic neuroendocrine neoplasms grading: Possible clinical impact of misclassification. Endosc Ultrasound 2021;10:372-80. [PMID: 34677159 DOI: 10.4103/EUS-D-20-00261] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
481 Hane Y, Tsuchikawa T, Takeuchi S, Tanaka K, Nakanishi Y, Asano T, Noji T, Kurashima Y, Ebihara Y, Murakami S, Nakamura T, Okamura K, Shichinohe T, Hirano S. Long-term survival after repetitive lymphadenectomy for nodal recurrence of pancreatic neuroendocrine neoplasms: a report of two cases. J Surg Case Rep 2021;2021:rjab446. [PMID: 34659739 DOI: 10.1093/jscr/rjab446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
482 Wang S, Wei J, Guo Y, Xu Q, Lv X, Yu Y, Liu M. Construction and Validation of a Nomogram Based on the Log Odds of Positive Lymph Based on the Log Odds of Positive Lymph Nodes to Predict the Prognosis of Lung Neuroendocrine Tumors.. [DOI: 10.1101/2021.10.12.21264905] [Reference Citation Analysis]
483 Yozgat A, Kekilli M, Altay M. Time to give up traditional methods for the management of gastrointestinal neuroendocrine tumours. World J Clin Cases 2021; 9(29): 8627-8646 [PMID: 34734042 DOI: 10.12998/wjcc.v9.i29.8627] [Reference Citation Analysis]
484 Trikalinos NA, Chrisinger JSA, Van Tine BA. Common Pitfalls in Ewing Sarcoma and Desmoplastic Small Round Cell Tumor Diagnosis Seen in a Study of 115 Cases. Med Sci (Basel) 2021;9:62. [PMID: 34698236 DOI: 10.3390/medsci9040062] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
485 Zhang JY, Kunz PL. Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors. JCO Oncol Pract 2021;:OP2100240. [PMID: 34652954 DOI: 10.1200/OP.21.00240] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
486 Manchec B, Kokabi N, Narayanan G, Niekamp A, Peña C, Powell A, Schiro B, Gandhi R. Radioembolization of Secondary Hepatic Malignancies. Semin Intervent Radiol 2021;38:445-52. [PMID: 34629712 DOI: 10.1055/s-0041-1732318] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
487 Maharjan CK, Ear PH, Tran CG, Howe JR, Chandrasekharan C, Quelle DE. Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets. Cancers (Basel) 2021;13:5117. [PMID: 34680266 DOI: 10.3390/cancers13205117] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
488 Yang KC, Kalloger SE, Aird JJ, Lee MKC, Rushton C, Mungall KL, Mungall AJ, Gao D, Chow C, Xu J, Karasinska JM, Colborne S, Jones SJM, Schrader J, Morin RD, Loree JM, Marra MA, Renouf DJ, Morin GB, Schaeffer DF, Gorski SM. Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms. Cell Rep 2021;37:109817. [PMID: 34644566 DOI: 10.1016/j.celrep.2021.109817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
489 Carpizo DR, Harris CR. Genetic Drivers of Ileal Neuroendocrine Tumors. Cancers (Basel) 2021;13:5070. [PMID: 34680217 DOI: 10.3390/cancers13205070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
490 Moncer F, Adhoum N, Catak D, Monser L. Electrochemical sensor based on MIP for highly sensitive detection of 5-hydroxyindole-3-acetic acid carcinoid cancer biomarker in human biological fluids. Anal Chim Acta 2021;1181:338925. [PMID: 34556226 DOI: 10.1016/j.aca.2021.338925] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
491 Li J, Zhang X, He Q, Feng W, Ding L, Wang Z, Yu H, Chen Q, Lu N, Xu D, Cui J. Pancreatic neuroendocrine tumor producing vasopressin: A case report. Medicine (Baltimore) 2021;100:e27453. [PMID: 34622867 DOI: 10.1097/MD.0000000000027453] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
492 Silva DJ, Dos Santos J, Vaz AP, Mesquita A. Rectal mixed adenoneuroendocrine carcinoma: Case report. Medicine (Baltimore) 2021;100:e27348. [PMID: 34622834 DOI: 10.1097/MD.0000000000027348] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
493 Kulke MH, Kennecke HF, Murali K, Joish VN. Changes in Carcinoid Syndrome Symptoms Among Patients Receiving Telotristat Ethyl in US Clinical Practice: Findings from the TELEPRO-II Real-World Study. Cancer Manag Res 2021;13:7439-46. [PMID: 34611437 DOI: 10.2147/CMAR.S330429] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
494 April-Monn SL, Andreasi V, Schiavo Lena M, Sadowski MC, Kim-Fuchs C, Buri MC, Ketkar A, Maire R, Di Domenico A, Schrader J, Muffatti F, Doglioni C, Partelli S, Falconi M, Perren A, Marinoni I. EZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs). Cancers (Basel) 2021;13:5014. [PMID: 34638497 DOI: 10.3390/cancers13195014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
495 Carvão J, Dinis-Ribeiro M, Pimentel-Nunes P, Libânio D. Neuroendocrine Tumors of the Gastrointestinal Tract: A Focused Review and Practical Approach for Gastroenterologists. GE Port J Gastroenterol 2021;28:336-48. [PMID: 34604465 DOI: 10.1159/000512089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
496 Li C, Zhang P, Sun X, Tong X, Chen X, Li C, Yang W, Liu W, Wang Z, Tao K. Risk Factors and Predictive Score Model for Early Recurrence After Curative Surgery in Patients With Poorly Differentiated Gastrointestinal Neuroendocrine Neoplasms. Front Surg 2021;8:703138. [PMID: 34604293 DOI: 10.3389/fsurg.2021.703138] [Reference Citation Analysis]
497 Waked B, De Maeyer F, Carton S, Pieter-Jan C, Vandamme T, Verslype C, Demetter P, Borbath I, Van Eycken L, Hoorens A, Geboes K, Van Damme N, Ribeiro S. Quality of pathology reporting and adherence to guidelines in rectal neuroendocrine neoplasms: a Belgian national study. Acta Clin Belg 2021;:1-9. [PMID: 34607538 DOI: 10.1080/17843286.2021.1985806] [Reference Citation Analysis]
498 Pedraza-Arevalo S, Ibáñez-Costa A, Blázquez-Encinas R, Branco MR, Vázquez-Borrego MC, Herrera-Martínez AD, Venegas-Moreno E, Serrano-Blanch R, Arjona-Sánchez Á, Gálvez-Moreno MA, Korbonits M, Soto-Moreno A, Gahete MD, Charalambous M, Luque RM, Castaño JP. Epigenetic and post-transcriptional regulation of somatostatin receptor subtype 5 (SST5 ) in pituitary and pancreatic neuroendocrine tumors. Mol Oncol 2022;16:764-79. [PMID: 34601790 DOI: 10.1002/1878-0261.13107] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
499 Srirajaskanthan R, Pavel M, Kulke M, Clement D, Houchard A, Keeber L, Weickert MO. Weight Maintenance up to 48 Weeks in Patients With Carcinoid Syndrome Treated With Telotristat Ethyl: Pooled Data From the Open-Label Extensions of the Phase III Clinical Trials TELESTAR and TELECAST. Clin Ther 2021;43:1779-85. [PMID: 34598813 DOI: 10.1016/j.clinthera.2021.08.014] [Reference Citation Analysis]
500 Galgano SJ, Calderone CE, Xie C, Smith EN, Porter KK, McConathy JE. Applications of PET/MRI in Abdominopelvic Oncology. Radiographics 2021;41:1750-65. [PMID: 34597228 DOI: 10.1148/rg.2021210035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
501 Koh TT, Bezak E, Chan D, Cehic G. Targeted alpha-particle therapy in neuroendocrine neoplasms: A systematic review. World J Nucl Med 2021;20:329-35. [PMID: 35018146 DOI: 10.4103/wjnm.wjnm_160_20] [Reference Citation Analysis]
502 Zvizdic Z, Milisic E, Ibisevic N, Pasic IS, Vranic S. Appendiceal carcinoid in a pediatric patient with Peutz-Jeghers syndrome: A case report and comprehensive literature review. Medicine (Baltimore) 2021;100:e27389. [PMID: 34596162 DOI: 10.1097/MD.0000000000027389] [Reference Citation Analysis]
503 Vega EA, Kutlu OC, Alarcon SV, Salehi O, Kazakova V, Kozyreva O, Chan JA, Conrad C. Clinical Prognosticators of Metastatic Potential in Patients with Small Pancreatic Neuroendocrine Tumors. J Gastrointest Surg 2021;25:2593-9. [PMID: 33660111 DOI: 10.1007/s11605-021-04946-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
504 Krug S, Michl P. Systemische Therapien neuroendokriner Tumoren und Karzinome. Im Fokus Onkologie 2021;24:28-31. [DOI: 10.1007/s15015-021-3621-1] [Reference Citation Analysis]
505 Thapi S, Baeg K, Kim MK, Gallagher EJ. Survival of Patients With Gastroenteropancreatic Neuroendocrine Tumors and Diabetes Mellitus. Pancreas 2021;50:1293-7. [PMID: 34860814 DOI: 10.1097/MPA.0000000000001911] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
506 Kaçmaz E, van Eeden S, Koppes JCC, Klümpen HJ, Bemelman WA, Nieveen van Dijkum EJM, Engelsman AF, Tanis PJ. Value of Laparoscopy for Resection of Small-Bowel Neuroendocrine Neoplasms Including Central Mesenteric Lymphadenectomy. Dis Colon Rectum 2021;64:1240-8. [PMID: 33661232 DOI: 10.1097/DCR.0000000000001915] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
507 Das S, Du L, Lee CL, Arhin ND, Chan JA, Kohn EC, Halperin DM, Berlin J, LaFerriere H, Singh S, Kunz PL, Dasari A. Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020. JAMA Netw Open 2021;4:e2131744. [PMID: 34705010 DOI: 10.1001/jamanetworkopen.2021.31744] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
508 Scalorbi F, Argiroffi G, Baccini M, Gherardini L, Fuoco V, Prinzi N, Pusceddu S, Garanzini EM, Centonze G, Kirienko M, Seregni E, Milione M, Maccauro M. Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT. Sci Rep 2021;11:19490. [PMID: 34593940 DOI: 10.1038/s41598-021-99048-8] [Reference Citation Analysis]
509 Das S, Al-Toubah T, Strosberg J. Chemotherapy in Neuroendocrine Tumors. Cancers (Basel) 2021;13:4872. [PMID: 34638356 DOI: 10.3390/cancers13194872] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
510 Alì G, Di Stefano I, Poma AM, Ricci S, Proietti A, Davini F, Lucchi M, Melfi F, Fontanini G. Prevalence of Delta-Like Protein 3 in a Consecutive Series of Surgically Resected Lung Neuroendocrine Neoplasms. Front Oncol 2021;11:729765. [PMID: 34568063 DOI: 10.3389/fonc.2021.729765] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
511 Thomas KE, Boudreaux JP, Thiagarajan R, Marsala A, Voros BA, Ramirez RA. A Peptide Meets a Radionuclide to Combat a Rare Tumor. Ochsner J 2021;21:306-11. [PMID: 34566515 DOI: 10.31486/toj.20.0098] [Reference Citation Analysis]
512 Petrick JL, Barber LE, Warren Andersen S, Florio AA, Palmer JR, Rosenberg L. Racial Disparities and Sex Differences in Early- and Late-Onset Colorectal Cancer Incidence, 2001-2018. Front Oncol 2021;11:734998. [PMID: 34568072 DOI: 10.3389/fonc.2021.734998] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
513 Yuan B, Shi Y, Li Y, Tan H, Jiao P, Su W, Liu M, Qi Z, Tan H, Luo J. Ki-67 index of 5% could better predict the clinical prognosis of well-differentiated pancreatic neuroendocrine tumours. Jpn J Clin Oncol 2021:hyab144. [PMID: 34580725 DOI: 10.1093/jjco/hyab144] [Reference Citation Analysis]
514 Pastorino L, Grillo F, Albertelli M, Ghiorzo P, Bruno W. Insights into Mechanisms of Tumorigenesis in Neuroendocrine Neoplasms. Int J Mol Sci 2021;22:10328. [PMID: 34638668 DOI: 10.3390/ijms221910328] [Reference Citation Analysis]
515 Kalligeros M, Diamantopoulos L, Toumpanakis C. Biomarkers in Small Intestine NETs and Carcinoid Heart Disease: A Comprehensive Review. Biology (Basel) 2021;10:950. [PMID: 34681049 DOI: 10.3390/biology10100950] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
516 Do MY, Jang SI, Kang HP, Kim EJ, Lee KJ, Park GE, Lee SJ, Lee DK, Woo SM, Cho JH. Comparison of the Clinical Features and Outcomes of Gallbladder Neuroendocrine Carcinoma with Those of Adenocarcinoma: A Propensity Score-Matched Analysis. Cancers (Basel) 2021;13:4713. [PMID: 34572940 DOI: 10.3390/cancers13184713] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
517 Koch C, Koca E, Filmann N, Husmann G, Bojunga J. Time from first tumor manifestation to diagnosis in patients with GEP-NET: Results from a large German tertiary referral center. Medicine (Baltimore) 2021;100:e27276. [PMID: 34664885 DOI: 10.1097/MD.0000000000027276] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
518 Guo X, Gao S, Li Z, Hao J. The role of biomarker in pancreatic neuroendocrine tumor: a narrative review. Journal of Pancreatology 2021;Publish Ahead of Print. [DOI: 10.1097/jp9.0000000000000076] [Reference Citation Analysis]
519 Escobar KM, Vicente-villardon JL, de la Hoz-m J, Useche-castro LM, Alarcón Cano DF, Siteneski A. Frequency of Neuroendocrine Tumor Studies: Using Latent Dirichlet Allocation and HJ-Biplot Statistical Methods. Mathematics 2021;9:2281. [DOI: 10.3390/math9182281] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
520 Gonulal B, Bilgic Y, Akbulut S, Karabulut E, Samdanci ET. Management and Survival Analysis of Gastrointestinal Neuroendocrine Tumors by Different Tumor Characteristics: Tertiary Center Experience. J Gastrointest Cancer 2021. [PMID: 34524616 DOI: 10.1007/s12029-021-00709-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
521 Underwood PW, Riner AN, Neal D, Cameron ME, Yakovenko A, Reddy S, Rose JB, Hughes SJ, Trevino JG. It's more than just cancer biology: Health disparities in patients with pancreatic neuroendocrine tumors. J Surg Oncol 2021. [PMID: 34499741 DOI: 10.1002/jso.26667] [Reference Citation Analysis]
522 Darden C, Price M, Ray D, Goldstein G, Goss D, Bennett L, Garbinsky D, Thota R. Patients' satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors. J Patient Rep Outcomes 2021;5:82. [PMID: 34491454 DOI: 10.1186/s41687-021-00355-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
523 Xu J. Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs). Ther Adv Med Oncol 2021;13:17588359211042689. [PMID: 34484432 DOI: 10.1177/17588359211042689] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
524 Alkhayyat M, Saleh MA, Coronado W, Abureesh M, Zmaili M, Qapaja T, Almomani A, Khoudari G, Mansoor E, Cooper G. Epidemiology of neuroendocrine tumors of the appendix in the USA: a population-based national study (2014-2019). Ann Gastroenterol 2021;34:713-20. [PMID: 34475743 DOI: 10.20524/aog.2021.0643] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
525 Lahner H, Mathew A, Klocker AL, Unger N, Theysohn J, Rekowski J, Jöckel KH, Theurer S, Schmid KW, Herrmann K, Führer D. Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy. Endocrine 2021. [PMID: 34480724 DOI: 10.1007/s12020-021-02859-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
526 Popa O, Taban SM, Pantea S, Plopeanu AD, Barna RA, Cornianu M, Pascu AA, Dema ALC. The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of somatostatin receptor 2 and 5. Exp Ther Med 2021;22:1179. [PMID: 34475969 DOI: 10.3892/etm.2021.10613] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
527 Scandurra C, Modica R, Maldonato NM, Dolce P, Dipietrangelo GG, Centello R, Di Vito V, Bottiglieri F, de Cicco F, Giannetta E, Isidori AM, Lenzi A, Muzii B, Faggiano A, Colao A. Quality of Life in Patients with Neuroendocrine Neoplasms: The Role of Severity, Clinical Heterogeneity, and Resilience. J Clin Endocrinol Metab 2021;106:e316-27. [PMID: 33084861 DOI: 10.1210/clinem/dgaa760] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
528 Elzein S, Bao F, Lin R, Schnickel G, Lowy AM, Botta GP. Tri-modal management of primary small cell carcinoma of the pancreas (SCCP): a rare neuroendocrine carcinoma (NEC). BMC Gastroenterol 2021;21:340. [PMID: 34479480 DOI: 10.1186/s12876-021-01901-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
529 Steck A, Nebiker C, Capraro J, Yurtsever H, Toutonji AA, Struja T. [VIPoma of the Pancreas]. Praxis (Bern 1994) 2021;110:637-42. [PMID: 34465193 DOI: 10.1024/1661-8157/a003714] [Reference Citation Analysis]
530 Kole C, Charalampakis N, Vailas M, Tolia M, Sotiropoulou M, Tsakatikas S, Kouris NI, Tsoli M, Koumarianou A, Karamouzis MV, Schizas D. Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 update. Cancer Immunol Immunother 2021. [PMID: 34471940 DOI: 10.1007/s00262-021-03046-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
531 Ozbas B, Karaca Z, Okcesiz I, Karahan I, Topaloglu N, Abdulrezzak U, Ozturk F, Unluhizarci K. Co-existence of two different types of pancreatic neuroendocrine tumors in a patient with multiple endocrine neoplasia type-1. Journal of Clinical and Translational Endocrinology: Case Reports 2021;21:100088. [DOI: 10.1016/j.jecr.2021.100088] [Reference Citation Analysis]
532 Ronde EM, Heidsma CM, Eskes AM, Schopman JE, Nieveen van Dijkum EJM. Health-related quality of life and treatment effects in patients with well-differentiated gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. Eur J Cancer Care (Engl) 2021;30:e13504. [PMID: 34462979 DOI: 10.1111/ecc.13504] [Reference Citation Analysis]
533 Galgano SJ, Wei B, Rose JB. PET Imaging of Neuroendocrine Tumors. Radiol Clin North Am 2021;59:789-99. [PMID: 34392919 DOI: 10.1016/j.rcl.2021.05.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
534 Xu Z, Wang L, Dai S, Chen M, Li F, Sun J, Luo F. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States. JAMA Netw Open 2021;4:e2124750. [PMID: 34554237 DOI: 10.1001/jamanetworkopen.2021.24750] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 18.5] [Reference Citation Analysis]
535 Khanna A, Cianci N, Abbas Shah H, Goel A, Jebril A, Chauhan J, Pipe M, Shetty S, Weston C, Venkataraman H, Smith S, Vickrage S, Kemp‐blake J, Shah T. Telotristat in the management of Carcinoid diarrhoea – A real world experience of patients from ENETs centre of excellence in Neuroendocrine tumours. GastroHep 2021;3:291-297. [DOI: 10.1002/ygh2.491] [Reference Citation Analysis]
536 Chan DL, Ulaner GA, Pattison D, Wyld D, Ladwa R, Kirchner J, Li BT, Lai WV, Pavlakis N, Roach PJ, Bailey DL. Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker. J Nucl Med 2021;62:1278-84. [PMID: 33579809 DOI: 10.2967/jnumed.120.257659] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
537 Rinke A, Auernhammer CJ, Bodei L, Kidd M, Krug S, Lawlor R, Marinoni I, Perren A, Scarpa A, Sorbye H, Pavel ME, Weber MM, Modlin I, Gress TM. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine? Gut 2021;70:1768-81. [PMID: 33692095 DOI: 10.1136/gutjnl-2020-321300] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
538 Nguyen AH, O'Leary MP, De Andrade JP, Ituarte PG, Warner SG, Melstrom LG, Kessler J, Fong Y, Li D, Singh G. Presentation and survival of gastro-entero-pancreatic neuroendocrine tumors in young adults versus older patients. Am J Surg 2021:S0002-9610(21)00513-4. [PMID: 34474917 DOI: 10.1016/j.amjsurg.2021.08.030] [Reference Citation Analysis]
539 Lin A, Feng J, Chen X, Wang D, Wong M, Zhang G, Na J, Zhang T, Chen Z, Chen YT, Nancy Du YC. High levels of truncated RHAMM cooperate with dysfunctional p53 to accelerate the progression of pancreatic cancer. Cancer Lett 2021;514:79-89. [PMID: 34044069 DOI: 10.1016/j.canlet.2021.05.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
540 Haddad T, Fard-Esfahani A, Vali R. A review of pediatric neuroendocrine tumors, their detection, and treatment by radioisotopes. Nucl Med Commun 2021;42:21-31. [PMID: 33044400 DOI: 10.1097/MNM.0000000000001305] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
541 Liaqat A, Farooq A, Gulzar Q, Stalcup S, Abdalsalam B. Central Vein Thrombosis in Pulmonary Neuroendocrine Neoplasm: A Novel Presentation. Cureus 2021;13:e16499. [PMID: 34430114 DOI: 10.7759/cureus.16499] [Reference Citation Analysis]
542 Gao H, Dong J, Zhang W, Xu H, Ye L, Li H, Ni Q, Wang W, Liu L. Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors. Endocr Pract 2021:S1530-891X(21)01179-4. [PMID: 34454077 DOI: 10.1016/j.eprac.2021.08.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
543 Kiňová S, Koreň M. Carcinoid syndroma - diagnosis and management. Vnitr Lek 2021;67:310-314. [DOI: 10.36290/vnl.2021.079] [Reference Citation Analysis]
544 Thompson R, Landry CS. Multiple endocrine neoplasia 1: a broad overview. Ther Adv Chronic Dis 2021;12:20406223211035288. [PMID: 34413971 DOI: 10.1177/20406223211035288] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
545 Sharma R, Lythgoe MP, Slaich B, Patel N. Exploring the Epigenome in Gastroenteropancreatic Neuroendocrine Neoplasias. Cancers (Basel) 2021;13:4181. [PMID: 34439335 DOI: 10.3390/cancers13164181] [Reference Citation Analysis]
546 Frizziero M, Durand A, Taboada RG, Zaninotto E, Luchini C, Chakrabarty B, Hervieu V, Claro LCL, Zhou C, Cingarlini S, Milella M, Walter T, Riechelmann RS, Lamarca A, Hubner RA, Mansoor W, Valle JW, McNamara MG. Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant? Cancers (Basel) 2021;13:4152. [PMID: 34439308 DOI: 10.3390/cancers13164152] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
547 Scott AT, Howe JR. Management of Small Bowel Neuroendocrine Tumors. Surg Oncol Clin N Am 2020;29:223-41. [PMID: 32151357 DOI: 10.1016/j.soc.2019.11.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
548 Vaghaiwalla T, Keutgen XM. Surgical Management of Pancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 2020;29:243-52. [PMID: 32151358 DOI: 10.1016/j.soc.2019.11.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
549 O'Dorisio TM, Harris AG, O'Dorisio MS. Evolution of Neuroendocrine Tumor Therapy. Surg Oncol Clin N Am 2020;29:145-63. [PMID: 32151353 DOI: 10.1016/j.soc.2019.11.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
550 Chandrasekharan C. Medical Management of Gastroenteropancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 2020;29:293-316. [PMID: 32151362 DOI: 10.1016/j.soc.2019.11.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
551 Laird AM, Libutti SK. Management of Other Gastric and Duodenal Neuroendocrine Tumors. Surg Oncol Clin N Am 2020;29:253-66. [PMID: 32151359 DOI: 10.1016/j.soc.2019.11.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
552 Xu R, Zhou B, Hu P, Xue B, Gu D, Li X, Tang Q. Development and validation of prognostic nomograms for patients with colon neuroendocrine neoplasms. World J Surg Oncol 2021;19:233. [PMID: 34364382 DOI: 10.1186/s12957-021-02338-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
553 Satapathy S, Mittal BR, Sood A, Sood A, Kapoor R, Gupta R, Khosla D. 177Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors: A Single-Institution Experience. JCO Glob Oncol 2021;7:1167-75. [PMID: 34288699 DOI: 10.1200/GO.21.00103] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
554 Malczewska A, Frampton AE, Mato Prado M, Ameri S, Dabrowska AF, Zagorac S, Clift AK, Kos-Kudła B, Faiz O, Stebbing J, Castellano L, Frilling A. Circulating MicroRNAs in Small-bowel Neuroendocrine Tumors: A Potential Tool for Diagnosis and Assessment of Effectiveness of Surgical Resection. Ann Surg 2021;274:e1-9. [PMID: 31373926 DOI: 10.1097/SLA.0000000000003502] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
555 Prantesh J, Dorth J, Asa SL, Mohamed A. Nasopharyngeal neuroendocrine neoplasms: Systematic review of the literature and case presentation. J Neuroendocrinol 2021;33:e13005. [PMID: 34342078 DOI: 10.1111/jne.13005] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
556 Webster AP, Thirlwell C. The evolving molecular landscape of intestinal and pulmonary neuroendocrine tumours. Current Opinion in Endocrine and Metabolic Research 2021;19:30-34. [DOI: 10.1016/j.coemr.2021.05.004] [Reference Citation Analysis]
557 Maccauro M, Lorenzoni A. La radioterapia selettiva interna nelle metastasi epatiche dei tumori neuroendocrini. L'Endocrinologo 2021;22:305-310. [DOI: 10.1007/s40619-021-00940-2] [Reference Citation Analysis]
558 Allmark A, Brubaker ML. Small cell neuroendocrine carcinoma disguised as an external hemorrhoid. JAAPA 2021;34:35-9. [PMID: 34320538 DOI: 10.1097/01.JAA.0000742960.70174.8d] [Reference Citation Analysis]
559 Spyroglou A, Bramis K, Alexandraki KI. Neuroendocrine neoplasms: Evolving and future treatments. Current Opinion in Endocrine and Metabolic Research 2021;19:15-21. [DOI: 10.1016/j.coemr.2021.05.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
560 Bonet I, Sanchez-cabús S, González JA, Moral A. Non-functioning neuroendocrine tumor retrograde. Gastroenterología y Hepatología (English Edition) 2021;44:495-496. [DOI: 10.1016/j.gastre.2020.07.018] [Reference Citation Analysis]
561 Ronot M, Vullierme M. Morphological imaging of gastrointestinal and lung neuroendocrine neoplasms. Current Opinion in Endocrine and Metabolic Research 2021;19:1-7. [DOI: 10.1016/j.coemr.2021.05.001] [Reference Citation Analysis]
562 Barrea L, Muscogiuri G, Pugliese G, Modica R, Laudisio D, Aprano S, Faggiano A, Colao A, Savastano S. Chronotype: what role in the context of gastroenteropancreatic neuroendocrine tumors? J Transl Med 2021;19:324. [PMID: 34330303 DOI: 10.1186/s12967-021-03010-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
563 Pellat A, Cottereau AS, Terris B, Coriat R. Neuroendocrine Carcinomas of the Digestive Tract: What Is New? Cancers (Basel) 2021;13:3766. [PMID: 34359666 DOI: 10.3390/cancers13153766] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
564 Mullangi S, Lekkala MR, Raghu Subramanian C, Nemer O, Singh J, Kichloo A, Moftakhar B. Incidental Finding of Squamous Cell Carcinoma on a 68Ga-DOTATATE PET Scan. J Investig Med High Impact Case Rep 2021;9:23247096211035232. [PMID: 34311624 DOI: 10.1177/23247096211035232] [Reference Citation Analysis]
565 Lania A, Ferraù F, Rubino M, Modica R, Colao A, Faggiano A. Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches. Front Endocrinol (Lausanne) 2021;12:651438. [PMID: 34381421 DOI: 10.3389/fendo.2021.651438] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
566 Han X, Yang J, Luo J, Chen P, Zhang Z, Alu A, Xiao Y, Ma X. Application of CT-Based Radiomics in Discriminating Pancreatic Cystadenomas From Pancreatic Neuroendocrine Tumors Using Machine Learning Methods. Front Oncol 2021;11:606677. [PMID: 34367940 DOI: 10.3389/fonc.2021.606677] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
567 Kjaer J, Stålberg P, Crona J, Welin S, Hellman P, Thornell A, Norlen O. Long-term outcome after resection and thermal hepatic ablation of pancreatic neuroendocrine tumour liver metastases. BJS Open 2021;5:zrab062. [PMID: 34291287 DOI: 10.1093/bjsopen/zrab062] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
568 Rinke A, Maintz C, Müller L, Weber MM, Lahner H, Pavel M, Saeger W, Houchard A, Ungewiss H, Petersenn S. Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria. Exp Clin Endocrinol Diabetes 2021;129:500-9. [PMID: 34293802 DOI: 10.1055/a-1342-2755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
569 Wang Y, Zhang Y, Lin H, Xu M, Zhou X, Zhuang J, Yang Y, Chen B, Liu X, Guan G. Risk factors for lymph node metastasis in rectal neuroendocrine tumors: A recursive partitioning analysis based on multicenter data. J Surg Oncol 2021. [PMID: 34291822 DOI: 10.1002/jso.26615] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
570 Trillo Aliaga P, Spada F, Peveri G, Bagnardi V, Fumagalli C, Laffi A, Rubino M, Gervaso L, Guerini Rocco E, Pisa E, Curigliano G, Fazio N. Should temozolomide be used on the basis of O6-methylguanine DNA methyltransferase status in patients with advanced neuroendocrine tumors? A systematic review and meta-analysis. Cancer Treat Rev 2021;99:102261. [PMID: 34332293 DOI: 10.1016/j.ctrv.2021.102261] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
571 Ha S, Song KB, Hong S, Shin D, Park Y, Kwon J, Lee W, Jun E, Lee JH, Hwang DW, Kim SC. The clinicopathologic and operative characteristics of patients with small nonfunctioning pancreatic neuroendocrine tumors. ANZ J Surg 2021;91:E484-92. [PMID: 34291544 DOI: 10.1111/ans.17055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
572 Chen Q, Li M, Wang P, Chen J, Zhao H, Zhao J. Optimal Cut-Off Values of the Positive Lymph Node Ratio and the Number of Removed Nodes for Patients Receiving Resection of Bronchopulmonary Carcinoids: A Propensity Score-Weighted Analysis of the SEER Database. Front Oncol 2021;11:696732. [PMID: 34367980 DOI: 10.3389/fonc.2021.696732] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
573 Gower-Fry L, Kronemann T, Dorian A, Pu Y, Jaworski C, Wängler C, Bartenstein P, Beyer L, Lindner S, Jurkschat K, Wängler B, Bailey JJ, Schirrmacher R. Recent Advances in the Clinical Translation of Silicon Fluoride Acceptor (SiFA) 18F-Radiopharmaceuticals. Pharmaceuticals (Basel) 2021;14:701. [PMID: 34358127 DOI: 10.3390/ph14070701] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
574 Kiesewetter B, Raderer M. How I treat neuroendocrine tumours. ESMO Open 2020;5:e000811. [PMID: 32817134 DOI: 10.1136/esmoopen-2020-000811] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
575 Hayes AR, Chan DLH, Chan BA, Pavlakis N. The quality of clinical trials in neuroendocrine tumours; have we learnt from our mistakes? An evaluation of phase II and phase III clinical trials. J Neuroendocrinol 2021;:e13015. [PMID: 34397130 DOI: 10.1111/jne.13015] [Reference Citation Analysis]
576 Hofland J, Kaltsas G, de Herder WW. Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. Endocr Rev. 2020;41. [PMID: 31555796 DOI: 10.1210/endrev/bnz004] [Cited by in Crossref: 61] [Cited by in F6Publishing: 69] [Article Influence: 30.5] [Reference Citation Analysis]
577 Wang M, Ding D, Qin T, Wang H, Liu Y, Liu J, Liu J, Zhang H, Zhao J, Wu CH, Javed A, Wolfgang C, Guo S, Chen Q, Zhao W, Shi W, Zhu F, Guo X, Li X, He R, Xu S, Edil B, Tien YW, Jin G, Zheng L, He J, Qin R; Minimally Invasive Pancreas Treatment Group in the Pancreatic Disease Branch of China's International Exchange and Promotion Association for Medicine and Healthcare. New staging classification for pancreatic neuroendocrine neoplasms combining TNM stage and WHO grade classification []. Cancer Lett 2021;518:207-13. [PMID: 34271105 DOI: 10.1016/j.canlet.2021.07.018] [Reference Citation Analysis]
578 Gonzalez RS. Diagnosis and Management of Gastrointestinal Neuroendocrine Neoplasms. Surg Pathol Clin 2020;13:377-97. [PMID: 32773190 DOI: 10.1016/j.path.2020.04.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
579 Pollard JH, Menda Y, Zamba KD, Madsen M, O'Dorisio MS, O'Dorisio T, Bushnell D. Potential for Increasing Uptake of Radiolabeled 68Ga-DOTATOC and 123I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat. Cancer Biother Radiopharm 2021. [PMID: 34252288 DOI: 10.1089/cbr.2020.4633] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
580 Heaphy CM, VandenBussche CJ. Prognostic biomarkers in pancreatic neuroendocrine tumors. Cancer Cytopathol 2021. [PMID: 34242496 DOI: 10.1002/cncy.22457] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
581 Gogna S, Samson D, Gachabayov M, Rojas A, Felsenreich DM, Koo D, Gu K, Quintero L, Miller KR, Azim A, Da Eric Dong X. Neuroendocrine neoplasms of the gallbladder: early detection and surgery is key to improved outcome. Langenbecks Arch Surg 2021. [PMID: 34236488 DOI: 10.1007/s00423-021-02256-z] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
582 Kaçmaz E, Chen JW, Tanis PJ, Nieveen van Dijkum EJM, Engelsman AF. Postoperative morbidity and mortality after surgical resection of small bowel neuroendocrine neoplasms: A systematic review and meta-analysis. J Neuroendocrinol 2021;33:e13008. [PMID: 34235792 DOI: 10.1111/jne.13008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
583 Krug S, Damm M, Garbe J, König S, Schmitz RL, Michl P, Schrader J, Rinke A. Finding the Appropriate Therapeutic Strategy in Patients with Neuroendocrine Tumors of the Pancreas: Guideline Recommendations Meet the Clinical Reality. J Clin Med 2021;10:3023. [PMID: 34300189 DOI: 10.3390/jcm10143023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
584 Saito K, Yamaoka Y, Shiomi A, Kagawa H, Hino H, Manabe S, Kato S, Hanaoka M. Short- and Long-Term Outcomes of Robotic Surgery for Rectal Neuroendocrine Tumor. Surg Innov 2021;:15533506211030436. [PMID: 34228945 DOI: 10.1177/15533506211030436] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
585 Assi HA, Hornbacker K, Shaheen S, Wittenberg T, Silberman R, Kunz PL. Rapid Progression After 177Lu-DOTATATE in Patients With Neuroendocrine Tumors. Pancreas 2021;50:890-4. [PMID: 34398071 DOI: 10.1097/MPA.0000000000001841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
586 Chen L, Guo Y, Zhang Y, Liu M, Zhang Y, Lin Y, Chen MH, Chen J. Development of a novel scoring system based on endoscopic appearance for management of rectal neuroendocrine tumors. Endoscopy 2021;53:702-9. [PMID: 32992347 DOI: 10.1055/a-1274-0161] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
587 Jackson T, Darwish M, Cho E, Nagatomo K, Osman H, Jeyarajah DR. 68Ga-DOTATATE PET/CT compared to standard imaging in metastatic neuroendocrine tumors: a more sensitive test to detect liver metastasis? Abdom Radiol (NY) 2021;46:3179-83. [PMID: 33665733 DOI: 10.1007/s00261-021-02990-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
588 Manoharan P, Lamarca A, Navalkissoor S, Calero J, Chan PS, Julyan P, Sierra M, Caplin M, Valle J. Safety, tolerability and clinical implementation of 'ready-to-use' 68gallium-DOTA0-Tyr3-octreotide (68Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs). ESMO Open 2020;5:e000650. [PMID: 32188715 DOI: 10.1136/esmoopen-2019-000650] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
589 Yu F, Fu J, Zhang C, Wu W, Ai S, Yao X, Meng Q, Huang Y, Lu G, Wang F, Qu W. Use of Chromogranin A for Monitoring Patients With Pancreatic Neuroendocrine Neoplasms. Pancreas 2021;50:882-9. [PMID: 34347728 DOI: 10.1097/MPA.0000000000001852] [Reference Citation Analysis]
590 Ribeiro S, De Maeyer F, De Man M, Carton S, Cuyle PJ, Verslype C, Borbath I, Demetter P, Van Damme N, Van Eycken L, Vandamme T, Hoorens A, Geboes K. Lessons learned about appendiceal neuroendocrine neoplasms from data analysis of the Belgian Cancer Registry 2010-2015. Acta Gastroenterol Belg 2021;84:458-66. [PMID: 34599571 DOI: 10.51821/84.3.011] [Reference Citation Analysis]
591 Muffatti F, Partelli S, Andreasi V, Falconi M. Diagnosis and Treatment of Pancreatic Neuroendocrine Tumors. Clinical Pancreatology for Practising Gastroenterologists and Surgeons 2021. [DOI: 10.1002/9781119570097.ch76] [Reference Citation Analysis]
592 Takagi K, Umeda Y, Yoshida R, Yoshida K, Yasui K, Sato H, Yagi T, Fujiwara T. Gastroenteropancreatic neuroendocrine tumor of the accessory papilla of the duodenum: a case report. Surg Case Rep 2021;7:156. [PMID: 34191176 DOI: 10.1186/s40792-021-01241-4] [Reference Citation Analysis]
593 Davis A, Clarke S, Ayesa S, Chan DL. Marked improvement in hyperammonaemic encephalopathy from multimodal treatment of metastatic neuroendocrine tumour. BMJ Case Rep 2021;14:e241191. [PMID: 34193447 DOI: 10.1136/bcr-2020-241191] [Reference Citation Analysis]
594 Lu X, Yan S, Koral KA, Chen Z. Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors. Expert Rev Anticancer Ther 2021;21:917-26. [PMID: 34142932 DOI: 10.1080/14737140.2021.1944110] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
595 Satapathy S, Bhattacharya A, Sood A, Kapoor R, Gupta R, Sood A, Sharma P, Khosla D, Mittal BR. Hematological Markers as Predictors of Treatment Outcomes with Lu-177 DOTATATE in Patients with Advanced Neuroendocrine Tumors. Cancer Biother Radiopharm 2021. [PMID: 34185573 DOI: 10.1089/cbr.2021.0053] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
596 Dawod M, Gordoa TA, Cives M, De Mestier L, Crona J, Spada F, Oberg K, Pavel M, Lamarca A. Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours. Curr Treat Options Oncol 2021;22:73. [PMID: 34185197 DOI: 10.1007/s11864-021-00863-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
597 Sun S, Wang W, He C. Cardiovascular Mortality Risk among Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Registry-Based Analysis. Oxid Med Cell Longev 2021;2021:9985814. [PMID: 34257826 DOI: 10.1155/2021/9985814] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
598 Kobayashi N, Wild D, Kaul F, Shimamura T, Takano S, Takeda Y, Okubo N, Suzuki A, Tokuhisa M, Ichikawa Y. Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors. J Hepatobiliary Pancreat Sci 2021. [PMID: 34174175 DOI: 10.1002/jhbp.1014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
599 Kim J, Kim J, Oh EH, Ham NS, Hwang SW, Park SH, Ye BD, Byeon JS, Myung SJ, Yang SK, Hong SM, Yang DH. Anchoring the snare tip is a feasible endoscopic mucosal resection method for small rectal neuroendocrine tumors. Sci Rep 2021;11:12918. [PMID: 34155319 DOI: 10.1038/s41598-021-92462-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
600 Alnimri F, Ng MW, Modak P. Rectal carcinoid tumour presenting as polyp: a challenge in management in rural settings. ANZ J Surg 2021;91:1318-9. [PMID: 34121291 DOI: 10.1111/ans.16857] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
601 Karls S, Gold R, Kravets S, Wang Y, Cheng S, Perez K, Chan J, Jacene H. Correlation of 68Ga-DOTATATE uptake on PET/CT with pathologic features of cellular proliferation in neuroendocrine neoplasms. Ann Nucl Med 2021;35:1066-77. [PMID: 34146243 DOI: 10.1007/s12149-021-01642-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
602 Mastoraki A, Schizas D, Papoutsi E, Ntella V, Kanavidis P, Sioulas A, Tsoli M, Charalampopoulos G, Vailas M, Felekouras E. Clinicopathological Data and Treatment Modalities for Pancreatic Somatostatinomas. In Vivo 2020;34:3573-82. [PMID: 33144470 DOI: 10.21873/invivo.12201] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
603 Steinkraus K, Andresen JR, Clift AK, Liedke MO, Frilling A. Multifocal neuroendocrine tumour of the small bowel presenting as an incarcerated incisional hernia: a surgical challenge in a high-risk patient. J Surg Case Rep 2021;2021:rjab219. [PMID: 34150191 DOI: 10.1093/jscr/rjab219] [Reference Citation Analysis]
604 Półtorak-Szymczak G, Budlewski T, Furmanek MI, Wierzba W, Sklinda K, Walecki J, Mruk B. Radiological Imaging of Gastro-Entero-Pancreatic Neuroendocrine Tumors. The Review of Current Literature Emphasizing the Diagnostic Value of Chosen Imaging Methods. Front Oncol 2021;11:670233. [PMID: 34211845 DOI: 10.3389/fonc.2021.670233] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
605 Derks JL, Rijnsburger N, Hermans BCM, Moonen L, Hillen LM, von der Thüsen JH, den Bakker MA, van Suylen RJ, Speel EM, Dingemans AC. Clinical-Pathologic Challenges in the Classification of Pulmonary Neuroendocrine Neoplasms and Targets on the Horizon for Future Clinical Practice. J Thorac Oncol 2021:S1556-0864(21)02228-0. [PMID: 34139363 DOI: 10.1016/j.jtho.2021.05.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
606 Mahdi M, Ozer M, Tahseen M. A Challenging Case of Carcinoid Crisis in a Patient With Neuroendocrine Tumor. Cureus 2021;13:e15626. [PMID: 34277243 DOI: 10.7759/cureus.15626] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
607 Exarchou K, Kamieniarz L, Tsoli M, Victor A, Oleinikov K, Khan MS, Srirajaskanthan R, Mandair D, Grozinsky-Glasberg S, Kaltsas G, Howes N, Pritchard DM, Toumpanakis C. Is local excision sufficient in selected grade 1 or 2 type III gastric neuroendocrine neoplasms? Endocrine 2021. [PMID: 34120313 DOI: 10.1007/s12020-021-02775-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
608 Cukier M, Vergara R, Mendez-Rios JD, Castillo O, Barrera I, Tello E, El Achtar O, Loo Y, Tapia H, Perez G, Peña M. Neuroendocrine tumors in Panama: A nationwide database analysis. Mol Clin Oncol 2021;15:157. [PMID: 34178328 DOI: 10.3892/mco.2021.2319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
609 Hiltunen N, Väyrynen JP, Böhm J, Helminen O. CD3+, CD8+, CD4+ and FOXP3+ T Cells in the Immune Microenvironment of Small Bowel Neuroendocrine Tumors. Diseases 2021;9:42. [PMID: 34208144 DOI: 10.3390/diseases9020042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
610 Lu L, Shang Y, Zechner D, Mullins CS, Linnebacher M, Zhang X, Gong P. Development and Validation of a Score for Screening Suicide of Patients With Neuroendocrine Neoplasms. Front Psychiatry 2021;12:638152. [PMID: 34177643 DOI: 10.3389/fpsyt.2021.638152] [Reference Citation Analysis]
611 Mollazadegan K, Welin S, Crona J. Systemic Treatment of Gastroenteropancreatic Neuroendocrine Carcinoma. Curr Treat Options Oncol 2021;22:68. [PMID: 34110508 DOI: 10.1007/s11864-021-00866-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
612 van Rees JM, Elferink MAG, Tanis PJ, de Wilt JHW, Burger JWA, Verhoef C. The incidence, treatment and survival of patients with rare types of rectal malignancies in the Netherlands: A population-based study between 1989 and 2018. Eur J Cancer 2021;152:183-92. [PMID: 34118528 DOI: 10.1016/j.ejca.2021.04.036] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
613 Hou J, Long T, He Z, Zhou M, Yang N, Chen D, Zeng S, Hu S. Evaluation of 18F-AlF-NOTA-octreotide for imaging neuroendocrine neoplasms: comparison with 68Ga-DOTATATE PET/CT. EJNMMI Res 2021;11:55. [PMID: 34106351 DOI: 10.1186/s13550-021-00797-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
614 Custodio A, Jimenez-Fonseca P, Carmona-Bayonas A, Gomez MJ, Del Olmo-García MI, Lorenzo I, Díaz JÁ, Canal N, De la Cruz G, Villabona C. Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study. Clin Transl Oncol 2021;23:2046-56. [PMID: 34109562 DOI: 10.1007/s12094-021-02608-7] [Reference Citation Analysis]
615 Søreide JA, Kvaløy JT, Lea D, Sandvik OM, Al-Saiddi M, Haslerud TM, Garresori H, Karlsen LN, Gudlaugsson E, Søreide K. The overriding role of surgery and tumor grade for long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based cohort study. Cancer Rep (Hoboken) 2021;:e1462. [PMID: 34105314 DOI: 10.1002/cnr2.1462] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
616 Anthony LB, O'Dorisio TM. Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP-NETs: A Review of Key Issues. Oncologist 2021;26:e1171-8. [PMID: 34097784 DOI: 10.1002/onco.13847] [Reference Citation Analysis]
617 Becker A, Schalin-Jäntti C, Itkonen O. Comparison of Serum and Urinary 5-Hydroxyindoleacetic Acid as Biomarker for Neuroendocrine Neoplasms. J Endocr Soc 2021;5:bvab106. [PMID: 34195530 DOI: 10.1210/jendso/bvab106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
618 Han D, Li YL, Zhou ZW, Yin F, Chen J, Liu F, Shi YF, Wang W, Zhang Y, Yu XJ, Xu JM, Yang RX, Tian C, Luo J, Tan HY. Clinicopathological characteristics and prognosis of 232 patients with poorly differentiated gastric neuroendocrine neoplasms. World J Gastroenterol 2021; 27(21): 2895-2909 [PMID: 34135560 DOI: 10.3748/wjg.v27.i21.2895] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
619 Cuthbertson DJ, Barriuso J, Lamarca A, Manoharan P, Westwood T, Jaffa M, Fenwick SW, Nuttall C, Lalloo F, Prachalias A, Pizanias M, Wieshmann H, McNamara MG, Hubner R, Srirajaskanthan R, Vivian G, Ramage J, Weickert MO, Pritchard DM, Vinjamuri S, Valle J, Yip VS. The Impact of 68Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours. Front Endocrinol (Lausanne) 2021;12:654975. [PMID: 34163434 DOI: 10.3389/fendo.2021.654975] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
620 Schmitz RL, Weissbach J, Kleilein J, Bell J, Hüttelmaier S, Viol F, Clauditz T, Grabowski P, Laumen H, Rosendahl J, Michl P, Schrader J, Krug S. Targeting HDACs in Pancreatic Neuroendocrine Tumor Models. Cells 2021;10:1408. [PMID: 34204116 DOI: 10.3390/cells10061408] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
621 O'Hagan K. Infrequent Offenders: Neuroendocrine Tumors and Cancers of the Appendix, Gallbladder, and Bile Duct. J Adv Pract Oncol 2021;12:315-8. [PMID: 34084582 DOI: 10.6004/jadpro.2021.12.3.20] [Reference Citation Analysis]
622 Noor M, Huber AR, Cates JMM, Gonzalez RS. Risk factors for progression of appendiceal neuroendocrine tumours: low-stage tumours <5 mm appear to be overwhelmingly indolent and may merit a separate designation. Histopathology 2021;79:416-26. [PMID: 33754384 DOI: 10.1111/his.14369] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
623 Debien V, Davidson G, Baltzinger P, Kurtz JE, Séverac F, Imperiale A, Pessaux P, Addeo P, Bachellier P, Su X, Davidson I, Chenard MP, Goichot B, Malouf GG. Involvement of Neutrophils in Metastatic Evolution of Pancreatic Neuroendocrine Tumors. Cancers (Basel) 2021;13:2771. [PMID: 34199561 DOI: 10.3390/cancers13112771] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
624 Sheikhbahaei S, Sadaghiani MS, Rowe SP, Solnes LB. Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice. AJR Am J Roentgenol 2021;217:495-506. [PMID: 34076455 DOI: 10.2214/AJR.20.23349] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
625 Maharjan CK, Umesalma S, Kaemmer CA, Muniz VP, Bauchle C, Mott SL, Zamba KD, Breheny P, Leidinger MR, Darbro BW, Stephens SB, Meyerholz DK, Quelle DE. RABL6A Promotes Pancreatic Neuroendocrine Tumor Angiogenesis and Progression In Vivo. Biomedicines 2021;9:633. [PMID: 34199469 DOI: 10.3390/biomedicines9060633] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
626 Chen KS, Lawhn-Heath C, Behr S, Juarez R, Whitman J, Paciorek A, Nakakura EK, Fidelman N, Feng MU, Bergsland EK, Anwar M. Outcomes after high-dose radiation in the management of neuroendocrine neoplasms. PLoS One 2021;16:e0252574. [PMID: 34077464 DOI: 10.1371/journal.pone.0252574] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
627 Vaghaiwalla T, Memeh K, Liao C, Keutgen XM. Metastatic well-differentiated pancreatic neuroendocrine tumors to the liver: a narrative review of systemic and surgical management. Journal of Pancreatology 2021;4:82-9. [DOI: 10.1097/jp9.0000000000000068] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
628 Trikalinos NA, Kim H, Iravani A, Henke L, Vijayan A. Severe metabolic acidosis and hyperkalemia after peptide receptor radionuclide therapy. A case report, review of the literature and proposed treatment algorithm. Journal of Onco-Nephrology 2021;5:122-128. [DOI: 10.1177/23993693211019762] [Reference Citation Analysis]
629 Daskalakis K. Functioning and nonfunctioning pNENs. Current Opinion in Endocrine and Metabolic Research 2021;18:284-290. [DOI: 10.1016/j.coemr.2021.04.007] [Reference Citation Analysis]
630 Andre A, Squittieri N, Patil SB. Evaluation of the Octreotide Acetate Pen Injector and its Instructions for Use in a Formative Human Factors Study. Adv Ther 2021;38:3129-42. [PMID: 33948925 DOI: 10.1007/s12325-021-01739-1] [Reference Citation Analysis]
631 Clift AK, Frilling A. Surgical treatment of neuroendocrine neoplasms. Current Opinion in Endocrine and Metabolic Research 2021;18:69-75. [DOI: 10.1016/j.coemr.2021.02.005] [Reference Citation Analysis]
632 Fazio N, Spada F, Bertani E. Looking for the right TNM staging system for pancreatic neuroendocrine tumors. Hepatobiliary Surg Nutr 2021;10:382-4. [PMID: 34159169 DOI: 10.21037/hbsn-2021-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
633 Lorenzo D, Maire F, Hentic O, Prat F, Ruszniewski P, de Mestier L. Endoscopic diagnosis and treatment of neuroendocrine tumors. Current Opinion in Endocrine and Metabolic Research 2021;18:201-206. [DOI: 10.1016/j.coemr.2021.03.014] [Reference Citation Analysis]
634 Ding X, Tian S, Hu J, Wang G, Yu X, Fu D, Yuan Y, Wang L, Wang Z. Risk and prognostic nomograms for colorectal neuroendocrine neoplasm with liver metastasis: a population-based study. Int J Colorectal Dis 2021;36:1915-27. [PMID: 34061225 DOI: 10.1007/s00384-021-03920-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
635 Toriyama K, Yamamura T, Nakamura M, Maeda K, Sawada T, Mizutani Y, Ishikawa E, Furukawa K, Ishikawa T, Ohno E, Kawashima H, Fujishiro M. An evaluation of resectability among endoscopic treatment methods for rectal neuroendocrine tumors <10 mm. Arab J Gastroenterol 2021;22:104-10. [PMID: 34053887 DOI: 10.1016/j.ajg.2021.05.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
636 El-haddad G, Strosberg J. Radioembolization for Metastatic Neuroendocrine Tumors. Digestive Disease Interventions 2021;05:103-112. [DOI: 10.1055/s-0041-1729755] [Reference Citation Analysis]
637 Iwaya H, Fukukura Y, Hashimoto S, Tanoue S, Kawahira M, Hinokuchi M, Fujita T, Komaki Y, Arima S, Sasaki F, Kanmura S, Higashi M, Tamada K, Ido A. Prognostic significance of extracellular volume fraction with equilibrium contrast-enhanced computed tomography for pancreatic neuroendocrine neoplasms. Pancreatology 2021;21:779-86. [PMID: 33714670 DOI: 10.1016/j.pan.2021.02.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
638 Fehrenbach U, Xin S, Hartenstein A, Auer TA, Dräger F, Froböse K, Jann H, Mogl M, Amthauer H, Geisel D, Denecke T, Wiedenmann B, Penzkofer T. Automatized Hepatic Tumor Volume Analysis of Neuroendocrine Liver Metastases by Gd-EOB MRI-A Deep-Learning Model to Support Multidisciplinary Cancer Conference Decision-Making. Cancers (Basel) 2021;13:2726. [PMID: 34072865 DOI: 10.3390/cancers13112726] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
639 Soczomski P, Jurecka-Lubieniecka B, Krzywon A, Cortez AJ, Zgliczynski S, Rogozik N, Oczko-Wojciechowska M, Pawlaczek A, Bednarczuk T, Jarzab B. A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotype-Phenotype Correlations. Front Endocrinol (Lausanne) 2021;12:681013. [PMID: 34122352 DOI: 10.3389/fendo.2021.681013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
640 Zhou YJ, Wang QW, Zhang QW, Chen JN, Wang XY, Gao YJ, Li XB. Patterns of Lymph Node Metastasis in Patients With T1/T2 Gastroduodenal Neuroendocrine Neoplasms: Implications for Endoscopic Treatment. Front Endocrinol (Lausanne) 2021;12:658392. [PMID: 34122337 DOI: 10.3389/fendo.2021.658392] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
641 Leng A, Zhong N, He S, Liu Y, Yang M, Jiao J, Xu W, Yang X, Xiao J. Symptomatic spinal metastases from neuroendocrine neoplasms: surgical outcomes and prognostic analysis. Clin Neurol Neurosurg 2021;207:106710. [PMID: 34298351 DOI: 10.1016/j.clineuro.2021.106710] [Reference Citation Analysis]
642 Soldevilla B, López-López A, Lens-Pardo A, Carretero-Puche C, Lopez-Gonzalvez A, La Salvia A, Gil-Calderon B, Riesco-Martinez MC, Espinosa-Olarte P, Sarmentero J, Rubio-Cuesta B, Rincón R, Barbas C, Garcia-Carbonero R. Comprehensive Plasma Metabolomic Profile of Patients with Advanced Neuroendocrine Tumors (NETs). Diagnostic and Biological Relevance. Cancers (Basel) 2021;13:2634. [PMID: 34072010 DOI: 10.3390/cancers13112634] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
643 Gordon LG, Elliott TM, Wakelin K, Leyden S, Leyden J, Michael M, Pavlakis N, Mumford J, Segelov E, Wyld DK. The Economic Impact on Australian Patients with Neuroendocrine Tumours. Patient 2020;13:363-73. [PMID: 32072460 DOI: 10.1007/s40271-020-00412-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
644 Mirallas O, Saoudi N, Gómez-Puerto D, Riveiro-Barciela M, Merino X, Auger C, Landolfi S, Blanco L, Garcia-Burillo A, Molero X, Salcedo-Allende MT, Capdevila J. Acquired hepatocerebral degeneration in a metastatic neuroendocrine tumor long-term survivor — an update on neuroendocrine neoplasm’s treatment: A case report. World J Hepatol 2021; 13(5): 611-619 [PMID: 34131474 DOI: 10.4254/wjh.v13.i5.611] [Reference Citation Analysis]
645 Carter AM, Kumar N, Herring B, Tan C, Guenter R, Telange R, Howse W, Viol F, Graham C, Mccaw TR, Bickerton H, Gillardon F, Woltering EA, Dhall D, Totenhagen J, Banerjee R, Kurian E, Reddy S, Chen H, Schrader J, Rose JB, Mukhtar MS, Bibb JA. Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors.. [DOI: 10.1101/2021.05.25.445594] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
646 Ahmadi Bidakhvidi N, Cuyle PJ, Sagaert X, Ballaux F, Deroose CM. 68Ga-DOTATATE PET/CT Distinguishes Neuroendocrine Tumor Mesenteric Lymph Node Metastasis From an Extensive IgG4-Positive Fibrosis Surrounding It. Clin Nucl Med 2021;46:e510-2. [PMID: 34034320 DOI: 10.1097/RLU.0000000000003722] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
647 Li Y, Wu ZQ, Xu Q, Goyal H, Xu HG. Development and Validation of Novel Nomograms Using Serum Tumor Markers for the Prediction of Preoperative Histologic Grades in Gastroenteropancreatic Neuroendocrine Tumors. Front Oncol 2021;11:681149. [PMID: 34109127 DOI: 10.3389/fonc.2021.681149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
648 Rustgi SD, Oh A, Yang JY, Kang D, Wolin E, Kong CY, Hur C, Kim MK. Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis. BMC Cancer 2021;21:597. [PMID: 34030646 DOI: 10.1186/s12885-021-08306-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
649 Mosenia A, Ward C, Yee A, Qorbani A, Corvera C. Multifocal pancreatic PPoma in the setting of MEN1: Case report and review of literature. Int J Surg Case Rep 2021;83:106008. [PMID: 34118524 DOI: 10.1016/j.ijscr.2021.106008] [Reference Citation Analysis]
650 Zhang Q, Huang J, He Y, Cao R, Shu J. Insulinoma-associated protein 1(INSM1) is a superior marker for the diagnosis of gastroenteropancreatic neuroendoerine neoplasms: a meta-analysis. Endocrine 2021. [PMID: 34021851 DOI: 10.1007/s12020-021-02754-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
651 Menshikov KV, Sultanbaev AV, Musin SI, Menshikova IA, Nasretdinov AF, Sultanbaeva NI, Shaykhutdinov IR. Neuroendocrine Tumours: a Literature Review. Kreativnaâ hirurgiâ i onkologiâ 2021;11:174-182. [DOI: 10.24060/2076-3093-2021-11-2-174-182] [Reference Citation Analysis]
652 Das S, Dasari A. Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors. Ther Adv Med Oncol 2021;13:17588359211018047. [PMID: 34093744 DOI: 10.1177/17588359211018047] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
653 Chauhan A, Das S, Miller R, Luque L, Cheuvront SN, Cloud J, Tarter Z, Siddiqui F, Ramirez RA, Anthony L. Can an amino acid mixture alleviate gastrointestinal symptoms in neuroendocrine tumor patients? BMC Cancer 2021;21:580. [PMID: 34016080 DOI: 10.1186/s12885-021-08315-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
654 Chow Z, Johnson J, Chauhan A, Izumi T, Cavnar M, Weiss H, Townsend CM Jr, Anthony L, Wasilchenko C, Melton ML, Schrader J, Evers BM, Rychahou P. PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine Tumors. Cells 2021;10:1261. [PMID: 34065268 DOI: 10.3390/cells10051261] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
655 Zimmerman NM, Ray D, Princic N, Moynihan M, Clarke C, Phan A. Exploration of machine learning techniques to examine the journey to neuroendocrine tumor diagnosis with real-world data. Future Oncol 2021;17:3217-30. [PMID: 34008426 DOI: 10.2217/fon-2020-1254] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
656 La Salvia A, Portigliatti Pomeri A, Persano I, Trevisi E, Parlagreco E, Colombi N, Brizzi MP, Picci RL, Oliva F. Serotoninergic brain dysfunction in neuroendocrine tumor patients: A scoping review. Compr Psychiatry 2021;109:152244. [PMID: 34120056 DOI: 10.1016/j.comppsych.2021.152244] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
657 Hu Y, Ye Z, Wang F, Qin Y, Xu X, Yu X, Ji S. Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy. Front Endocrinol (Lausanne) 2021;12:679000. [PMID: 34093445 DOI: 10.3389/fendo.2021.679000] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
658 Modlin IM, Kidd M, Oberg K, Falconi M, Filosso PL, Frilling A, Malczewska A, Salem R, Toumpanakis C, Laskaratos FM, Partelli S, Roffinella M, von Arx C, Kudla BK, Bodei L, Drozdov IA, Kitz A. Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest). Ann Surg Oncol 2021. [PMID: 34008138 DOI: 10.1245/s10434-021-10021-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
659 Zhang Z, Zhao X, Li Z, Wu Y, Liu Y, Li Z, Li G. Development of a nomogram model to predict survival outcomes in patients with primary hepatic neuroendocrine tumors based on SEER database. BMC Cancer 2021;21:567. [PMID: 34006241 DOI: 10.1186/s12885-021-08337-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
660 Xu SS, Li H, Li TJ, Li S, Xia HY, Long J, Wu CT, Wang WQ, Zhang WH, Gao HL, Han X, Ye LY, Lin X, Xu HX, Yu XJ, Liu L. Neutrophil Extracellular Traps and Macrophage Extracellular Traps Predict Postoperative Recurrence in Resectable Nonfunctional Pancreatic Neuroendocrine Tumors. Front Immunol 2021;12:577517. [PMID: 34084158 DOI: 10.3389/fimmu.2021.577517] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
661 Bongiovanni A, Maiorano BA, Azzali I, Liverani C, Bocchini M, Fausti V, Di Menna G, Grassi I, Sansovini M, Riva N, Ibrahim T. Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis. Pharmaceuticals (Basel) 2021;14:476. [PMID: 34067837 DOI: 10.3390/ph14050476] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
662 Grossi U, Bonis A, Carrington EV, Mazzobel E, Santoro GA, Cattaneo L, Centonze G, Gallo G, Kazemi Nava A, Romano M, Di Tanna GL, Zanus G. Mixed adenoneuroendocrine carcinoma (MANEC) of the lower gastrointestinal tract: A systematic review with Bayesian hierarchical survival analysis. Eur J Surg Oncol 2021:S0748-7983(21)00497-2. [PMID: 34052038 DOI: 10.1016/j.ejso.2021.05.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
663 Kaemmer CA, Umesalma S, Maharjan CK, Moose DL, Narla G, Mott SL, Zamba GKD, Breheny P, Darbro BW, Bellizzi AM, Henry MD, Quelle DE. Development and comparison of novel bioluminescent mouse models of pancreatic neuroendocrine neoplasm metastasis. Sci Rep 2021;11:10252. [PMID: 33986468 DOI: 10.1038/s41598-021-89866-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
664 Carnie LE, Lamarca A, Vaughan K, Kapacee ZA, McCallum L, Backen A, Barriuso J, McNamara MG, Hubner RA, Abraham M, Valle JW. Prospective observational study of prevalence, assessment and treatment of pancreatic exocrine insufficiency in patients with inoperable pancreatic malignancy (PANcreatic cancer Dietary Assessment (PanDA): a study protocol. BMJ Open 2021;11:e042067. [PMID: 33986039 DOI: 10.1136/bmjopen-2020-042067] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
665 Bevilacqua A, Calabrò D, Malavasi S, Ricci C, Casadei R, Campana D, Baiocco S, Fanti S, Ambrosini V. A [68Ga]Ga-DOTANOC PET/CT Radiomic Model for Non-Invasive Prediction of Tumour Grade in Pancreatic Neuroendocrine Tumours. Diagnostics (Basel) 2021;11:870. [PMID: 34065981 DOI: 10.3390/diagnostics11050870] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
666 Landry I, Medina Mora LA, Siddiqui R, Tumarinson T, Reich DM. Atypical Carcinoid Tumor of the Mediastinum Presenting as Cushing's Syndrome in an Otherwise Healthy Young Male. Cureus 2021;13:e14940. [PMID: 34123637 DOI: 10.7759/cureus.14940] [Reference Citation Analysis]
667 Ohlsson H, Wahlberg G, Malmström M, Gustafsson R, Sundlöv A, Nordenström E, Almquist M. Impact of Specific Bowel Symptoms on Quality of Life in Patients with Midgut Neuroendocrine Tumours. World J Surg 2021;45:2793-803. [PMID: 33969447 DOI: 10.1007/s00268-021-06146-9] [Reference Citation Analysis]
668 Heidsma CM, Tsilimigras DI, Rocha F, Abbott DE, Fields R, Poultsides GA, Cho CS, Lopez-Aguiar AG, Kanji Z, Fisher AV, Krasnick BA, Idrees K, Makris E, Beems M, van Eijck CHJ, Nieveen van Dijkum EJM, Maithel SK, Pawlik TM. Identifying Risk Factors and Patterns for Early Recurrence of Pancreatic Neuroendocrine Tumors: A Multi-Institutional Study. Cancers (Basel) 2021;13:2242. [PMID: 34067017 DOI: 10.3390/cancers13092242] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
669 Chevalier B, Dupuis H, Jannin A, Lemaitre M, Do Cao C, Cardot-Bauters C, Espiard S, Vantyghem MC. Phakomatoses and Endocrine Gland Tumors: Noteworthy and (Not so) Rare Associations. Front Endocrinol (Lausanne) 2021;12:678869. [PMID: 34025587 DOI: 10.3389/fendo.2021.678869] [Reference Citation Analysis]
670 Rodriguez-Freixinos V, Thawer A, Capdevila J, Ferone D, Singh S. Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With? Curr Oncol Rep 2021;23:80. [PMID: 33937962 DOI: 10.1007/s11912-021-01071-5] [Reference Citation Analysis]
671 Marchal E. Imagerie fonctionnelle en endocrinologie : nouveaux paradigmes à l’horizon 2020. Médecine Nucléaire 2021;45:158-161. [DOI: 10.1016/j.mednuc.2021.03.003] [Reference Citation Analysis]
672 Sanguedolce F, Zanelli M, Ascani S, Zizzo M, Tortorella S, Soriano A, Fiorelli A, Cocco G, Ardò N, Sollitto F, Loizzi D. PD-L1 as a prognostic and predictive biomarker in neuroendocrine tumors of the lung: state of the art and future perspectives. Minerva Respir Med 2021;60. [DOI: 10.23736/s2784-8477.20.01900-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
673 Baretti M, Zhu Q, Zahurak M, Bhaijee F, Xu H, Engle EL, Kotte A, Pawlik TM, Anders RA, De Jesus-Acosta A. Prognostic Implications of the Immune Tumor Microenvironment in Patients With Pancreatic and Gastrointestinal Neuroendocrine Tumors. Pancreas 2021;50:719-26. [PMID: 34016898 DOI: 10.1097/MPA.0000000000001831] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
674 Aktypis C, Spei ME, Yavropoulou M, Wallin G, Koumarianou A, Kaltsas G, Kassi E, Daskalakis K. Cardiovascular Toxicities Secondary to Biotherapy and Molecular Targeted Therapies in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Cancers (Basel) 2021;13:2159. [PMID: 33946147 DOI: 10.3390/cancers13092159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
675 Beyer L, Gosewisch A, Lindner S, Völter F, Mittlmeier LM, Tiling R, Brendel M, Cyran CC, Unterrainer M, Rübenthaler J, Auernhammer CJ, Spitzweg C, Böning G, Gildehaus FJ, Jurkschat K, Wängler C, Wängler B, Schirrmacher R, Wenter V, Todica A, Bartenstein P, Ilhan H. Dosimetry and optimal scan time of [18F]SiTATE-PET/CT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2021. [PMID: 33928401 DOI: 10.1007/s00259-021-05351-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
676 Huang J, Chen J, Xu M, Zheng Y, Lin M, Huang G, Xie X, Xie X. Contrast-Enhanced Ultrasonography Findings Correlate with Pathologic Grades of Pancreatic Neuroendocrine Tumors. Ultrasound Med Biol 2021;47:2097-106. [PMID: 33934943 DOI: 10.1016/j.ultrasmedbio.2021.02.013] [Reference Citation Analysis]
677 Roll W, Weckesser M, Seifert R, Bodei L, Rahbar K. Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management. Eur J Nucl Med Mol Imaging 2021. [PMID: 33903926 DOI: 10.1007/s00259-021-05359-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
678 Soldath P, Binderup T, Kjær A, Federspiel B, Langer SW, Knigge U, Petersen RH. Long-term survival and recurrence after resection of bronchopulmonary carcinoids: A single-center cohort study of 236 patients. Lung Cancer 2021;156:109-16. [PMID: 33940543 DOI: 10.1016/j.lungcan.2021.04.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
679 Coriat R. Better Management for Neuroendocrine Neoplasms: A Complex Task Ahead. J Clin Med 2021;10:1859. [PMID: 33922910 DOI: 10.3390/jcm10091859] [Reference Citation Analysis]
680 Effraimidis G, Knigge U, Rossing M, Oturai P, Rasmussen ÅK, Feldt-Rasmussen U. Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs). Semin Cancer Biol 2021:S1044-579X(21)00112-7. [PMID: 33905872 DOI: 10.1016/j.semcancer.2021.04.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
681 Figueira ERR, Ribeiro JF, Ribeiro TC, Jureidini R, Namur GN, Costa TN, Bacchella T, Cecconello I. Insights of Outcome after Resection of Small Nonfunctioning Neuroendocrine Pancreatic Tumors. Gastroenterol Res Pract 2021;2021:6650386. [PMID: 33986797 DOI: 10.1155/2021/6650386] [Reference Citation Analysis]
682 Kaçmaz E, Sarasqueta AF, van Eeden S, Dreijerink KMA, Klümpen HJ, Tanis PJ, van Dijkum EJMN, Engelsman AF. Update on Incidence, Prevalence, Treatment and Survival of Patients with Small Bowel Neuroendocrine Neoplasms in the Netherlands. World J Surg 2021;45:2482-91. [PMID: 33895862 DOI: 10.1007/s00268-021-06119-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
683 Dou D, Li XK, Xia QS, Chen YY, Li YL, Wang C, Qi ZR, Tan HY. Circulating miRNA-202-3p is a potential novel biomarker for diagnosis of type 1 gastric neuroendocrine neoplasms. BMC Gastroenterol 2021;21:188. [PMID: 33892648 DOI: 10.1186/s12876-021-01769-7] [Reference Citation Analysis]
684 Jeong H, Shin J, Jeong JH, Kim KP, Hong SM, Kim YI, Ryu JS, Ryoo BY, Yoo C. Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study. ESMO Open 2021;6:100119. [PMID: 33901869 DOI: 10.1016/j.esmoop.2021.100119] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
685 Pettersson OJ, Fröss-Baron K, Crona J, Sundin A. Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with 177Lu-DOTATATE. Endocr Connect 2021;10:422-31. [PMID: 33875614 DOI: 10.1530/EC-21-0027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
686 Aoki T, Kubota K, Kiritani S, Arita J, Morizane C, Masui T, Kudo A, Komoto I, Hatano E, Ito T, Osamura RY, Unno M, Uemoto S, Kokudo N; Japanese Neuroendocrine Tumor Society (JNETS). Survey of surgical resections for neuroendocrine liver metastases: A project study of the Japan Neuroendocrine Tumor Society (JNETS). J Hepatobiliary Pancreat Sci 2021;28:489-97. [PMID: 33792204 DOI: 10.1002/jhbp.956] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
687 Hayes AR, Smith K, Liu M, Jenkinson S, Grossman AB, Youle M, Burns F, Thirlwell C, Caplin ME. Treating neuroendocrine neoplasms in the setting of HIV infection. TRD 2021;5:143-159. [DOI: 10.3233/trd-200046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
688 Vida Navas EM, Martínez Lorca A, Sancho Gutiérrez A, Sanz Gómez L, Navarro Martínez T, Grande Pulido E, Carrato Mena A, Gajate Borau P. Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors. Front Endocrinol (Lausanne) 2021;12:676973. [PMID: 33935979 DOI: 10.3389/fendo.2021.676973] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
689 Yang Z, Gao H, Lu J, Niu Z, Zhu H, Zong Y, Song X, Yang F, Zhou X. Comparison of clinical outcomes between enucleation and regular pancreatectomy in patients with non-functional pancreatic neuroendocrine tumors: a retrospective multicenter and propensity score-matched study. Jpn J Clin Oncol 2021;51:595-603. [PMID: 33395471 DOI: 10.1093/jjco/hyaa246] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
690 Gillette AA, Babiarz CP, VanDommelen AR, Pasch CA, Clipson L, Matkowskyj KA, Deming DA, Skala MC. Autofluorescence Imaging of Treatment Response in Neuroendocrine Tumor Organoids. Cancers (Basel) 2021;13:1873. [PMID: 33919802 DOI: 10.3390/cancers13081873] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
691 Michael M, Chantrill L, Price T, Chan DL, Wakelin K, Cummins M. Real-world management and patient perspectives on QOL with neuroendocrine tumors: An ANZ perspective. Asia Pac J Clin Oncol 2021;17 Suppl 2:3-10. [PMID: 33851520 DOI: 10.1111/ajco.13587] [Reference Citation Analysis]
692 Stankard M, Soule E, Matteo J. Inferior Vena Cava Syndrome as a Manifestation of Metastatic Carcinoid Tumor. Gastrointest Tumors 2021;8:138-43. [PMID: 34307313 DOI: 10.1159/000514113] [Reference Citation Analysis]
693 Larose LD, Vroman PJ, Musick SR, Beauvais AA. A Case Report: Insulinoma in a Military Pilot Detected by 68Ga-Dotatate PET/CT. Mil Med 2020;185:e1887-90. [PMID: 32617565 DOI: 10.1093/milmed/usaa100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
694 Chang JS, Chen LT, Shan YS, Chu PY, Tsai CR, Tsai HJ. An updated analysis of the epidemiologic trends of neuroendocrine tumors in Taiwan. Sci Rep 2021;11:7881. [PMID: 33846396 DOI: 10.1038/s41598-021-86839-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
695 Espinosa-Olarte P, La Salvia A, Riesco-Martinez MC, Anton-Pascual B, Garcia-Carbonero R. Chemotherapy in NEN: still has a role? Rev Endocr Metab Disord 2021;22:595-614. [PMID: 33843007 DOI: 10.1007/s11154-021-09638-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
696 Alevroudis E, Spei ME, Chatziioannou SN, Tsoli M, Wallin G, Kaltsas G, Daskalakis K. Clinical Utility of 18F-FDG PET in Neuroendocrine Tumors Prior to Peptide Receptor Radionuclide Therapy: A Systematic Review and Meta-Analysis. Cancers (Basel) 2021;13:1813. [PMID: 33920195 DOI: 10.3390/cancers13081813] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
697 Mowrey K, Northrup H, Rougeau P, Hashmi SS, Krueger DA, Ebrahimi-Fakhari D, Towbin AJ, Trout AT, Capal JK, Franz DN, Rodriguez-Buritica D. Frequency, Progression, and Current Management: Report of 16 New Cases of Nonfunctional Pancreatic Neuroendocrine Tumors in Tuberous Sclerosis Complex and Comparison With Previous Reports. Front Neurol 2021;12:627672. [PMID: 33897589 DOI: 10.3389/fneur.2021.627672] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
698 Ni K, Yang JY, Baeg K, Leiter AC, Mhango G, Gallagher EJ, Wisnivesky JP, Kim MK. Association between somatostatin analogues and diabetes mellitus in gastroenteropancreatic neuroendocrine tumor patients: A Surveillance, Epidemiology, and End Results-Medicare analysis of 5235 patients. Cancer Rep (Hoboken) 2021;4:e1387. [PMID: 33835729 DOI: 10.1002/cnr2.1387] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
699 Chen L, Navalkissoor S, Quigley AM, Gnanasegaran G, Mandair D, Toumpanakis C, Caplin ME, Hayes AR. 177Lu-DOTATATE in older patients with metastatic neuroendocrine tumours: safety, efficacy and health-related quality of life. Eur J Nucl Med Mol Imaging 2021;48:3582-94. [PMID: 33835221 DOI: 10.1007/s00259-021-05332-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
700 Shah S, Gosain R, Groman A, Gosain R, Dasari A, Halfdanarson TR, Mukherjee S. Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States. Cancers (Basel) 2021;13:1753. [PMID: 33916960 DOI: 10.3390/cancers13081753] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
701 Gao Y, Moua T, Midthun DE, Mullon JJ, Decker PA, Ryu JH. Diagnostic Yield and Bleeding Complications Associated With Bronchoscopic Biopsy of Endobronchial Carcinoid Tumors. J Bronchology Interv Pulmonol 2020;27:184-9. [PMID: 31876538 DOI: 10.1097/LBR.0000000000000639] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
702 La Salvia A, Espinosa-Olarte P, Riesco-Martinez MDC, Anton-Pascual B, Garcia-Carbonero R. Targeted Cancer Therapy: What's New in the Field of Neuroendocrine Neoplasms? Cancers (Basel) 2021;13:1701. [PMID: 33916707 DOI: 10.3390/cancers13071701] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
703 Yoon JY, Kumta NA, Kim MK. The Role of Endoscopy in Small Bowel Neuroendocrine Tumors. Clin Endosc 2021. [PMID: 33794563 DOI: 10.5946/ce.2020.296] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
704 Chatani PD, Aversa JG, McDonald JD, Khan TM, Keutgen XM, Nilubol N. Preoperative serum chromogranin-a is predictive of survival in locoregional jejuno-ileal small bowel neuroendocrine tumors. Surgery 2021;170:106-13. [PMID: 33814188 DOI: 10.1016/j.surg.2021.01.048] [Reference Citation Analysis]
705 Hasegawa S, Kobayashi N, Okubo N, Tokuhisa M, Goto A, Kurita Y, Sato T, Hosono K, Endo I, Nakajima A, Ichikawa Y. Pathological Findings of the Host Immune Reaction in the Tumor Microenvironment of Gastroenteropancreatic Neuroendocrine Neoplasms. Intern Med 2021;60:977-83. [PMID: 33162477 DOI: 10.2169/internalmedicine.5648-20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
706 Cruz Castellanos P, Sánchez Cabrero D, Esteban MI, de Castro J. Estudio retrospectivo descriptivo sobre el tumor carcinoide pulmonar: experiencia de un centro español de tercer nivel. Revista Española de Patología 2021;54:85-91. [DOI: 10.1016/j.patol.2020.04.004] [Reference Citation Analysis]
707 Rinzivillo M, De Felice I, Magi L, Annibale B, Panzuto F. Octreotide long-acting release (LAR) in combination with other therapies for treatment of neuroendocrine neoplasia: a systematic review. J Gastrointest Oncol 2021;12:845-55. [PMID: 34012671 DOI: 10.21037/jgo-20-292] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
708 Chan H, Zhang L, Choti MA, Kulke M, Yao JC, Nakakura EK, Bloomston M, Benson AB, Shah MH, Strosberg JR, Bergsland EK, Van Loon K. Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database. Pancreas 2021;50:506-12. [PMID: 33939661 DOI: 10.1097/MPA.0000000000001791] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
709 Chung HG, Goh MJ, Kim ER, Hong SN, Kim TJ, Chang DK, Kim YH. Recurrence pattern and surveillance strategy for rectal neuroendocrine tumors after endoscopic resection. J Gastroenterol Hepatol 2021;36:968-73. [PMID: 32864790 DOI: 10.1111/jgh.15231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
710 Sigfridsson J, Lindström E, Iyer V, Holstensson M, Velikyan I, Sundin A, Lubberink M. Prospective data-driven respiratory gating of [68Ga]Ga-DOTATOC PET/CT. EJNMMI Res 2021;11:33. [PMID: 33788025 DOI: 10.1186/s13550-021-00775-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
711 Kaçmaz E, Klümpen HJ, Bemelman WA, Nieveen van Dijkum EJM, Engelsman AF, Tanis PJ. Evaluating Nationwide Application of Minimally Invasive Surgery for Treatment of Small Bowel Neuroendocrine Neoplasms. World J Surg 2021;45:2463-70. [PMID: 33783584 DOI: 10.1007/s00268-021-06036-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
712 Apostolidis L, Schrader J, Jann H, Rinke A, Krug S. Leptomeningeal Carcinomatosis: A Clinical Dilemma in Neuroendocrine Neoplasms. Biology 2021;10:277. [DOI: 10.3390/biology10040277] [Reference Citation Analysis]
713 Fernandez CJ, Agarwal M, Pottakkat B, Haroon NN, George AS, Pappachan JM. Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot. World J Gastrointest Surg 2021;13:231-55. [PMID: 33796213 DOI: 10.4240/wjgs.v13.i3.231] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
714 Imam R, Chang Q, Black M, Yu C, Cao W. CD47 expression and CD163+ macrophages correlated with prognosis of pancreatic neuroendocrine tumor. BMC Cancer 2021;21:320. [PMID: 33765961 DOI: 10.1186/s12885-021-08045-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
715 Qi Z, Tan H. Association between MGMT status and response to alkylating agents in patients with neuroendocrine neoplasms: a systematic review and meta-analysis. Biosci Rep 2020;40:BSR20194127. [PMID: 32141507 DOI: 10.1042/BSR20194127] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
716 Jin XF, Spöttl G, Maurer J, Nölting S, Auernhammer CJ. Antitumoral Activity of the MEK Inhibitor Trametinib (TMT212) Alone and in Combination with the CDK4/6 Inhibitor Ribociclib (LEE011) in Neuroendocrine Tumor Cells In Vitro. Cancers (Basel) 2021;13:1485. [PMID: 33807122 DOI: 10.3390/cancers13061485] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
717 Kolarova T, Bouvier C. The Role of Patient Support Groups in Neuroendocrine Neoplasms. Curr Oncol Rep 2021;23:53. [PMID: 33754245 DOI: 10.1007/s11912-021-01046-6] [Reference Citation Analysis]
718 Hackeng WM, Schelhaas W, Morsink FHM, Heidsma CM, van Eeden S, Valk GD, Vriens MR, Heaphy CM, Nieveen van Dijkum EJM, Offerhaus GJA, Dreijerink KMA, Brosens LAA. Alternative Lengthening of Telomeres and Differential Expression of Endocrine Transcription Factors Distinguish Metastatic and Non-metastatic Insulinomas. Endocr Pathol 2020;31:108-18. [PMID: 32103422 DOI: 10.1007/s12022-020-09611-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
719 Legoux JL, Lombard-Bohas C, Brixi H, Le Malicot K, Lecomte T, Dahan L, Ruszniewski P, Mahamat-Abakar A, Etienne PL, Caroli-Bosc FX, Dominguez S, Paule B, Terrebonne E, Michel P, Lepage C, Choukroun G; for Streptotox-FFCD0906 investigators. Renal function in patients receiving streptozocin for locally advanced or metastatic digestive neuroendocrine tumours: results of the Streptotox-FFCD 0906 study. Clin Res Hepatol Gastroenterol 2021;45:101572. [PMID: 33751987 DOI: 10.1016/j.clinre.2020.10.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
720 Yazdanpanah O, Surapaneni S, Shanah L, Kabashneh S. Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors: A Comprehensive Literature Review. Cureus 2021;13:e14006. [PMID: 33884247 DOI: 10.7759/cureus.14006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
721 Kitada T, Masui T, Kasai Y, Uchida Y, Ogiso S, Ito T, Ishii T, Seo S, Katsuragawa H, Uemoto S. A subcentimeter duodenal neuroendocrine neoplasm with a liver metastasis upgraded to G3: a case report. Surg Case Rep 2021;7:72. [PMID: 33742297 DOI: 10.1186/s40792-021-01155-1] [Reference Citation Analysis]
722 Watanabe A, Yip L, Hamilton TD, Loree JM, Stuart HC. Tumour grade and primary site predict patterns of recurrence and survival in patients with resected gastroenteropancreatic neuroendocrine tumors. Am J Surg 2021;221:1141-9. [PMID: 33795127 DOI: 10.1016/j.amjsurg.2021.03.027] [Reference Citation Analysis]
723 Barrea L, Muscogiuri G, Modica R, Altieri B, Pugliese G, Minotta R, Faggiano A, Colao A, Savastano S. Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors. Front Endocrinol (Lausanne) 2021;12:649496. [PMID: 33815296 DOI: 10.3389/fendo.2021.649496] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
724 Camus B, Cottereau AS, Palmieri LJ, Dermine S, Tenenbaum F, Brezault C, Coriat R. Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review. J Clin Med 2021;10:1267. [PMID: 33803817 DOI: 10.3390/jcm10061267] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
725 de Vries FE, Godthelp A, Spruit JR, Ruissen AM, Tesselaar MET, Boekhout AH. Coping with social consequences of disease-related symptoms in patients with a metastatic small intestinal neuroendocrine tumour: A qualitative study. J Neuroendocrinol 2021;33:e12956. [PMID: 33733525 DOI: 10.1111/jne.12956] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
726 Yu S, Hornick JL, Gonzalez RS. An algorithmic approach utilizing CK7, TTF1, beta-catenin, CDX2, and SSTR2A can help differentiate between gastrointestinal and pulmonary neuroendocrine carcinomas. Virchows Arch 2021. [PMID: 33733343 DOI: 10.1007/s00428-021-03085-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
727 Maharjan CK, Kaemmer CA, Muniz VP, Bauchle C, Mott SL, Zamba K, Breheny P, Leidinger MR, Darbro BW, Stephens SB, Meyerholz DK, Quelle DE. RABL6A promotes pancreatic neuroendocrine tumor angiogenesis and progression in vivo.. [DOI: 10.1101/2021.03.17.435790] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
728 Fang L, Arvind D, Dowlati A, Mohamed A. Role of immunotherapy in gastro-enteropancreatic neuroendocrine neoplasms (gep-nens): Current advances and future directions. J Neuroendocrinol 2021;33:e12943. [PMID: 33724586 DOI: 10.1111/jne.12943] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
729 Ricci C, Partelli S, Landoni L, Rinzivillo M, Ingaldi C, Andreasi V, Nessi C, Muffatti F, Fontana M, Tamburrino D, Deiro G, Alberici L, Campana D, Panzuto F, Bassi C, Falconi M, Casadei R. Sporadic non-functioning pancreatic neuroendocrine tumours: multicentre analysis. Br J Surg 2021;108:811-6. [PMID: 33724300 DOI: 10.1093/bjs/znaa141] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
730 Laskaratos FM, Davar J, Toumpanakis C. Carcinoid Heart Disease: a Review. Curr Oncol Rep 2021;23:48. [PMID: 33725214 DOI: 10.1007/s11912-021-01031-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
731 Minczeles NS, Hofland J, de Herder WW, Brabander T. Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy. Curr Oncol Rep 2021;23:46. [PMID: 33721105 DOI: 10.1007/s11912-021-01037-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
732 Clift AK, Frilling A. Liver-Directed Therapies for Neuroendocrine Neoplasms. Curr Oncol Rep 2021;23:44. [PMID: 33721122 DOI: 10.1007/s11912-021-01030-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
733 Das S, Dasari A. Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences? Curr Oncol Rep 2021;23:43. [PMID: 33719003 DOI: 10.1007/s11912-021-01029-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 22.0] [Reference Citation Analysis]
734 Lamarca A, Cives M, de Mestier L, Crona J, Spada F, Öberg K, Pavel M, Alonso-Gordoa T. Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3rd-line treatment. World J Gastroenterol 2021; 27(10): 976-989 [PMID: 33776367 DOI: 10.3748/wjg.v27.i10.976] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
735 De los Reyes A, Llamas-olier A, Martí A, Fierro F, Rojas L, Martínez MC, Granados CE, Varela H, Calderón Á, Barbosa N, Delgado N, Rada J, Cuéllar DI, Lozano A, Muleth Y. Eficacia de lutecio-177 DOTATATE/TOC en pacientes con tumores neuroendocrinos bien diferenciados en estado avanzado. Ensayo clínico fase II. Rev colomb cancerol 2021;25. [DOI: 10.35509/01239015.132] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
736 Jung SW. Endoscopic Treatment of Gastric and Duodenal Neuroendocrine Tumors: Present and Future. Korean J Helicobacter Up Gastrointest Res 2021;21:29-34. [DOI: 10.7704/kjhugr.2020.0055] [Reference Citation Analysis]
737 Quiroga-centeno AC, Quiroga-centeno CA, Serrano Pastrana JP, Gómez-ochoa SA. Diseño y validación de un nomograma pronóstico de supervivencia en pacientes con tumores neuroendocrinos primarios del apéndice cecal. Rev Colomb Cir 2021;36:221-36. [DOI: 10.30944/20117582.836] [Reference Citation Analysis]
738 Song YL, Xu J, Zhao DC, Zhang TP, Jin KZ, Zhu LM, Yu S, Chen YJ. Mutation and Expression of Gene YY1 in Pancreatic Neuroendocrine Tumors and Its Clinical Significance. Endocr Pract 2021;27:874-80. [PMID: 33705973 DOI: 10.1016/j.eprac.2021.02.016] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
739 Wan L, Tu C, Qi L, Li Z. Survivorship and prognostic factors for pleomorphic liposarcoma: a population-based study. J Orthop Surg Res 2021;16:175. [PMID: 33663547 DOI: 10.1186/s13018-021-02327-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
740 Yadav D, Kumar R. Critical Role of 2-[18F]-fluoro-2-deoxy-glucose in Hormonally Active Malignancies. PET Clin 2021;16:177-89. [PMID: 33648663 DOI: 10.1016/j.cpet.2020.12.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
741 Vitali E, Piccini S, Trivellin G, Smiroldo V, Lavezzi E, Zerbi A, Pepe G, Lania AG. The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors. Mol Cell Endocrinol 2021;527:111226. [PMID: 33675866 DOI: 10.1016/j.mce.2021.111226] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
742 Ansquer C, Touchefeu Y, Faivre-Chauvet A, Leux C, Le Bras M, Régenet N, Fleury V, Maucherat B, Senellart H, Guyetant S, Carlier T, Scotet-Cérato E, Rauscher A, Frampas E, Kraeber-Bodéré F. Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine Tumors. Clin Nucl Med 2021;46:181-6. [PMID: 33315677 DOI: 10.1097/RLU.0000000000003450] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
743 Wu W, Chen J, Bai C, Chi Y, Du Y, Feng S, Huo L, Jiang Y, Li J, Lou W, Luo J, Shao C, Shen L, Wang F, Wang L, Wang O, Wang Y, Wu H, Xing X, Xu J, Xue H, Xue L, Yang Y, Yu X, Yuan C, Zhao H, Zhu X, Zhao Y. The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020). Journal of Pancreatology 2021;4:1-17. [DOI: 10.1097/jp9.0000000000000064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
744 Zheng-Pywell R, Fang A, AlKashash A, Awad S, Reddy S, Vickers S, Heslin M, Dudeja V, Chen H, Rose JB. Prognostic Impact of Tumor Size on Pancreatic Neuroendocrine Tumor Recurrence May Have Racial Variance. Pancreas 2021;50:347-52. [PMID: 33835965 DOI: 10.1097/MPA.0000000000001776] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
745 Chen X, Lee SK, Song M, Zhang T, Han MS, Chen Y, Chen Z, Ma X, Tung C, Du YN. RHAMMB-mediated bifunctional nanotherapy targeting Bcl-xL and mitochondria for pancreatic neuroendocrine tumor treatment.. [DOI: 10.1101/2021.02.28.432124] [Reference Citation Analysis]
746 Yi C, Dai J, Song N, Wu C, Zhang L, Zhu Y, Jiang G, Zhang H, Zhang P. Improvement of pathological staging system for neuroendocrine tumors of the lung. Ann Transl Med 2021;9:447. [PMID: 33850844 DOI: 10.21037/atm-20-5910] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
747 Heidsma CM, Tsilimigras DI, van Dieren S, Rocha F, Abbott DE, Fields R, Smith PM, Poultsides GA, Cho C, Dillhoff M, Lopez-Aguiar AG, Kanji Z, Fisher A, Krasnick BA, Idrees K, Makris E, Beems M, van Eijck CHJ, Nieveen van Dijkum EJM, Maithel SK, Pawlik TM. Indications and outcomes of enucleation versus formal pancreatectomy for pancreatic neuroendocrine tumors. HPB (Oxford) 2021;23:413-21. [PMID: 32771338 DOI: 10.1016/j.hpb.2020.06.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
748 Massironi S, Campana D, Pusceddu S, Albertelli M, Faggiano A, Panzuto F, Smiroldo V, Andreasi V, Rossi RE, Maggio I, Torchio M, Dotto A, Modica R, Rinzivillo M, Carnaghi C, Partelli S, Fanetti I, Lamberti G, Corti F, Ferone D, Colao A, Annibale B, Invernizzi P, Falconi M; ItaNet (Italian Association for Neuroendocrine Tumours) Study Group. Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study. Dig Liver Dis 2021;53:367-74. [PMID: 33645508 DOI: 10.1016/j.dld.2020.09.031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
749 Song Z, Wang S, Wu Y, Zhang J, Liu S. Prognostic Nomograms to Predict Overall Survival and Cancer-Specific Survival of Patients With Pancreatic Neuroendocrine Tumors: A Population-Based Study. Pancreas 2021;50:414-22. [PMID: 33835974 DOI: 10.1097/MPA.0000000000001779] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
750 Haider M, Das S, Al-Toubah T, Pelle E, El-Haddad G, Strosberg J. Somatostatin receptor radionuclide therapy in neuroendocrine tumors. Endocr Relat Cancer 2021;28:R81-93. [PMID: 33608483 DOI: 10.1530/ERC-20-0360] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
751 Crinò SF, Ammendola S, Meneghetti A, Bernardoni L, Conti Bellocchi MC, Gabbrielli A, Landoni L, Paiella S, Pin F, Parisi A, Mastrosimini MG, Amodio A, Frulloni L, Facciorusso A, Larghi A, Manfrin E. Comparison between EUS-guided fine-needle aspiration cytology and EUS-guided fine-needle biopsy histology for the evaluation of pancreatic neuroendocrine tumors. Pancreatology 2021;21:443-50. [PMID: 33390343 DOI: 10.1016/j.pan.2020.12.015] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 22.0] [Reference Citation Analysis]
752 Lim JY, Pommier RF. Clinical Features, Management, and Molecular Characteristics of Familial Small Bowel Neuroendocrine Tumors. Front Endocrinol (Lausanne) 2021;12:622693. [PMID: 33732215 DOI: 10.3389/fendo.2021.622693] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
753 Zheng K, Liu T, Zhao J, Meng P, Bian Y, Ni C, Wang H, Pan Y, Wu S, Jiang H, Jin G. Mutational landscape and potential therapeutic targets for sporadic pancreatic neuroendocrine tumors based on target next-generation sequencing. Exp Ther Med 2021;21:415. [PMID: 33747156 DOI: 10.3892/etm.2021.9859] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
754 Fujii Y, Kobayashi K, Kimura S, Uehara S, Miyai H, Takiguchi S. Indications for lateral lymph node dissection in patients with rectal neuroendocrine tumors: A case report and review of the literature. Mol Clin Oncol 2021;14:80. [PMID: 33758661 DOI: 10.3892/mco.2021.2242] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
755 Zakaria A, Alnimer L, Byrd G, Piper M, Raphael M, Warren B, Piper M. Asymptomatic Ileal Neuroendocrine "Carcinoid" Tumor Incidentally Diagnosed on Colorectal Cancer Screening Colonoscopy: Does Routine TI Intubation Matter? Case Rep Gastrointest Med 2021;2021:6620036. [PMID: 33623719 DOI: 10.1155/2021/6620036] [Reference Citation Analysis]
756 Laskaratos FM, Levi A, Schwach G, Pfragner R, Hall A, Xia D, von Stempel C, Bretherton J, Thanapirom K, Alexander S, Ogunbiyi O, Watkins J, Luong TV, Toumpanakis C, Mandair D, Caplin M, Rombouts K. Transcriptomic Profiling of In Vitro Tumor-Stromal Cell Paracrine Crosstalk Identifies Involvement of the Integrin Signaling Pathway in the Pathogenesis of Mesenteric Fibrosis in Human Small Intestinal Neuroendocrine Neoplasms. Front Oncol 2021;11:629665. [PMID: 33718208 DOI: 10.3389/fonc.2021.629665] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
757 Weich A, Rogoll D, Gawlas S, Mayer L, Weich W, Pongracz J, Kudlich T, Meining A, Scheurlen M. Wnt/β-Catenin Signaling Regulates CXCR4 Expression and [68Ga] Pentixafor Internalization in Neuroendocrine Tumor Cells. Diagnostics (Basel) 2021;11:367. [PMID: 33671498 DOI: 10.3390/diagnostics11020367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
758 Feng J, Lin A, Chen X, Wang D, Wong M, Zhang G, Na J, Zhang T, Chen Z, Chen Y, Nancy Du Y. High levels of truncated RHAMM cooperate with dysfunctional p53 to accelerate the progression of pancreatic cancer.. [DOI: 10.1101/2021.02.19.432042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
759 Garcia-Torralba E, Spada F, Lim KHJ, Jacobs T, Barriuso J, Mansoor W, McNamara MG, Hubner RA, Manoharan P, Fazio N, Valle JW, Lamarca A. Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis. Cancer Treat Rev 2021;94:102168. [PMID: 33730627 DOI: 10.1016/j.ctrv.2021.102168] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
760 Tirosh A, Killian JK, Petersen D, Zhu YJ, Walker RL, Blau JE, Nilubol N, Patel D, Agarwal SK, Weinstein LS, Meltzer P, Kebebew E. Distinct DNA Methylation Signatures in Neuroendocrine Tumors Specific for Primary Site and Inherited Predisposition. J Clin Endocrinol Metab 2020;105:dgaa477. [PMID: 32706863 DOI: 10.1210/clinem/dgaa477] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
761 Froelich MF, Schnitzer ML, Holzgreve A, Gassert FG, Gresser E, Overhoff D, Schwarze V, Fabritius MP, Nörenberg D, von Münchhausen N, Hokamp NG, Auernhammer CJ, Ilhan H, Todica A, Rübenthaler J. Cost-Effectiveness Analysis of 68Ga DOTA-TATE PET/CT, 111In-Pentetreotide SPECT/CT and CT for Diagnostic Workup of Neuroendocrine Tumors. Diagnostics (Basel) 2021;11:334. [PMID: 33670457 DOI: 10.3390/diagnostics11020334] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
762 Punekar SR, Kaakour D, Masri-Lavine L, Hajdu C, Newman E, Becker DJ. Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database. Am J Clin Oncol 2020;43:846-9. [PMID: 32910023 DOI: 10.1097/COC.0000000000000761] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
763 Kusne YN, Kosiorek HE, Buras MR, Verona PM, Coppola KE, Rone KA, Cook CB, Karlin NJ. Implications of neuroendocrine tumor and diabetes mellitus on patient outcomes and care: a matched case-control study. Future Sci OA 2021;7:FSO684. [PMID: 34046189 DOI: 10.2144/fsoa-2020-0190] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
764 Ortega C, Wong RK, Schaefferkoetter J, Veit-haibach P, Myrehaug S, Juergens R, Laidley D, Anconina R, Liu A, Metser U. Quantitative 68 Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177 Lu-DOTATATE. J Nucl Med 2021;62:1406-14. [DOI: 10.2967/jnumed.120.256727] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
765 Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, Cremonesi M, de Herder WW, Dromain C, Falconi M, Fani M, Fanti S, Hicks RJ, Kabasakal L, Kaltsas G, Lewington V, Minozzi S, Cinquini M, Öberg K, Oyen WJG, O'Toole D, Pavel M, Ruszniewski P, Scarpa A, Strosberg J, Sundin A, Taïeb D, Virgolini I, Wild D, Herrmann K, Yao J. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer 2021;146:56-73. [PMID: 33588146 DOI: 10.1016/j.ejca.2021.01.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 20.5] [Reference Citation Analysis]
766 Zhang T, Zhang Y, Liu X, Xu H, Chen C, Zhou X, Liu Y, Ma X. Application of Radiomics Analysis Based on CT Combined With Machine Learning in Diagnostic of Pancreatic Neuroendocrine Tumors Patient's Pathological Grades. Front Oncol 2020;10:521831. [PMID: 33643890 DOI: 10.3389/fonc.2020.521831] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
767 Wyld D, Moore J, Tran N, Youl P. Incidence, survival and stage at diagnosis of small intestinal neuroendocrine tumours in Queensland, Australia, 2001-2015. Asia Pac J Clin Oncol 2021;17:350-8. [PMID: 33567164 DOI: 10.1111/ajco.13503] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
768 Holmager P, Willemoe GL, Nielsen K, Grøndahl V, Klose M, Andreassen M, Langer SW, Hansen CP, Kjær A, Federspiel BH, Knigge U. Neuroendocrine neoplasms of the appendix: Characterization of 335 patients referred to the Copenhagen NET Center of Excellence. Eur J Surg Oncol 2021;47:1357-63. [PMID: 33589240 DOI: 10.1016/j.ejso.2021.02.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
769 Ho K, Fleseriu M, Kaiser U, Salvatori R, Brue T, Lopes MB, Kunz P, Molitch M, Camper SA, Gadelha M, Syro LV, Laws E, Reincke M, Nishioka H, Grossman A, Barkan A, Casanueva F, Wass J, Mamelak A, Katznelson L, van der Lely AJ, Radovick S, Bidlingmaier M, Boguszewski M, Bollerslev J, Hoffman AR, Oyesiku N, Raverot G, Ben-Shlomo A, Fowkes R, Shimon I, Fukuoka H, Pereira AM, Greenman Y, Heaney AP, Gurnell M, Johannsson G, Osamura RY, Buchfelder M, Zatelli MC, Korbonits M, Chanson P, Biermasz N, Clemmons DR, Karavitaki N, Bronstein MD, Trainer P, Melmed S. Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time? J Endocr Soc 2021;5:bvaa205. [PMID: 33604494 DOI: 10.1210/jendso/bvaa205] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
770 Baeg K, Harris C, Naparst MS, Ahn E, Thapi S, Martin J, Rustgi S, Mhango G, Wisnivesky J, Kim MK. Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients. BMC Cancer 2021;21:146. [PMID: 33563241 DOI: 10.1186/s12885-021-07868-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
771 Davis LM, Nicou N, Martin W, Corcoran B, Mulholland N, Srirajaskanthan R, Ramage J, Wendler O, Vivian G. Timing of peptide receptor radiotargeted therapy in relation to cardiac valve surgery for carcinoid heart disease in patients with neuroendocrine metastases and cardiac syndrome. A single-centre study from a centre of excellence. Nucl Med Commun 2020;41:575-81. [PMID: 32371675 DOI: 10.1097/MNM.0000000000001200] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
772 Gagliardi I, Tarquini M, Ambrosio MR, Giannetta E, Borges de Souza P, Gafà R, Carnevale A, Franceschetti P, Zatelli MC. NEP-Score Thresholds Predict Survival of Patients With Bronchial Carcinoids. Front Endocrinol (Lausanne) 2020;11:621557. [PMID: 33628200 DOI: 10.3389/fendo.2020.621557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
773 Koumarianou A, Kaltsas GA, Chatzellis E, Kyriakopoulos G, Kolomodi D, Alexandraki KI. Immunotherapeutics at the spearhead: current status in targeting neuroendocrine neoplasms. Endocrine 2021;73:232-9. [PMID: 33544352 DOI: 10.1007/s12020-021-02639-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
774 Nguyen AH, O'Leary MP, De Andrade JP, Ituarte PHG, Kessler J, Li D, Singh G, Chang S. Natural History of Renal Neuroendocrine Neoplasms: A NET by Any Other Name? Front Endocrinol (Lausanne) 2020;11:624251. [PMID: 33613455 DOI: 10.3389/fendo.2020.624251] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
775 Ruhwedel T, Rogasch JMM, Huang K, Jann H, Schatka I, Furth C, Amthauer H, Wetz C. The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [177Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis. Cancers (Basel) 2021;13:635. [PMID: 33562643 DOI: 10.3390/cancers13040635] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
776 Inzani F, Rindi G. Una nomenclatura universale per le neoplasie neuroendocrine. L'Endocrinologo 2021;22:1-7. [DOI: 10.1007/s40619-021-00814-7] [Reference Citation Analysis]
777 Tsuchikawa T, Tanaka K, Nakanishi Y, Asano T, Noji T, Nakamura T, Okamura K, Shichinohe T, Hirano S. Clinical Impact of Organ-Preserving Surgery for Pancreatic Neuroendocrine Neoplasms: A Single-Center Experience. Pancreas 2021;50:196-200. [PMID: 33565795 DOI: 10.1097/MPA.0000000000001739] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
778 Mastracci L, Rindi G, Grillo F, Solcia E, Campora M, Fassan M, Parente P, Vanoli A, La Rosa S. Neuroendocrine neoplasms of the esophagus and stomach. Pathologica 2021;113:5-11. [PMID: 33686305 DOI: 10.32074/1591-951X-229] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
779 Inzani F, Rindi G. Introduction to neuroendocrine neoplasms of the digestive system: definition and classification. Pathologica 2021;113:1-4. [PMID: 33686304 DOI: 10.32074/1591-951X-227] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
780 Chan DL, Yao JC, Carnaghi C, Buzzoni R, Herbst F, Ridolfi A, Strosberg J, Kulke MH, Pavel M, Singh S. Markers of Systemic Inflammation in Neuroendocrine Tumors: A Pooled Analysis of the RADIANT-3 and RADIANT-4 Studies. Pancreas 2021;50:130-7. [PMID: 33560090 DOI: 10.1097/MPA.0000000000001745] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
781 Andreasi V, Partelli S, Muffatti F, Manzoni MF, Capurso G, Falconi M. Update on gastroenteropancreatic neuroendocrine tumors. Dig Liver Dis 2021;53:171-82. [PMID: 32912771 DOI: 10.1016/j.dld.2020.08.031] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
782 Pu N, Habib JR, Bejjani M, Yin H, Nagai M, Chen J, Kinny-Köster B, Chen Q, Zhang J, Yu J, Wu W, Lou W. The effect of primary site, functional status and treatment modality on survival in gastroenteropancreatic neuroendocrine neoplasms with synchronous liver metastasis: a US population-based study. Ann Transl Med 2021;9:329. [PMID: 33708956 DOI: 10.21037/atm-20-5348] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
783 Baghdadi A, Ghadimi M, Mirpour S, Hazhirkarzar B, Motaghi M, Pawlik TM, Kamel IR. Imaging neuroendocrine tumors: Characterizing the spectrum of radiographic findings. Surg Oncol 2021;37:101529. [PMID: 33549952 DOI: 10.1016/j.suronc.2021.101529] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
784 Kim JW, Gwon DI, Kim H. Liver Directed Interventional Treatments for Pancreatic Neuroendocrine Tumor with Liver Metastasis. Korean J Pancreas Biliary Tract 2021;26:15-23. [DOI: 10.15279/kpba.2021.26.1.15] [Reference Citation Analysis]
785 Lock G, Oelckers M, Clauditz TS, Schrader J. Gastric NET Subtypes: Do We Need An Additional One? Z Gastroenterol 2021;59:255-8. [PMID: 33506449 DOI: 10.1055/a-1348-2727] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
786 Shi M, Zhou B. Clinical Characteristics and Prognostic Factors of Early-Onset Pancreatic Neuroendocrine Tumors. Cancer Control 2021;28:1073274820986827. [PMID: 33491476 DOI: 10.1177/1073274820986827] [Reference Citation Analysis]
787 Magi L, Rinzivillo M, Panzuto F. Tumor Heterogenity in Gastro-Entero-Pancreatic Neuroendocrine Neoplasia. Endocrines 2021;2:28-36. [DOI: 10.3390/endocrines2010003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
788 Pathipati MP, Yohannan TK, Tian L, Hornbacker K, Benson JA, Berry GJ, Lui NS, Kunz PL, Padda SK. Examination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort study. Lung Cancer 2021;154:186-94. [PMID: 33551175 DOI: 10.1016/j.lungcan.2021.01.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
789 Wedin M, Mehta S, Angerås-Kraftling J, Wallin G, Daskalakis K. The Role of Serum 5-HIAA as a Predictor of Progression and an Alternative to 24-h Urine 5-HIAA in Well-Differentiated Neuroendocrine Neoplasms. Biology (Basel) 2021;10:76. [PMID: 33494283 DOI: 10.3390/biology10020076] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
790 Jepsen DNM, Fiehn AK, Garbyal RS, Engel U, Holm J, Federspiel B. Immunohistochemical Staining With Neuroendocrine Markers is Essential in the Diagnosis of Neuroendocrine Neoplasms of the Esophagogastric Junction. Appl Immunohistochem Mol Morphol 2021;29:454-61. [PMID: 33480601 DOI: 10.1097/PAI.0000000000000906] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
791 Jiménez B, Abellona U MR, Drymousis P, Kyriakides M, Clift AK, Liu DSK, Rees E, Holmes E, Nicholson JK, Kinross JM, Frilling A. Neuroendocrine Neoplasms: Identification of Novel Metabolic Circuits of Potential Diagnostic Utility. Cancers (Basel) 2021;13:374. [PMID: 33498434 DOI: 10.3390/cancers13030374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
792 Baudin E, Caplin M, Garcia-Carbonero R, Fazio N, Ferolla P, Filosso PL, Frilling A, de Herder WW, Hörsch D, Knigge U, Korse CM, Lim E, Lombard-Bohas C, Pavel M, Scoazec JY, Sundin A, Berruti A;  ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2021;32:439-451. [PMID: 33482246 DOI: 10.1016/j.annonc.2021.01.003] [Cited by in Crossref: 43] [Cited by in F6Publishing: 52] [Article Influence: 21.5] [Reference Citation Analysis]
793 Chatani PD, Agarwal SK, Sadowski SM. Molecular Signatures and Their Clinical Utility in Pancreatic Neuroendocrine Tumors. Front Endocrinol (Lausanne) 2020;11:575620. [PMID: 33537001 DOI: 10.3389/fendo.2020.575620] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
794 Machairas N, Daskalakis K, Felekouras E, Alexandraki KI, Kaltsas G, Sotiropoulos GC. Currently available treatment options for neuroendocrine liver metastases. Ann Gastroenterol 2021;34:130-41. [PMID: 33654350 DOI: 10.20524/aog.2021.0574] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
795 Georgiopoulos G, Mitropoulou P, Masci PG, Schwitter J. A concealed carcinoid cardiac metastasis uncovered by comprehensive cardiovascular magnetic resonance-based tissue characterization: a case report. Eur Heart J Case Rep 2020;4:1-5. [PMID: 33442650 DOI: 10.1093/ehjcr/ytaa354] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
796 Tran CG, Sherman SK, Howe JR. The Landmark Series: Management of Small Bowel Neuroendocrine Tumors. Ann Surg Oncol 2021;28:2741-51. [PMID: 33452604 DOI: 10.1245/s10434-020-09566-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
797 Xie S, Li L, Wang X, Li L. Development and validation of a nomogram for predicting the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms. Medicine (Baltimore) 2021;100:e24223. [PMID: 33466202 DOI: 10.1097/MD.0000000000024223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
798 Zhuge X, Wang Y, Chen X, Guo C. Diabetes in Patients With Pancreatic Neuroendocrine Neoplasms. Front Endocrinol (Lausanne) 2020;11:615082. [PMID: 33424776 DOI: 10.3389/fendo.2020.615082] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
799 Chen J, Yang Y, Liu Y, Kan H. Prognosis analysis of patients with pancreatic neuroendocrine tumors after surgical resection and the application of enucleation. World J Surg Oncol 2021;19:11. [PMID: 33436017 DOI: 10.1186/s12957-020-02115-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
800 Özdirik B, Jann H, Bischoff P, Fehrenbach U, Tacke F, Roderburg C, Wiedenmann B. PD-L1 - inhibitors in neuroendocrine neoplasia: Results from a real-life study. Medicine (Baltimore) 2021;100:e23835. [PMID: 33429744 DOI: 10.1097/MD.0000000000023835] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
801 Grenader T, Pavel ME, Ruszniewski PB, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Truong Thanh XM, Caplin ME; CLARINET Study Group. Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors. Anticancer Drugs 2020;31:216-22. [PMID: 31977567 DOI: 10.1097/CAD.0000000000000909] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
802 Kessler J, Singh G, Ituarte PHG, Allen R, Chang S, Li D. A Comparison of Liver-Directed Therapy and Systemic Therapy for the Treatment of Liver Metastases in Patients with Gastrointestinal Neuroendocrine Tumors: Analysis of the California Cancer Registry. J Vasc Interv Radiol 2021;32:393-402. [PMID: 33358144 DOI: 10.1016/j.jvir.2020.10.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
803 Lu L, Shang Y, Mullins CS, Zhang X, Linnebacher M. Epidemiologic trends and prognostic risk factors of patients with pancreatic neuroendocrine neoplasms in the US: an updated population-based study. Future Oncol 2021;17:549-63. [PMID: 33401958 DOI: 10.2217/fon-2020-0543] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
804 Liverani C, Bongiovanni A, Mercatali L, Pieri F, Spadazzi C, Miserocchi G, Di Menna G, Foca F, Ravaioli S, De Vita A, Cocchi C, Rossi G, Recine F, Ibrahim T. Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms. Endocr Pathol 2021;32:309-17. [PMID: 33409812 DOI: 10.1007/s12022-020-09657-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
805 Dromain C, Loaiza-Bonilla A, Mirakhur B, Beveridge TJR, Fojo AT. Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors. Oncologist 2021;26:e632-8. [PMID: 33393112 DOI: 10.1002/onco.13669] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
806 Smith-Palmer J, Leeuwenkamp OR, Virk J, Reed N. Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland. BMC Cancer 2021;21:10. [PMID: 33402120 DOI: 10.1186/s12885-020-07710-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
807 Butler OL, Mekhael MM, Ahmed A, Cuthbertson DJ, Pritchard DM. Frequency and Causes of False-Positive Elevated Plasma Concentrations of Fasting Gut Hormones in a Specialist Neuroendocrine Tumor Center. Front Endocrinol (Lausanne) 2020;11:606264. [PMID: 33391185 DOI: 10.3389/fendo.2020.606264] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
808 MacFarlane AW 4th, Yeung HM, Alpaugh RK, Dulaimi E, Engstrom PF, Dasari A, Campbell KS, Vijayvergia N. Impacts of pembrolizumab therapy on immune phenotype in patients with high-grade neuroendocrine neoplasms. Cancer Immunol Immunother 2021;70:1893-906. [PMID: 33398390 DOI: 10.1007/s00262-020-02811-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
809 Weber M, Kessler L, Schaarschmidt B, Fendler WP, Lahner H, Antoch G, Umutlu L, Herrmann K, Rischpler C. Textural analysis of hybrid DOTATOC-PET/MRI and its association with histological grading in patients with liver metastases from neuroendocrine tumors. Nucl Med Commun 2020;41:363-9. [PMID: 31977752 DOI: 10.1097/MNM.0000000000001150] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
810 Muffatti F, Andreasi V, Partelli S, Falconi M. Non Functional Pancreatic Neuroendocrine Tumors. Neuroendocrine Tumors 2021. [DOI: 10.1007/978-3-030-62241-1_8] [Reference Citation Analysis]
811 Stier MW, Chapman CG, Shamah S, Donboli K, Yassan L, Waxman I, Siddiqui UD. Endoscopic resection is more effective than biopsy or EUS to detect residual rectal neuroendocrine tumor. Endosc Int Open 2021;9:E4-8. [PMID: 33403229 DOI: 10.1055/a-1300-1017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
812 La Rosa S. Gastric Neuroendocrine Neoplasm. Encyclopedia of Pathology 2021. [DOI: 10.1007/978-3-319-28845-1_5187-1] [Reference Citation Analysis]
813 Fazio N, Spada F, Rossi RE, Ambrosini V, Incorvaia L, Passiglia F, Cani M, Badalamenti G. Neuroendocrine Neoplasms (NENs). Practical Medical Oncology Textbook 2021. [DOI: 10.1007/978-3-030-56051-5_60] [Reference Citation Analysis]
814 Sonbol MB, Saad AM, Gonzalez-Velez M, Starr J, Halfdanarson TR. Causes of Death After Neuroendocrine Tumors Diagnosis: A US Population-Based Analysis. Pancreas 2021;50:47-53. [PMID: 33370022 DOI: 10.1097/MPA.0000000000001723] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
815 Mahvi DA, Clancy TE. Gastroduodenal NETs. Neuroendocrine Tumors 2021. [DOI: 10.1007/978-3-030-62241-1_7] [Reference Citation Analysis]
816 Aydogan S, Kaya T, Surmelioglu A, Demirli S. Appendix Tumors. Colon Polyps and Colorectal Cancer 2021. [DOI: 10.1007/978-3-030-57273-0_14] [Reference Citation Analysis]
817 La Rosa S, Uccella S, Rindi G. Neuroendocrine Neoplasms of the Gut. The Spectrum of Neuroendocrine Neoplasia 2021. [DOI: 10.1007/978-3-030-54391-4_10] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
818 Bhutiani N, Bruenderman EH, Jones JM, Wehry JH, Egger ME, Philips P, Scoggins CR, McMasters KM, Martin RCG. A literature-based treatment algorithm for low-grade neuroendocrine liver metastases. HPB (Oxford) 2021;23:63-70. [PMID: 32448647 DOI: 10.1016/j.hpb.2020.04.012] [Reference Citation Analysis]
819 Andreasi V, Partelli S, Muffatti F, Falconi M. New Surgical Strategies. Neuroendocrine Neoplasia Management 2021. [DOI: 10.1007/978-3-030-72830-4_8] [Reference Citation Analysis]
820 Bennett SA, Law CHL, Assal A, Myrehaug S, Hallet J. Functional Pancreatic Neuroendocrine Tumors. Neuroendocrine Tumors 2021. [DOI: 10.1007/978-3-030-62241-1_9] [Reference Citation Analysis]
821 Kessel E, Naparst M, Alpert N, Diaz K, Ahn E, Wolin E, Taioli E, Kim MK. Racial Differences in Gastroenteropancreatic Neuroendocrine Tumor Treatment and Survival in the United States. Pancreas 2021;50:29-36. [PMID: 33370020 DOI: 10.1097/MPA.0000000000001707] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
822 Aoki Y, Miyake H, Nagai H, Yoshioka Y, Tsuruta S, Yuasa N, Fujino M. A Case of Synchronous Triple Gastric Cancer with MiNEN (MANEC). Nihon Rinsho Geka Gakkai Zasshi (J Jpn Surg Assoc) 2021;82:2185-2193. [DOI: 10.3919/jjsa.82.2185] [Reference Citation Analysis]
823 Mafficini A, Corbo V, Barbi S, Luchini C, Simbolo M, Scarpa A. Molecular Biology of Neuroendocrine Tumors. Neuroendocrine Neoplasia Management 2021. [DOI: 10.1007/978-3-030-72830-4_4] [Reference Citation Analysis]
824 Bajetta E, De Toma D, Antonucci A, Bajetta R, Valente M. History of Neuroendocrine Neoplasia. Neuroendocrine Neoplasia Management 2021. [DOI: 10.1007/978-3-030-72830-4_1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
825 Rinke A, Denzer UW. Kolorektale NEN (ohne Fernmetastasen). Springer Reference Medizin 2021. [DOI: 10.1007/978-3-662-61724-3_48-1] [Reference Citation Analysis]
826 Pérez-soto RH, Trolle-silva AM, Herrera MF. Large Intestine NETs. Endocrine Surgery Comprehensive Board Exam Guide 2021. [DOI: 10.1007/978-3-030-84737-1_30] [Reference Citation Analysis]
827 董 玉. Clinical Characteristics and Treatment of Hepatic Neurorndorine Neoplasms. ACM 2021;11:5391-5397. [DOI: 10.12677/acm.2021.1111797] [Reference Citation Analysis]
828 Hodge C, Fahy BN. Palliative Interventions for Metastatic Neuroendocrine Tumors. Neuroendocrine Tumors 2021. [DOI: 10.1007/978-3-030-62241-1_19] [Reference Citation Analysis]
829 Nagy G. Ectopic ACTH Syndrome Caused by a Bronchial Neuroendocrine Tumor. Practical Clinical Endocrinology 2021. [DOI: 10.1007/978-3-030-62011-0_45] [Reference Citation Analysis]
830 Gupta M, Prinzing G, Iyer R. Emerging Systemic Therapies for Neuroendocrine Tumors. Neuroendocrine Tumors 2021. [DOI: 10.1007/978-3-030-62241-1_20] [Reference Citation Analysis]
831 Clift AK, Frilling A. Neuroendocrine Liver Metastases. Neuroendocrine Tumors 2021. [DOI: 10.1007/978-3-030-62241-1_17] [Reference Citation Analysis]
832 Tai E, Kennedy S, Farrell A, Jaberi A, Kachura J, Beecroft R. Comparison of transarterial bland and chemoembolization for neuroendocrine tumours: a systematic review and meta-analysis. Curr Oncol 2020;27:e537-46. [PMID: 33380868 DOI: 10.3747/co.27.6205] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
833 Ravizza D, Fiori G. Gastric Neuroendocrine Tumors. Neuroendocrine Neoplasia Management 2021. [DOI: 10.1007/978-3-030-72830-4_13] [Reference Citation Analysis]
834 Das S, Soares H, Dasari A. Neoadjuvant and Adjuvant Treatment Strategies for Well-Differentiated Neuroendocrine Tumors. Neuroendocrine Tumors 2021. [DOI: 10.1007/978-3-030-62241-1_5] [Reference Citation Analysis]
835 Goldmann A, Clerici T. Small Intestine NETs. Endocrine Surgery Comprehensive Board Exam Guide 2021. [DOI: 10.1007/978-3-030-84737-1_29] [Reference Citation Analysis]
836 Acikgoz Y, Bal O, Dogan M. Albumin-to-Alkaline Phosphatase Ratio: Does It Predict Survival in Grade 1 and Grade 2 Neuroendocrine Tumors? Pancreas 2021;50:111-7. [PMID: 33370032 DOI: 10.1097/MPA.0000000000001720] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
837 Kurowski JA, Conjeevaram Selvakumar PK. Neoplasms of the Gastrointestinal Tract. Pediatric Gastrointestinal and Liver Disease 2021. [DOI: 10.1016/b978-0-323-67293-1.00047-5] [Reference Citation Analysis]
838 Sukrithan V, Konda B. Epidemiology and Diagnosis of Neuroendocrine Tumors. Neuroendocrine Tumors 2021. [DOI: 10.1007/978-3-030-62241-1_1] [Reference Citation Analysis]
839 Milione M, Cattaneo L, Mangogna A. New Concepts in Pathology. Neuroendocrine Neoplasia Management 2021. [DOI: 10.1007/978-3-030-72830-4_3] [Reference Citation Analysis]
840 Wang J, Doherty G. Neuroendocrine Tumors: Stomach. Endocrine Surgery Comprehensive Board Exam Guide 2021. [DOI: 10.1007/978-3-030-84737-1_26] [Reference Citation Analysis]
841 Larson BK, Dhall D. Neuroendocrine Neoplasms of the Gastrointestinal Tract. Practical Gastrointestinal Pathology 2021. [DOI: 10.1007/978-3-030-51268-2_17] [Reference Citation Analysis]
842 Liu X, Chin W, Pan C, Zhang W, Yu J, Zheng S, Liu Y. Risk of malignancy and prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors. Gland Surg 2021;10:219-32. [PMID: 33633978 DOI: 10.21037/gs-20-582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
843 Sherman SK, Howe JR. Jejunoileal Neuroendocrine Tumors. Neuroendocrine Tumors 2021. [DOI: 10.1007/978-3-030-62241-1_10] [Reference Citation Analysis]
844 Fields AC, Lu PW, Melnitchouk N. Colon and Rectal Neuroendocrine Tumors. Neuroendocrine Tumors 2021. [DOI: 10.1007/978-3-030-62241-1_11] [Reference Citation Analysis]
845 Trama A. Epidemiology of Neuroendocrine Neoplasms. Neuroendocrine Neoplasia Management 2021. [DOI: 10.1007/978-3-030-72830-4_2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
846 Yoo C, Oh CR, Kim ST, Bae WK, Choi HJ, Oh DY, Lee MA, Ryoo BY. Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion. Cancer Res Treat 2021;53:291-300. [PMID: 33421978 DOI: 10.4143/crt.2020.1233] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
847 Koffas A, Toumpanakis C. Comparative safety review of the current therapies for gastroenteropancreatic neuroendocrine tumors. Expert Opin Drug Saf 2021;20:321-34. [PMID: 33338383 DOI: 10.1080/14740338.2021.1867097] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
848 Fahmy JN, Varsanik MA, Hubbs D, Eguia E, Abood G, Knab LM. Pancreatic neuroendocrine tumors: Surgical outcomes and survival analysis. Am J Surg 2021;221:529-33. [PMID: 33375953 DOI: 10.1016/j.amjsurg.2020.12.037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
849 Partelli S, Ramage JK, Massironi S, Zerbi A, Kim HB, Niccoli P, Panzuto F, Landoni L, Tomazic A, Ibrahim T, Kaltsas G, Bertani E, Sauvanet A, Segelov E, Caplin M, Coppa J, Armstrong T, Weickert MO, Butturini G, Staettner S, Boesch F, Cives M, Moulton CA, He J, Selberherr A, Twito O, Castaldi A, De Angelis CG, Gaujoux S, Almeamar H, Frilling A, Vigia E, Wilson C, Muffatti F, Srirajaskanthan R, Invernizzi P, Lania A, Kwon W, Ewald J, Rinzivillo M, Nessi C, Smid LM, Gardini A, Tsoli M, Picardi EE, Hentic O, Croagh D, Toumpanakis C, Citterio D, Ramsey E, Mosterman B, Regi P, Gasteiger S, Rossi RE, Smiroldo V, Jang JY, Falconi M. Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm: Study Protocol for a Prospective Observational Study. Front Med (Lausanne) 2020;7:598438. [PMID: 33425946 DOI: 10.3389/fmed.2020.598438] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
850 Kim YI. Salvage peptide receptor radionuclide therapy in patients with progressive neuroendocrine tumors: a systematic review and meta-analysis. Nucl Med Commun 2021;42:451-8. [PMID: 33346603 DOI: 10.1097/MNM.0000000000001350] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
851 La Rosa S, Solcia E. New insights into the classification of gastric neuroendocrine tumours, expanding the spectrum of ECL-cell tumours related to hypergastrinaemia. Histopathology 2020;77:862-4. [PMID: 33190337 DOI: 10.1111/his.14226] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
852 Colao A, de Nigris F, Modica R, Napoli C. Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead. Front Endocrinol (Lausanne) 2020;11:604341. [PMID: 33384663 DOI: 10.3389/fendo.2020.604341] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
853 Li YL, Qiu XD, Chen J, Zhang Y, Li J, Xu JM, Wang C, Qi ZR, Luo J, Tan HY. Clinicopathological characteristics and prognosis of 77 cases with type 3 gastric neuroendocrine tumours. World J Gastrointest Oncol 2020; 12(12): 1416-1427 [PMID: 33362912 DOI: 10.4251/wjgo.v12.i12.1416] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
854 Liberini V, Huellner MW, Grimaldi S, Finessi M, Thuillier P, Muni A, Pellerito RE, Papotti MG, Piovesan A, Arvat E, Deandreis D. The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future. Diagnostics (Basel) 2020;10:E1083. [PMID: 33322819 DOI: 10.3390/diagnostics10121083] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
855 Nath E, Sawyer MB, Choy J. First Case of Regression of Carcinoid Heart Disease on Serial Transthoracic Echocardiograms following Octreotide Monotherapy in a Patient with Metastatic Pancreatic Neuroendocrine Tumor. Case Rep Oncol 2020;13:1454-1462. [DOI: 10.1159/000511414] [Reference Citation Analysis]
856 Arakelyan J, Zohrabyan D, Philip PA. Molecular profile of pancreatic neuroendocrine neoplasms (PanNENs): Opportunities for personalized therapies. Cancer 2021;127:345-53. [PMID: 33270905 DOI: 10.1002/cncr.33354] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
857 Bispo M, Caldeira A, Leite S, Marques S, Moreira T, Moutinho-Ribeiro P, Nunes N. Endoscopic Ultrasound-Guided Ablation of Focal Pancreatic Lesions: The GRUPUGE Perspective. GE Port J Gastroenterol 2020;27:410-6. [PMID: 33251290 DOI: 10.1159/000507895] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
858